yoqerepskckmcszamohopqrsfebmaoeitqmqmkjq length 6 409521 page 409521 

<!DOCTYPE html>

<html id="doc" lang="en" class="page-article">
<head id="Head1">
    <!-- charset must appear in the first 1024 bytes of the document -->
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

<script>
      var SCM = SCM || {};
      if (SCM.AMA && SCM.AMA.DataLayerAsync) {
        SCM.AMA.DataLayerAsync.push("arrSisAffinity", "", "array");
        SCM.AMA.DataLayerAsync.push("SubStatus", "no", "string");
      }

      var googletag = window.googletag || {};
      googletag.cmd = googletag.cmd || [];

          
          if (typeof Storage !== "undefined")
          {
              var targetingParamStr = localStorage.getItem("bcDFPTargetingParams");
              if (targetingParamStr)
              {
                  var targetingParameters = JSON.parse(targetingParamStr);     // set page-level targeting parameters
                  jQuery.each(targetingParameters, function (index, param) {
                      googletag.cmd.push(function () {
                          window.googletag.pubads().setTargeting(param.key, param.value);
                      });
                  });
              }
          }
          
      if (!googletag.pubads) {
        (function () {
          var gads = document.createElement('script');
          var useSSL = 'https:' == document.location.protocol;
          gads.src = (useSSL ? 'https:' : 'http:') +
            '//securepubads.g.doubleclick.net/tag/js/gpt.js';
              gads.setAttribute("async", "");
              gads.setAttribute("defer", "");
          var node = document.getElementsByTagName('script')[0];
          node.parentNode.insertBefore(gads, node);
          })();

        var App = App || {};
        App.Ads = App.Ads || {};
        App.Ads.adPath = App.Ads.adPath || '/6479/' + 'ama.jama';
        App.Ads.Mappings = App.Ads.Mappings || {};
        App.Ads.slots = App.Ads.slots || [];
        App.Ads.fromGoogle = !('yes' === 'yes');

        App.isCollection = App.isCollection || !!document.getElementsByClassName('pg_collection').length;

        
        googletag.cmd.push(function () {

          googletag.pubads()
            .setTargeting('environment', ['newjama'])
            .setTargeting('site', ['ama.jama'])
            .setTargeting('sect', ['scholarly'])
            .setTargeting('sub', ['no'])
            .setTargeting('device', ['cis5550-crawler'])
            .setTargeting('usaphys', ['no'])
            .setTargeting('memberstat', ['no'])
            .setTargeting('pracset', [''])
            .setTargeting('specialty', ['other'])
            .setTargeting('occupation', [''])
            .setTargeting('useraffinity', [''])
            .setTargeting('direct', ['yes'])
            .setTargeting('bot', ['yes'])
            .setTargeting('datacenter', ['no'])
            .setTargeting('selfMPA', [''])
            .setTargeting('selfSpecialty', ['']);

          if (App.isCollection) {
            googletag.pubads().setTargeting('collection', ['']);
          }

          var testParam = getQueryVariable('test');

          if (testParam) {
            googletag.pubads().setTargeting('test', [testParam]);
          }

          function getQueryVariable(variable) {
            var query = window.location.search.substring(1);
            var vars = query.split('&');
            for (var i = 0; i < vars.length; i++) {
              var pair = vars[i].split('=');
              if (decodeURIComponent(pair[0]) == variable) {
                return decodeURIComponent(pair[1]);
              }
            }
          }

          googletag.pubads().disableInitialLoad();
          googletag.enableServices();
        });
      }
</script>


<meta name="viewport" content="width=device-width, initial-scale=1" /><meta name="format-detection" content="telephone=no" /><link rel="shortcut icon" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico">
<link rel="icon" type="image/png" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon-192x192.png" sizes="192x192">
<link rel="apple-touch-icon" sizes="180x180" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/apple-touch-icon-180x180.png">
<meta http-equiv="X-UA-Compatible" content="IE=Edge" /><script type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"8d76ca6f26","applicationID":"237359554","transactionName":"ZQBRMkVUCEtRVkINXlxKcjVnGgdKRFxVCFQcBEAWTw==","queueTime":0,"applicationTime":1357,"agent":"","atts":""}</script><script type="text/javascript">(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}};(window.NREUM||(NREUM={})).loader_config={xpid:"XAYBV15WGwEDU1JXDgQCUg==",licenseKey:"8d76ca6f26",applicationID:"237359554"};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var i=e[n]={exports:{}};t[n][0].call(i.exports,function(e){var i=t[n][1][e];return r(i||e)},i,i.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var i=0;i<n.length;i++)r(n[i]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var i,o=t("ee"),a=t(27),s={};try{i=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(s.console=!0,i.indexOf("dev")!==-1&&(s.dev=!0),i.indexOf("nr_dev")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&o.on("internal-error",function(t){r(t.stack)}),s.dev&&o.on("fn-err",function(t,e,n){r(n.stack)}),s.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(s,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{p?p-=1:i(s||new UncaughtException(t,e,n),!0)}catch(f){try{o("ierr",[f,c.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function i(t,e){var n=e?null:c.now();o("err",[t,n])}var o=t("handle"),a=t(28),s=t("ee"),c=t("loader"),f=t("gos"),u=window.onerror,d=!1,l="nr@seenError";if(!c.disabled){var p=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(10),t(9),"addEventListener"in window&&t(6),c.xhrWrappable&&t(11),d=!0)}s.on("fn-start",function(t,e,n){d&&(p+=1)}),s.on("fn-err",function(t,e,n){d&&!n[l]&&(f(n,l,function(){return!0}),this.thrown=!0,i(n))}),s.on("fn-end",function(){d&&!this.thrown&&p>0&&(p-=1)}),s.on("internal-error",function(t){o("ierr",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t("loader");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:["resource"]})}catch(e){}}function i(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance["c"+l])try{window.performance[h](m,i,!1)}catch(t){}else try{window.performance[h]("webkit"+m,i,!1)}catch(t){}}function o(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t("ee"),s=t("handle"),c=t(10),f=t(9),u=t(5),d=t(19),l="learResourceTimings",p="addEventListener",h="removeEventListener",m="resourcetimingbufferfull",v="bstResource",w="resource",g="-start",y="-end",x="fn"+g,b="fn"+y,E="bstTimer",R="pushState",S=t("loader");if(!S.disabled){S.features.stn=!0,t(8),"addEventListener"in window&&t(6);var O=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof O&&(this.bstStart=S.now())}),a.on(b,function(t,e){var n=t[0];n instanceof O&&s("bst",[n,e,this.bstStart,S.now()])}),c.on(x,function(t,e,n){this.bstStart=S.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,S.now(),this.bstType])}),f.on(x,function(){this.bstStart=S.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,S.now(),"requestAnimationFrame"])}),a.on(R+g,function(t){this.time=S.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType("resource")]),r()):p in window.performance&&(window.performance["c"+l]?window.performance[p](m,i,d(!1)):window.performance[p]("webkit"+m,i,d(!1))),document[p]("scroll",o,d(!1)),document[p]("keypress",o,d(!1)),document[p]("click",o,d(!1))}}},{}],5:[function(t,e,n){e.exports=function(){return"PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver}},{}],6:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&i(e)}function i(t){s.inPlace(t,[u,d],"-",o)}function o(t,e){return t[1]}var a=t("ee").get("events"),s=t("wrap-function")(a,!0),c=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(i(window),i(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],7:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=o(arguments),e={};i.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return i.emit(n+"start",[t,a],s),s.then(function(t){return i.emit(n+"end",[null,t],s),t},function(t){throw i.emit(n+"end",[t],s),t})})}var i=t("ee").get("fetch"),o=t(28),a=t(27);e.exports=i;var s=window,c="fetch-",f=c+"body-",u=["arrayBuffer","blob","json","text","formData"],d=s.Request,l=s.Response,p=s.fetch,h="prototype",m="nr@context";d&&l&&p&&(a(u,function(t,e){r(d[h],e,f),r(l[h],e,f)}),r(s,"fetch",c),i.on(c+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),i.emit(c+"done",[null,e],n)}else i.emit(c+"done",[t],n)}))},{}],8:[function(t,e,n){var r=t("ee").get("history"),i=t("wrap-function")(r);e.exports=r;var o=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;o&&o.pushState&&o.replaceState&&(a=o),i.inPlace(a,["pushState","replaceState"],"-")},{}],9:[function(t,e,n){var r=t("ee").get("raf"),i=t("wrap-function")(r),o="equestAnimationFrame";e.exports=r,i.inPlace(window,["r"+o,"mozR"+o,"webkitR"+o,"msR"+o],"raf-"),r.on("raf-start",function(t){t[0]=i(t[0],"fn-")})},{}],10:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function i(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var o=t("ee").get("timer"),a=t("wrap-function")(o),s="setTimeout",c="setInterval",f="clearTimeout",u="-start",d="-";e.exports=o,a.inPlace(window,[s,"setImmediate"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,"clearImmediate"],f+d),o.on(c+u,r),o.on(s+u,i)},{}],11:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",s)}function i(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,y,"fn-",s)}function o(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,S.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(6);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),l=t(19),p=NREUM.o,h=p.XHR,m=p.MO,v=p.PR,w=p.SI,g="readystatechange",y=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit("new-xhr",[e],e),e.addEventListener(g,i,l(!1))}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,["open","send"],"-xhr-",s),u.on("send-xhr-start",function(t,e){r(t,e),o(e)}),u.on("open-xhr-start",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,S=document.createTextNode(R);new m(a).observe(S,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===g||a()})},{}],12:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=p.generateSpanId(),m=p.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&l())&&(w.traceContextParentHeader=i(h,m),w.traceContextStateHeader=o(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function i(t,e){return"00-"+e+"-"+t+"-01"}function o(t,e,n,r,i){var o=0,a="",s=1,c="",f="";return i+"@nr="+o+"-"+s+"-"+n+"-"+r+"-"+t+"-"+a+"-"+c+"-"+f+"-"+e}function a(t,e,n,r,i,o){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:"Browser",ac:r,ap:i,id:t,tr:e,ti:n}};return o&&r!==o&&(s.d.tk=o),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var i=h(n.allowed_origins[r]);if(t.hostname===i.hostname&&t.protocol===i.protocol&&t.port===i.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function l(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var p=t(24),h=t(14);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],13:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<l;r++)t.removeEventListener(d[r],this.listener,!1);return e.protocol&&"data"===e.protocol?void g("Ajax/DataUrl/Excluded"):void(e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):o(this,t),n.cbTime=this.cbTime,s("xhr",[e,n,this.startTime,this.endTime,"xhr"],this)))}}function i(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function o(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable&&!a.disabled){var s=t("handle"),c=t(14),f=t(12).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],l=d.length,p=t("id"),h=t(20),m=t(18),v=t(15),w=t(19),g=t(21).recordSupportability,y=NREUM.o.REQ,x=window.XMLHttpRequest;a.features.xhr=!0,t(11),t(7),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener("load",function(n){o(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener("progress",function(t){e.lastSize=t.loaded},w(!1))}),u.on("open-xhr-start",function(t){this.params={method:t[0]},i(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],i=this;if(n&&r){var o=m(r);o&&(n.txSize=o)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||i.loadCaptureCalled||(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var s=0;s<l;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+p(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+p(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("xhr-resolved",function(){this.endTime=a.now()}),u.on("addEventListener-end",function(t,e){e instanceof x&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof x&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof x&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=f(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if("string"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),e(o.headers,i)&&(this.dt=i),t.length>1?t[1]=o:t.push(o)}else t[0]&&t[0].headers&&e(t[0].headers,i)&&(this.dt=i)}),u.on("fetch-start",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},o=this.target;if("string"==typeof o?n=o:"object"==typeof o&&o instanceof y?n=o.url:window.URL&&"object"==typeof o&&o instanceof URL&&(n=o.href),i(this,n),"data"!==this.params.protocol){var s=(""+(o&&o instanceof y&&o.method||r.method||"GET")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}}),u.on("fetch-done",function(t,e){if(this.endTime=a.now(),this.params||(this.params={}),"data"===this.params.protocol)return void g("Ajax/DataUrl/Excluded");this.params.status=e?e.status:0;var n;"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s("xhr",[this.params,r,this.startTime,this.endTime,"fetch"],this)})}},{}],14:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];if(0===(t||"").indexOf("data:"))return{protocol:"data"};var e=document.createElement("a"),n=window.location,i={};e.href=t,i.port=e.port;var o=e.href.split("://");!i.port&&o[1]&&(i.port=o[1].split("/")[0].split("@").pop().split(":")[1]),i.port&&"0"!==i.port||(i.port="https"===o[0]?"443":"80"),i.hostname=e.hostname||n.hostname,i.pathname=e.pathname,i.protocol=o[0],"/"!==i.pathname.charAt(0)&&(i.pathname="/"+i.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return i.sameOrigin=a&&(!e.hostname||s),"/"===i.pathname&&(r[t]=i),i}},{}],15:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?i(t.response):"text"===n||""===n||void 0===n?i(t.responseText):void 0}var i=t(18);e.exports=r},{}],16:[function(t,e,n){function r(){}function i(t,e,n,r){return function(){return u.recordSupportability("API/"+e+"/called"),o(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var o=t("handle"),a=t(27),s=t(28),c=t("ee").get("tracer"),f=t("loader"),u=t(21),d=NREUM;"undefined"==typeof window.newrelic&&(newrelic=d);var l=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],p="api-",h=p+"ixn-";a(l,function(t,e){d[e]=i(p,e,!0,"api")}),d.addPageAction=i(p,"addPageAction",!0),d.setCurrentRouteName=i(p,"routeName",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,i="function"==typeof e;return o(h+"tracer",[f.now(),t,n],r),function(){if(c.emit((i?"":"no-")+"fn-start",[f.now(),r,i],n),i)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=i(h,e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),u.recordSupportability("API/noticeError/called"),o("err",[t,f.now(),!1,e])}},{}],17:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],18:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],19:[function(t,e,n){var r=!1;try{var i=Object.defineProperty({},"passive",{get:function(){r=!0}});window.addEventListener("testPassive",null,i),window.removeEventListener("testPassive",null,i)}catch(o){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],20:[function(t,e,n){var r=0,i=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);i&&(r=+i[1]),e.exports=r},{}],21:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return o("storeMetric",n,null,"api"),n}function i(t,e){var n=[s,t,{name:t},e];return o("storeEventMetrics",n,null,"api"),n}var o=t("handle"),a="sm",s="cm";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:i}},{}],22:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(o=Math.max((new Date).getTime(),o))-a}function i(){return o}var o=(new Date).getTime(),a=o,s=t(29);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=i},{}],23:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?p("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&p("timing",["fcp",Math.floor(t.startTime)])})}function i(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(f&&f<r.startTime)return;var i=[r],o=a({});o&&i.push(o),p("lcp",i)}}function o(t){t.getEntries().forEach(function(t){t.hadRecentInput||p("cls",[t])})}function a(t){var e=navigator.connection||navigator.mozConnection||navigator.webkitConnection;if(e)return e.type&&(t["net-type"]=e.type),e.effectiveType&&(t["net-etype"]=e.effectiveType),e.rtt&&(t["net-rtt"]=e.rtt),e.downlink&&(t["net-dlink"]=e.downlink),t}function s(t){if(t instanceof w&&!y){var e=Math.round(t.timeStamp),n={type:t.type};a(n),e<=h.now()?n.fid=h.now()-e:e>h.offset&&e<=Date.now()?(e-=h.offset,n.fid=h.now()-e):e=h.now(),y=!0,p("timing",["fi",e,n])}}function c(t){"hidden"===t&&(f=h.now(),p("pageHide",[f]))}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var f,u,d,l,p=t("handle"),h=t("loader"),m=t(26),v=t(19),w=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){u=new PerformanceObserver(r);try{u.observe({entryTypes:["paint"]})}catch(g){}d=new PerformanceObserver(i);try{d.observe({entryTypes:["largest-contentful-paint"]})}catch(g){}l=new PerformanceObserver(o);try{l.observe({type:"layout-shift",buffered:!0})}catch(g){}}if("addEventListener"in document){var y=!1,x=["click","keydown","mousedown","pointerdown","touchstart"];x.forEach(function(t){document.addEventListener(t,s,v(!1))})}m(c)}},{}],24:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var i,o="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",s=0;s<o.length;s++)i=o[s],"x"===i?a+=t().toString(16):"y"===i?(i=3&t()|8,a+=i.toString(16)):a+=i;return a}function i(){return a(16)}function o(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,i=window.crypto||window.msCrypto;i&&i.getRandomValues&&Uint8Array&&(n=i.getRandomValues(new Uint8Array(t)));for(var o=[],a=0;a<t;a++)o.push(e().toString(16));return o.join("")}e.exports={generateUuid:r,generateSpanId:i,generateTraceId:o}},{}],25:[function(t,e,n){function r(t,e){if(!i)return!1;if(t!==i)return!1;if(!e)return!0;if(!o)return!1;for(var n=o.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var i=null,o=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf("Chrome")===-1&&s.indexOf("Chromium")===-1&&(i="Safari",o=c[1])}e.exports={agent:i,version:o,match:r}},{}],26:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[o]?"hidden":"visible")}"addEventListener"in document&&a&&document.addEventListener(a,e,i(!1))}var i=t(19);e.exports=r;var o,a,s;"undefined"!=typeof document.hidden?(o="hidden",a="visibilitychange",s="visibilityState"):"undefined"!=typeof document.msHidden?(o="msHidden",a="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(o="webkitHidden",a="webkitvisibilitychange",s="webkitVisibilityState")},{}],27:[function(t,e,n){function r(t,e){var n=[],r="",o=0;for(r in t)i.call(t,r)&&(n[o]=e(r,t[r]),o+=1);return n}var i=Object.prototype.hasOwnProperty;e.exports=r},{}],28:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,i=n-e||0,o=Array(i<0?0:i);++r<i;)o[r]=t[e+r];return o}e.exports=r},{}],29:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function i(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,i,o,a){if(a!==!1&&(a=!0),!p.aborted||o){t&&a&&t(n,r,i);for(var s=e(i),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var l=d[y[n]];return l&&l.push([x,n,r,s]),s}}function o(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return l[t]=l[t]||i(n)}function w(t,e){p.aborted||u(t,function(t,n){e=e||"feature",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:o,addEventListener:o,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function o(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(p.aborted=!0,d=p.backlog={})}var c="nr@context",f=t("gos"),u=t(27),d={},l={},p=e.exports=i();e.exports.getOrSetContext=o,p.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(i.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(o){}return t[e]=r,r}var i=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){i.buffer([t],r),i.emit(t,e,n)}var i=t("ee").get("handle");e.exports=r,r.ee=i},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,o,function(){return i++})}var i=1,o="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!O++){var t=S.info=NREUM.info,e=m.getElementsByTagName("script")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(E,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+S.offset],null,"api"),s("timing",["load",n]);var r=m.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=p+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function i(){"complete"===m.readyState&&o()}function o(){s("mark",["domContent",a()+S.offset],null,"api")}var a=t(22),s=t("handle"),c=t(27),f=t("ee"),u=t(25),d=t(17),l=t(19),p=d.getConfiguration("ssl")===!1?"http":"https",h=window,m=h.document,v="addEventListener",w="attachEvent",g=h.XMLHttpRequest,y=g&&g.prototype,x=!1;NREUM.o={ST:setTimeout,SI:h.setImmediate,CT:clearTimeout,XHR:g,REQ:h.Request,EV:h.Event,PR:h.Promise,MO:h.MutationObserver};var b=""+location,E={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1216.min.js"},R=g&&y&&y[v]&&!/CriOS/.test(navigator.userAgent),S=e.exports={offset:a.getLastTimestamp(),now:a,origin:b,features:{},xhrWrappable:R,userAgent:u,disabled:x};if(!x){t(16),t(23),m[v]?(m[v]("DOMContentLoaded",o,l(!1)),h[v]("load",r,l(!1))):(m[w]("onreadystatechange",i),h[w]("onload",r)),s("mark",["firstbyte",a.getLastTimestamp()],null,"api");var O=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var o,a,u,l;try{a=this,o=d(arguments),u="function"==typeof r?r(o,a):r||{}}catch(p){i([p,"",[o,a,c],u],t)}s(n+"start",[o,a,c],u,f);try{return l=e.apply(a,o)}catch(h){throw s(n+"err",[o,a,h],u,f),h}finally{s(n+"end",[o,a,l],u,f)}}return a(e)?e:(n||(n=""),nrWrapper[l]=e,o(e,nrWrapper,t),nrWrapper)}function r(t,e,r,i,o){r||(r="");var s,c,f,u="-"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,i,c,o))}function s(n,r,o,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,o,e,a)}catch(c){i([c,n,r,o],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=l,n}function i(t,e){e||(e=u);try{e.emit("internal-error",t)}catch(n){}}function o(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(o){i([o],n)}for(var a in t)p.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[l])}function s(t,e){var n=e(t);return n[l]=t,o(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t("ee"),d=t(28),l="nr@original",p=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},["loader",2,13,4,3]);</script>
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/dist/app.min.css?v=638488852237037766">
    
    
    
    
    <link href="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.css" type="text/css" rel="stylesheet" />
    

    <meta property="og:title" content="Aspirin Use and Survival After Diagnosis of Colorectal Cancer" />
    <meta property="og:type" content="Article" />
    <meta property="og:url" content="https://jamanetwork.com/journals/jama/fullarticle/184381" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f1.png?Expires=2147483647&amp;Signature=WQmLYzkkQhOVSsjngPpsZIV1rFulm8iXycz7~U358Z2UCy5~d1rQyBcsfc5ex8ETOF635qbxjtQev3~snbATh4TzZdeDEZElkMB2ww09rjZKmmKC9TO66HbdvFxyXh1a7XqvYEffCbdUx0C5H8Sxo20G5pXfLNtM70zAXxmdCz5aUWbkLzw9hpzpJw5fRfX2KHDP5mrecka8VpFXw6np~tjLbx5sjAS3LdhVIhXeaor9k3TZSSd9LrsaXjV2EkAH7jfbzISWMPBfwhGEK9ZaMh2J0uYZ-SfqUwURp-D16mX5S1U0XAyfm60m2RyZwA2h5gXqq8eusUEpPGvd11KUUw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t1.png?Expires=2147483647&amp;Signature=xqyXJ6CIGAhO1-0SxiBM1ZwP~EaRoVnjbIRhsySJFHQIejpckkjy5NPBf29FAn1Wolk7aDpmgsonzRHWylYLea31YOJH762v1c3mrZGT-WgbR5rUV0qcc-D4V9YRucXUS1m9xI0AW-p5DMk6ofUXRUL2bUuqXi5ZUzyjGq1mxeo2ubEjUWo-vY8xTyfk8YDMGXA4AtpX~Y8hmVfB1WQe6HQUFR95Q4rjX1uPH5-K7j7dYTbC6HeQLnFeAkiBHFurpgEeOMJl3iyAERANk2rNiCYyXZ9IGMT2VQ2oGWzX6FjXuhkQ5y6VBUT86AhIxsU1HpGLlPtG2ItGQUUWK7itJw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f2.png?Expires=2147483647&amp;Signature=YXJBBte11~Wz48C1-i8qMcrPoqV58DDKHOoXRj5e~VaTJ0~mhsvEE57aQYz9q5oqzOtGWwN3P~Kf6a3F04G6lJBNDyZD-RqP~S-ohNFhFDzdJA9ZfpBvt9xYqLuoe-Mbx7RNY60Sl0qYvq8KwGdT-1mJ1UEJMbWjDdKeO1cBtQd~oQ9Nha3SuhgLjRghIHbX6WPNese-YOrdDGem2xWsYH3OrHFz-M~KZIAFApjdMhOZJj7sfxrE0RZyv5szK1oScc62PGAigOALTo6l9N8DBH7xxY3x8-x~7tM8tJoFqP8oyhM0aUvIGXvUce3mjmdh-35G6zzJw-sEmMcYy1nGkg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t2.png?Expires=2147483647&amp;Signature=O-74jfen4CnxgBZUcctSyI-ijfgfD~OlQylDQw81BV5Sv7U9~algkpn9ARI7MYk~UTqCIz6M8Pf7gWqqq7BKjaETvAzP5l7WJJEtpJKl0bznP1o5gWzKubkhzCoTGFLyOf5ig8LmoRt8ZMmnWjNq8G8P1jYPRrDBNrhlyWRdCyfPdxgsUxZEglBpQSSqnWUW2jOpkfHVnOs6jYFihZqxxRQfhqkF3kUzvsq9Tda1HvfnB0w0k9l8QBoUmflCIQxoN8fmJnaTzEhpdHnSJgGsd1cps3IoShXVlLyVe3Cc2T2LNXYhQgmMjFD7RVeMyb-rlACEHgUQ5vZg9Cah1eGbsw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t3.png?Expires=2147483647&amp;Signature=G5VcFihH39XWkIPqd1rM0qckeAgtFx8VE71mWCA-Jb0CIPCllnbXCPKiuM4vCDP8rG9WpeguEOAdOzQKmDM1O5KHuHJDM1xsc2g~P48qKEzGW3frJoMMQsBLjfYOXUOk4UpUXt-EBkvCRkLUn2qKEEEk-JoA7pHZzftoasc3-Mr~y-WvmPqrNSiPc5bvmuXhmZKSzIdWsbtS3h66qhpjuroVKFlnVRvqemBJwsBIkUD7C9i9RlSZGnT0OHZjGopbSvEHeN1D4H3nmCKpmmNifpxc6az26fvRPCd3HgniUAvb5FHgCDPZfBEDNnli~H1-sWIL5FTvi2bbiKUpOz8ZPA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f3.png?Expires=2147483647&amp;Signature=nYpss6m0nflPBFwz05lkgNRDX5ShW-PDUlO8rd6PaqQJ0sbs0mnvOwKdGTphJzFuIKzQTMjWffn3NjbMyINxredGmpqGrRK-zyCKZF2dBy99BNGSS-n5AzSPaAHm0GZsSRYsQ4w5j3jI8StVPSq0xl8iVDi3JIr8GE6VP2x6yLvyWiLz5GaVGrsYmu13mrtJwikWROWOX0R0lBFJyEn22llBTr-ApoW7rpEkuqyV3oligZ3OpmO4mtUlf48AShyL0K3H7wGtKwuHhPMByqwq4ITj0sIAKPwpjPGNaRFvlQlr2ydnf-i0PE9RQHJYfFCBHDze8gN76dkoO0AKMHKunA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:description" content="Context&#160;Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown.Objective&#160;To examine the association between aspirin use after colorectal..." />
        <meta property="fb:pages" content="87087958340" />
        <meta property="fb:pages" content="122228711814384" />
        <meta property="fb:pages" content="1648414928738217" />
        <meta property="fb:pages" content="117506346528" />
        <meta property="fb:pages" content="97538728726" />
        <meta property="fb:pages" content="114116793520" />
        <meta property="fb:pages" content="100679858757" />
        <meta property="fb:pages" content="759822190741773" />
        <meta property="fb:pages" content="100265333750" />
        <meta property="fb:pages" content="234770525256" />
        <meta property="fb:pages" content="98784919862" />
        <meta property="fb:pages" content="120829458202" />
        <meta property="fb:pages" content="124842870398" />
        <meta property="fb:pages" content="110245330325636" />
        <meta name="twitter:card" content="summary_large_image" />
        <meta name="twitter:site" content="@JAMA_current" />
        <meta name="twitter:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f1.png?Expires=2147483647&amp;Signature=WQmLYzkkQhOVSsjngPpsZIV1rFulm8iXycz7~U358Z2UCy5~d1rQyBcsfc5ex8ETOF635qbxjtQev3~snbATh4TzZdeDEZElkMB2ww09rjZKmmKC9TO66HbdvFxyXh1a7XqvYEffCbdUx0C5H8Sxo20G5pXfLNtM70zAXxmdCz5aUWbkLzw9hpzpJw5fRfX2KHDP5mrecka8VpFXw6np~tjLbx5sjAS3LdhVIhXeaor9k3TZSSd9LrsaXjV2EkAH7jfbzISWMPBfwhGEK9ZaMh2J0uYZ-SfqUwURp-D16mX5S1U0XAyfm60m2RyZwA2h5gXqq8eusUEpPGvd11KUUw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />




<script type="application/ld+json">
    {
  "@context": "https://schema.org/",
  "@type": "Article",
  "headline": "Aspirin Use and Survival After Diagnosis of Colorectal Cancer",
  "author": "Andrew T. Chan, MD, MPH",
  "url": "https://jamanetwork.com/journals/jama/fullarticle/184381",
  "datePublished": "2009-08-12",
  "description": "Context Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown. Objective To examine the association between aspirin use after colorectal cancer diagnosis on colorectal cancer−specific and overall survival. Design, Setting, and Participants Prospective cohort study of 1279 men and women diagnosed with stage I, II, or III colorectal cancer. Participants were enrolled in 2 nationwide health professional cohorts in 1980 and 1986 prior to diagnosis and followed up through June 1, 2008. Main Outcome Measure Colorectal cancer−specific and overall mortality. Results After a median follow-up of 11.8 years, there were 193 total deaths (35%) and 81 colorectal cancer−specific deaths (15%) among 549 participants who regularly used aspirin after colorectal cancer diagnosis, compared with 287 total deaths (39%) and 141 colorectal cancer−specific deaths (19%) among 730 participants who did not use aspirin. Compared with nonusers, participants who regularly used aspirin after diagnosis experienced a multivariate hazard ratio (HR) for colorectal cancer−specific mortality of 0.71 (95% confidence interval [CI], 0.53-0.95) and for overall mortality of 0.79 (95% CI, 0.65-0.97). Among 719 participants who did not use aspirin before diagnosis, aspirin use initiated after diagnosis was associated with a multivariate HR for colorectal cancer−specific mortality of 0.53 (95% CI, 0.33-0.86). Among 459 participants with colorectal cancers that were accessible for immunohistochemical assessment, the effect of aspirin differed significantly according to cyclooxygenase 2 (COX-2) expression ( P for interaction = .04). Regular aspirin use after diagnosis was associated with a lower risk of colorectal cancer−specific mortality among participants in whom primary tumors overexpressed COX-2 (multivariate HR, 0.39; 95% CI, 0.20-0.76), whereas aspirin use was not associated with lower risk among those with primary tumors with weak or absent expression (multivariate HR,...",
  "publisher": {
    "@type": "Organization",
    "name": "JAMA Network",
    "logo": {
      "@type": "ImageObject",
      "url": "//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico"
    }
  },
  "image": [
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f1.png?Expires=2147483647&Signature=WQmLYzkkQhOVSsjngPpsZIV1rFulm8iXycz7~U358Z2UCy5~d1rQyBcsfc5ex8ETOF635qbxjtQev3~snbATh4TzZdeDEZElkMB2ww09rjZKmmKC9TO66HbdvFxyXh1a7XqvYEffCbdUx0C5H8Sxo20G5pXfLNtM70zAXxmdCz5aUWbkLzw9hpzpJw5fRfX2KHDP5mrecka8VpFXw6np~tjLbx5sjAS3LdhVIhXeaor9k3TZSSd9LrsaXjV2EkAH7jfbzISWMPBfwhGEK9ZaMh2J0uYZ-SfqUwURp-D16mX5S1U0XAyfm60m2RyZwA2h5gXqq8eusUEpPGvd11KUUw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t1.png?Expires=2147483647&Signature=xqyXJ6CIGAhO1-0SxiBM1ZwP~EaRoVnjbIRhsySJFHQIejpckkjy5NPBf29FAn1Wolk7aDpmgsonzRHWylYLea31YOJH762v1c3mrZGT-WgbR5rUV0qcc-D4V9YRucXUS1m9xI0AW-p5DMk6ofUXRUL2bUuqXi5ZUzyjGq1mxeo2ubEjUWo-vY8xTyfk8YDMGXA4AtpX~Y8hmVfB1WQe6HQUFR95Q4rjX1uPH5-K7j7dYTbC6HeQLnFeAkiBHFurpgEeOMJl3iyAERANk2rNiCYyXZ9IGMT2VQ2oGWzX6FjXuhkQ5y6VBUT86AhIxsU1HpGLlPtG2ItGQUUWK7itJw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f2.png?Expires=2147483647&Signature=YXJBBte11~Wz48C1-i8qMcrPoqV58DDKHOoXRj5e~VaTJ0~mhsvEE57aQYz9q5oqzOtGWwN3P~Kf6a3F04G6lJBNDyZD-RqP~S-ohNFhFDzdJA9ZfpBvt9xYqLuoe-Mbx7RNY60Sl0qYvq8KwGdT-1mJ1UEJMbWjDdKeO1cBtQd~oQ9Nha3SuhgLjRghIHbX6WPNese-YOrdDGem2xWsYH3OrHFz-M~KZIAFApjdMhOZJj7sfxrE0RZyv5szK1oScc62PGAigOALTo6l9N8DBH7xxY3x8-x~7tM8tJoFqP8oyhM0aUvIGXvUce3mjmdh-35G6zzJw-sEmMcYy1nGkg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t2.png?Expires=2147483647&Signature=O-74jfen4CnxgBZUcctSyI-ijfgfD~OlQylDQw81BV5Sv7U9~algkpn9ARI7MYk~UTqCIz6M8Pf7gWqqq7BKjaETvAzP5l7WJJEtpJKl0bznP1o5gWzKubkhzCoTGFLyOf5ig8LmoRt8ZMmnWjNq8G8P1jYPRrDBNrhlyWRdCyfPdxgsUxZEglBpQSSqnWUW2jOpkfHVnOs6jYFihZqxxRQfhqkF3kUzvsq9Tda1HvfnB0w0k9l8QBoUmflCIQxoN8fmJnaTzEhpdHnSJgGsd1cps3IoShXVlLyVe3Cc2T2LNXYhQgmMjFD7RVeMyb-rlACEHgUQ5vZg9Cah1eGbsw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t3.png?Expires=2147483647&Signature=G5VcFihH39XWkIPqd1rM0qckeAgtFx8VE71mWCA-Jb0CIPCllnbXCPKiuM4vCDP8rG9WpeguEOAdOzQKmDM1O5KHuHJDM1xsc2g~P48qKEzGW3frJoMMQsBLjfYOXUOk4UpUXt-EBkvCRkLUn2qKEEEk-JoA7pHZzftoasc3-Mr~y-WvmPqrNSiPc5bvmuXhmZKSzIdWsbtS3h66qhpjuroVKFlnVRvqemBJwsBIkUD7C9i9RlSZGnT0OHZjGopbSvEHeN1D4H3nmCKpmmNifpxc6az26fvRPCd3HgniUAvb5FHgCDPZfBEDNnli~H1-sWIL5FTvi2bbiKUpOz8ZPA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f3.png?Expires=2147483647&Signature=nYpss6m0nflPBFwz05lkgNRDX5ShW-PDUlO8rd6PaqQJ0sbs0mnvOwKdGTphJzFuIKzQTMjWffn3NjbMyINxredGmpqGrRK-zyCKZF2dBy99BNGSS-n5AzSPaAHm0GZsSRYsQ4w5j3jI8StVPSq0xl8iVDi3JIr8GE6VP2x6yLvyWiLz5GaVGrsYmu13mrtJwikWROWOX0R0lBFJyEn22llBTr-ApoW7rpEkuqyV3oligZ3OpmO4mtUlf48AShyL0K3H7wGtKwuHhPMByqwq4ITj0sIAKPwpjPGNaRFvlQlr2ydnf-i0PE9RQHJYfFCBHDze8gN76dkoO0AKMHKunA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
  ],
  "articleSection": [
    "Methods",
    "Study Population",
    "Assessment of COX-2 Expression",
    "Ascertainment of Death",
    "Assessment of Medication Use",
    "Power Analysis",
    "Statistical Analysis",
    "Table 1. Baseline Characteristics of the Study Cohort by Aspirin Use a",
    "Results",
    "Table 2. Risk of Colorectal Cancer−Specific Mortality and Overall Mortality According to Use of Aspirin After Diagnosis a",
    "Table 3. Risk of Colorectal Cancer−Specific Mortality and Overall Mortality According to Dose of Aspirin Used After Colorectal Cancer Diagnosis a",
    "Comment"
  ],
  "keyWords": "aspirin, carcinoma of the large intestine, cyclooxygenase 2, neoplasms"
}
</script>
<meta name="citation_author" content="Andrew T. Chan" /><meta name="citation_author" content="Shuji Ogino" /><meta name="citation_author" content="Charles S. Fuchs" /><meta name="citation_title" content="Aspirin Use and Survival After Diagnosis of Colorectal Cancer" /><meta name="citation_firstpage" content="649" /><meta name="citation_lastpage" content="658" /><meta name="citation_doi" content="10.1001/jama.2009.1112" /><meta name="citation_keyword" content="aspirin" /><meta name="citation_keyword" content="colorectal cancer" /><meta name="citation_keyword" content="cyclooxygenase-2" /><meta name="citation_keyword" content="neoplasms" /><meta name="citation_abstract" content="&lt;h3&gt;Context&lt;/h3&gt;Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown.&lt;h3&gt;Objective&lt;/h3&gt;To examine the association between aspirin use after colorectal cancer diagnosis on colorectal cancer−specific and overall survival.&lt;h3&gt;Design, Setting, and Participants&lt;/h3&gt;Prospective cohort study of 1279 men and women diagnosed with stage I, II, or III colorectal cancer. Participants were enrolled in 2 nationwide health professional cohorts in 1980 and 1986 prior to diagnosis and followed up through June 1, 2008.&lt;h3&gt;Main Outcome Measure&lt;/h3&gt;Colorectal cancer−specific and overall mortality.&lt;h3&gt;Results&lt;/h3&gt;After a median follow-up of 11.8 years, there were 193 total deaths (35%) and 81 colorectal cancer−specific deaths (15%) among 549 participants who regularly used aspirin after colorectal cancer diagnosis, compared with 287 total deaths (39%) and 141 colorectal cancer−specific deaths (19%) among 730 participants who did not use aspirin. Compared with nonusers, participants who regularly used aspirin after diagnosis experienced a multivariate hazard ratio (HR) for colorectal cancer−specific mortality of 0.71 (95% confidence interval [CI], 0.53-0.95) and for overall mortality of 0.79 (95% CI, 0.65-0.97). Among 719 participants who did not use aspirin before diagnosis, aspirin use initiated after diagnosis was associated with a multivariate HR for colorectal cancer−specific mortality of 0.53 (95% CI, 0.33-0.86). Among 459 participants with colorectal cancers that were accessible for immunohistochemical assessment, the effect of aspirin differed significantly according to cyclooxygenase 2 (COX-2) expression (P for interaction = .04). Regular aspirin use after diagnosis was associated with a lower risk of colorectal cancer−specific mortality among participants in whom primary tumors overexpressed COX-2 (multivariate HR, 0.39; 95% CI, 0.20-0.76), whereas aspirin use was not associated with lower risk among those with primary tumors with weak or absent expression (multivariate HR, 1.22; 95% CI, 0.36-4.18).&lt;h3&gt;Conclusion&lt;/h3&gt;Regular aspirin use after the diagnosis of colorectal cancer is associated with lower risk of colorectal cancer−specific and overall mortality, especially among individuals with tumors that overexpress COX-2." /><meta name="citation_journal_title" content="JAMA" /><meta name="citation_journal_abbrev" content="JAMA" /><meta name="citation_volume" content="302" /><meta name="citation_issue" content="6" /><meta name="citation_publication_date" content="2009/08/12" /><meta name="citation_issn" content="0098-7484" /><meta name="citation_publisher" content="American Medical Association" /><meta name="citation_reference" content="citation_org=US Preventive Services Task Force; citation_title=The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force.;  citation_authors=Dubé  C; Rostom  A; Lewin  G;  citation_journal_title=Ann Intern Med;  citation_year=2007;  citation_volume=146;  citation_issue=5;  citation_pages=365-375; " /><meta name="citation_reference" content="citation_title=A randomized trial of aspirin to prevent colorectal adenomas.;  citation_authors=Baron  JA; Cole  BF; Sandler  RS;  citation_journal_title=N Engl J Med;  citation_year=2003;  citation_volume=348;  citation_issue=10;  citation_pages=891-899; " /><meta name="citation_reference" content="citation_title=A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.;  citation_authors=Sandler  RS; Halabi  S; Baron  JA;  citation_journal_title=N Engl J Med;  citation_year=2003;  citation_volume=348;  citation_issue=10;  citation_pages=883-890; " /><meta name="citation_reference" content="citation_title=Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.;  citation_authors=Benamouzig  R; Deyra  J; Martin  A;  citation_journal_title=Gastroenterology;  citation_year=2003;  citation_volume=125;  citation_issue=2;  citation_pages=328-336; " /><meta name="citation_reference" content="citation_org=ukCAP Trial Group; citation_title=Aspirin and folic acid for the prevention of recurrent colorectal adenomas.;  citation_authors=Logan  RF; Grainge  MJ; Shepherd  VC; Armitage  NC; Muir  KR;  citation_journal_title=Gastroenterology;  citation_year=2008;  citation_volume=134;  citation_issue=1;  citation_pages=29-38; " /><meta name="citation_reference" content="citation_org=APC Study Investigators; citation_title=Celecoxib for the prevention of sporadic colorectal adenomas.;  citation_authors=Bertagnolli  MM; Eagle  CJ; Zauber  AG;  citation_journal_title=N Engl J Med;  citation_year=2006;  citation_volume=355;  citation_issue=9;  citation_pages=873-884; " /><meta name="citation_reference" content="citation_org=PreSAP Trial Investigators; citation_title=Celecoxib for the prevention of colorectal adenomatous polyps.;  citation_authors=Arber  N; Eagle  CJ; Spicak  J;  citation_journal_title=N Engl J Med;  citation_year=2006;  citation_volume=355;  citation_issue=9;  citation_pages=885-895; " /><meta name="citation_reference" content="citation_org=APPROVe Trial Investigators; citation_title=A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.;  citation_authors=Baron  JA; Sandler  RS; Bresalier  RS;  citation_journal_title=Gastroenterology;  citation_year=2006;  citation_volume=131;  citation_issue=6;  citation_pages=1674-1682; " /><meta name="citation_reference" content="citation_title=Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.;  citation_authors=Chan  AT; Ogino  S; Fuchs  CS;  citation_journal_title=N Engl J Med;  citation_year=2007;  citation_volume=356;  citation_issue=21;  citation_pages=2131-2142; " /><meta name="citation_reference" content="citation_title=Aspirin and colon cancer-targeting prevention?;  citation_author=Markowitz  SD;  citation_journal_title=N Engl J Med;  citation_year=2007;  citation_volume=356;  citation_issue=21;  citation_pages=2195-2198; " /><meta name="citation_reference" content="citation_title=COX-2: a molecular target for colorectal cancer prevention.;  citation_authors=Brown  JR; DuBois  RN;  citation_journal_title=J Clin Oncol;  citation_year=2005;  citation_volume=23;  citation_issue=12;  citation_pages=2840-2855; " /><meta name="citation_reference" content="citation_title=Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.;  citation_authors=Eberhart  CE; Coffey  RJ; Radhika  A; Giardiello  FM; Ferrenbach  S; DuBois  RN;  citation_journal_title=Gastroenterology;  citation_year=1994;  citation_volume=107;  citation_issue=4;  citation_pages=1183-1188; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.;  citation_authors=Soumaoro  LT; Uetake  H; Higuchi  T; Takagi  Y; Enomoto  M; Sugihara  K;  citation_journal_title=Clin Cancer Res;  citation_year=2004;  citation_volume=10;  citation_issue=24;  citation_pages=8465-8471; " /><meta name="citation_reference" content="citation_title=The relationship between cyclooxygenase-2 expression and colorectal cancer.;  citation_authors=Sheehan  KM; Sheahan  K; O'Donoghue  DP;  citation_journal_title=JAMA;  citation_year=1999;  citation_volume=282;  citation_issue=13;  citation_pages=1254-1257; " /><meta name="citation_reference" content="citation_title=Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.;  citation_authors=Uchida  K; Schneider  S; Yochim  JM;  citation_journal_title=Clin Cancer Res;  citation_year=2005;  citation_volume=11;  citation_issue=9;  citation_pages=3363-3368; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.;  citation_authors=Ogino  S; Kirkner  GJ; Nosho  K;  citation_journal_title=Clin Cancer Res;  citation_year=2008;  citation_volume=14;  citation_issue=24;  citation_pages=8221-8227; " /><meta name="citation_reference" content="citation_title=Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer.;  citation_authors=Zhang  H; Sun  XF;  citation_journal_title=Am J Gastroenterol;  citation_year=2002;  citation_volume=97;  citation_issue=4;  citation_pages=1037-1041; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.;  citation_authors=Fux  R; Schwab  M; Thon  KP; Gleiter  CH; Fritz  P;  citation_journal_title=Clin Cancer Res;  citation_year=2005;  citation_volume=11;  citation_issue=13;  citation_pages=4754-4760; " /><meta name="citation_reference" content="citation_title=Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.;  citation_authors=Tomozawa  S; Nagawa  H; Tsuno  N;  citation_journal_title=Br J Cancer;  citation_year=1999;  citation_volume=81;  citation_issue=8;  citation_pages=1274-1279; " /><meta name="citation_reference" content="citation_title=Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.;  citation_authors=Williams  CS; Watson  AJ; Sheng  H; Helou  R; Shao  J; DuBois  RN;  citation_journal_title=Cancer Res;  citation_year=2000;  citation_volume=60;  citation_issue=21;  citation_pages=6045-6051; " /><meta name="citation_reference" content="citation_title=A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.;  citation_authors=Williams  CS; Sheng  H; Brockman  JA;  citation_journal_title=Neoplasia;  citation_year=2001;  citation_volume=3;  citation_issue=5;  citation_pages=428-436; " /><meta name="citation_reference" content="citation_title=The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.;  citation_authors=Yamauchi  T; Watanabe  M; Hasegawa  H;  citation_journal_title=Anticancer Res;  citation_year=2003;  citation_volume=23;  citation_issue=1A;  citation_pages=245-249; " /><meta name="citation_reference" content="citation_title=Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.;  citation_authors=Yao  M; Kargman  S; Lam  EC;  citation_journal_title=Cancer Res;  citation_year=2003;  citation_volume=63;  citation_issue=3;  citation_pages=586-592; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.;  citation_authors=Yao  M; Lam  EC; Kelly  CR; Zhou  W; Wolfe  MM;  citation_journal_title=Br J Cancer;  citation_year=2004;  citation_volume=90;  citation_issue=3;  citation_pages=712-719; " /><meta name="citation_reference" content="citation_title=Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.;  citation_authors=Yao  M; Zhou  W; Sangha  S;  citation_journal_title=Clin Cancer Res;  citation_year=2005;  citation_volume=11;  citation_issue=4;  citation_pages=1618-1628; " /><meta name="citation_reference" content="citation_title=Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803 [abstract].;  citation_authors=Fuchs  C; Meyerhardt  JA; Heseltine  DL;  citation_journal_title=J Clin Oncol;  citation_year=2005;  citation_volume=23;  citation_issue=suppl 16;  citation_pages=3530" /><meta name="citation_reference" content="citation_title=Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.;  citation_authors=Chan  AT; Giovannucci  EL; Meyerhardt  JA; Schernhammer  ES; Curhan  GC; Fuchs  CS;  citation_journal_title=JAMA;  citation_year=2005;  citation_volume=294;  citation_issue=8;  citation_pages=914-923; " /><meta name="citation_reference" content="citation_title=Aspirin dose and duration of use and risk of colorectal cancer in men.;  citation_authors=Chan  AT; Giovannucci  EL; Meyerhardt  JA; Schernhammer  ES; Wu  K; Fuchs  CS;  citation_journal_title=Gastroenterology;  citation_year=2008;  citation_volume=134;  citation_issue=1;  citation_pages=21-28; " /><meta name="citation_reference" content="citation_title=Reproducibility and validity of a semiquantitative food frequency questionnaire.;  citation_authors=Willett  WC; Sampson  L; Stampfer  MJ;  citation_journal_title=Am J Epidemiol;  citation_year=1985;  citation_volume=122;  citation_issue=1;  citation_pages=51-65; " /><meta name="citation_reference" content="citation_title=A prospective study of aspirin use and primary prevention of cardiovascular disease in women.;  citation_authors=Manson  JE; Stampfer  MJ; Colditz  GA;  citation_journal_title=JAMA;  citation_year=1991;  citation_volume=266;  citation_issue=4;  citation_pages=521-527; " /><meta name="citation_reference" content="citation_title=Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals.;  citation_authors=Rimm  EB; Giovannucci  E; Stampfer  M; Colditz  G; Litin  L; Willett  W;  citation_journal_title=Am J Epidemiol;  citation_year=1992;  citation_volume=135;  citation_issue=10;  citation_pages=1114-1126, discussion 1127-1136; " /><meta name="citation_reference" content="citation_title=Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.;  citation_authors=Giovannucci  E; Rimm  EB; Stampfer  MJ; Colditz  GA; Ascherio  A; Willett  WC;  citation_journal_title=Ann Intern Med;  citation_year=1994;  citation_volume=121;  citation_issue=4;  citation_pages=241-246; " /><meta name="citation_reference" content="citation_title=AJCC Cancer Staging Handbook.;  citation_authors=Greene  FL; Fleming  ID; Fritz  A; Balch  CM;  citation_text=6th ed. Page DL. New York, NY: Springer-Verlag; 2002; " /><meta name="citation_reference" content="citation_title=Physical activity and survival after colorectal cancer diagnosis.;  citation_authors=Meyerhardt  JA; Giovannucci  EL; Holmes  MD;  citation_journal_title=J Clin Oncol;  citation_year=2006;  citation_volume=24;  citation_issue=22;  citation_pages=3527-3534; " /><meta name="citation_reference" content="citation_title=Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.;  citation_authors=Ogino  S; Brahmandam  M; Cantor  M;  citation_journal_title=Mod Pathol;  citation_year=2006;  citation_volume=19;  citation_issue=1;  citation_pages=59-68; " /><meta name="citation_reference" content="citation_title=Test of the National Death Index.;  citation_authors=Stampfer  MJ; Willett  WC; Speizer  FE;  citation_journal_title=Am J Epidemiol;  citation_year=1984;  citation_volume=119;  citation_issue=5;  citation_pages=837-839; " /><meta name="citation_reference" content="citation_title=Test of the National Death Index and Equifax Nationwide Death Search.;  citation_authors=Rich-Edwards  JW; Corsano  KA; Stampfer  MJ;  citation_journal_title=Am J Epidemiol;  citation_year=1994;  citation_volume=140;  citation_issue=11;  citation_pages=1016-1019; " /><meta name="citation_reference" content="citation_title=Aspirin and the risk of colorectal cancer in women.;  citation_authors=Giovannucci  E; Egan  KM; Hunter  DJ;  citation_journal_title=N Engl J Med;  citation_year=1995;  citation_volume=333;  citation_issue=10;  citation_pages=609-614; " /><meta name="citation_reference" content="citation_title=A prospective study of aspirin use and the risk of colorectal adenoma.;  citation_authors=Chan  AT; Giovannucci  EL; Schernhammer  ES;  citation_journal_title=Ann Intern Med;  citation_year=2004;  citation_volume=140;  citation_issue=3;  citation_pages=157-166; " /><meta name="citation_reference" content="citation_title=Fundamentals of Biostatistics.;  citation_author=Rosner  B;  citation_text=5th ed. Pacific Grove, CA: Duxbury Thomson Learning; 2000; " /><meta name="citation_reference" content="citation_title=The combination of estimates from different experiments.;  citation_author=Cochran  WG;  citation_journal_title=Biometrics;  citation_year=1954;  citation_volume=10;  citation_issue=1;  citation_pages=101-129; " /><meta name="citation_reference" content="citation_title=Applied Logistic Regression.;  citation_authors=Hosmer  DW; Lemeshow  S;  citation_text=2nd ed. Hoboken, NJ: John Wiley &amp; Sons, Inc; 2000; " /><meta name="citation_reference" content="citation_title=Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis.;  citation_authors=Gum  PA; Thamilarasan  M; Watanabe  J; Blackstone  EH; Lauer  MS;  citation_journal_title=JAMA;  citation_year=2001;  citation_volume=286;  citation_issue=10;  citation_pages=1187-1194; " /><meta name="citation_reference" content="citation_title=Inhibition of NF-kappa B by sodium salicylate and aspirin.;  citation_authors=Kopp  E; Ghosh  S;  citation_journal_title=Science;  citation_year=1994;  citation_volume=265;  citation_issue=5174;  citation_pages=956-959; " /><meta name="citation_reference" content="citation_title=Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation.;  citation_authors=Schwenger  P; Bellosta  P; Vietor  I; Basilico  C; Skolnik  EY; Vilcek  J;  citation_journal_title=Proc Natl Acad Sci U S A;  citation_year=1997;  citation_volume=94;  citation_issue=7;  citation_pages=2869-2873; " /><meta name="citation_reference" content="citation_title=Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.;  citation_authors=Martinez  ME; O'Brien  TG; Fultz  KE;  citation_journal_title=Proc Natl Acad Sci U S A;  citation_year=2003;  citation_volume=100;  citation_issue=13;  citation_pages=7859-7864; " /><meta name="citation_reference" content="citation_title=Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.;  citation_authors=Lundholm  K; Gelin  J; Hyltander  A;  citation_journal_title=Cancer Res;  citation_year=1994;  citation_volume=54;  citation_issue=21;  citation_pages=5602-5606; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.;  citation_authors=Masunaga  R; Kohno  H; Dhar  DK;  citation_journal_title=Clin Cancer Res;  citation_year=2000;  citation_volume=6;  citation_issue=10;  citation_pages=4064-4068; " /><meta name="citation_reference" content="citation_title=Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.;  citation_authors=Cianchi  F; Cortesini  C; Bechi  P;  citation_journal_title=Gastroenterology;  citation_year=2001;  citation_volume=121;  citation_issue=6;  citation_pages=1339-1347; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.;  citation_authors=Tomozawa  S; Tsuno  NH; Sunami  E;  citation_journal_title=Br J Cancer;  citation_year=2000;  citation_volume=83;  citation_issue=3;  citation_pages=324-328; " /><meta name="citation_reference" content="citation_title=COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome.;  citation_authors=Petersen  S; Haroske  G; Hellmich  G; Ludwig  K; Petersen  C; Eicheler  W;  citation_journal_title=Anticancer Res;  citation_year=2002;  citation_volume=22;  citation_issue=2B;  citation_pages=1225-1230; " /><meta name="citation_reference" content="citation_title=Expression of cyclooxygenase-2 protein in colorectal carcinomas.;  citation_authors=Joo  YE; Kim  HS; Min  SW;  citation_journal_title=Int J Gastrointest Cancer;  citation_year=2002;  citation_volume=31;  citation_issue=1-3;  citation_pages=147-154; " /><meta name="citation_reference" content="citation_title=Prognostic importance of COX-2 expression in patients with colorectal cancer.;  citation_authors=Yamac  D; Celenkoglu  G; Coskun  U;  citation_journal_title=Pathol Res Pract;  citation_year=2005;  citation_volume=201;  citation_issue=7;  citation_pages=497-502; " /><meta name="citation_reference" content="citation_title=Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.;  citation_authors=Sheng  H; Shao  J; Kirkland  SC;  citation_journal_title=J Clin Invest;  citation_year=1997;  citation_volume=99;  citation_issue=9;  citation_pages=2254-2259; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase regulates angiogenesis induced by colon cancer cells.;  citation_authors=Tsujii  M; Kawano  S; Tsuji  S; Sawaoka  H; Hori  M; DuBois  RN;  citation_journal_title=Cell;  citation_year=1998;  citation_volume=93;  citation_issue=5;  citation_pages=705-716; " /><meta name="citation_reference" content="citation_title=Host cyclooxygenase-2 modulates carcinoma growth.;  citation_authors=Williams  CS; Tsujii  M; Reese  J; Dey  SK; DuBois  RN;  citation_journal_title=J Clin Invest;  citation_year=2000;  citation_volume=105;  citation_issue=11;  citation_pages=1589-1594; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.;  citation_authors=Tsujii  M; Kawano  S; DuBois  RN;  citation_journal_title=Proc Natl Acad Sci USA;  citation_year=1997;  citation_volume=94;  citation_issue=7;  citation_pages=3336-3340; " /><meta name="citation_reference" content="citation_title=Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2–selective inhibitor, etodolac.;  citation_authors=Chen  WS; Wei  SJ; Liu  JM; Hsiao  M; Kou-Lin  J; Yang  WK;  citation_journal_title=Int J Cancer;  citation_year=2001;  citation_volume=91;  citation_issue=6;  citation_pages=894-899; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.;  citation_authors=Trifan  OC; Durham  WF; Salazar  VS;  citation_journal_title=Cancer Res;  citation_year=2002;  citation_volume=62;  citation_issue=20;  citation_pages=5778-5784; " /><meta name="citation_reference" content="citation_title=Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.;  citation_authors=Lin  J; Hsiao  PW; Chiu  TH; Chao  JI;  citation_journal_title=Biochem Pharmacol;  citation_year=2005;  citation_volume=70;  citation_issue=5;  citation_pages=658-667; " /><meta name="citation_reference" content="citation_title=A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells.;  citation_authors=Goel  A; Chang  DK; Ricciardiello  L; Gasche  C; Boland  CR;  citation_journal_title=Clin Cancer Res;  citation_year=2003;  citation_volume=9;  citation_issue=1;  citation_pages=383-390; " /><meta name="citation_reference" content="citation_title=Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.;  citation_authors=Sheng  H; Shao  J; Washington  MK; DuBois  RN;  citation_journal_title=J Biol Chem;  citation_year=2001;  citation_volume=276;  citation_issue=21;  citation_pages=18075-18081; " /><meta name="citation_reference" content="citation_title=Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor.;  citation_authors=Buchanan  FG; Chang  W; Sheng  H; Shao  J; Morrow  JD; DuBois  RN;  citation_journal_title=Gastroenterology;  citation_year=2004;  citation_volume=127;  citation_issue=5;  citation_pages=1391-1400; " /><meta name="citation_reference" content="citation_title=Systemic therapy for colorectal cancer.;  citation_authors=Meyerhardt  JA; Mayer  RJ;  citation_journal_title=N Engl J Med;  citation_year=2005;  citation_volume=352;  citation_issue=5;  citation_pages=476-487; " /><meta name="citation_reference" content="citation_title=Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.;  citation_author=Arber  N;  citation_journal_title=Cancer Epidemiol Biomarkers Prev;  citation_year=2008;  citation_volume=17;  citation_issue=8;  citation_pages=1852-1857; " /><meta name="citation_fulltext_world_readable" content="" /><meta name="citation_pdf_url" content="https://jamanetwork.com/journals/jama/articlepdf/184381/joc90066_649_659.pdf" />

    
        <title>Aspirin Use and Survival After Diagnosis of Colorectal Cancer | Colorectal Cancer | JAMA | JAMA Network</title>

    <meta name="description" content="ContextAspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence">


    <link rel="canonical" href="https://jamanetwork.com/journals/jama/fullarticle/184381" />









    
    <script src="//cdn.jamanetwork.com/UI/app/dist/head.min.js?v=638488852268208351"></script>
     
     <script src="https://r451.jamanetwork.com/script.js"></script>
        <div class="widget-WidgetLoader widget-instance-AMA_AdTag_HeaderScript">
        
    <meta class="SCM-SharedWidgets-AsyncHeaderAdLoader" data-url="/AMA/AdTag/AMA_AdTag_HeaderScript" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:0,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}">
 
    </div>
</head>

<body data-sitename="jama" class="pg_article " data-thm="jama">
    
    <script>
        
        var App = App || {};
        App.suppressAds = App.suppressAds || !!document.getElementsByClassName('suppress-ads').length;
        App.suppressGtm = App.suppressGtm || !!document.getElementsByClassName('suppress-gtm').length;
    </script>

    

        <div id="ad-interstitial" class="ad-interstitial">
            <script>
      googletag.cmd.push(function() {
        if (App.suppressAds) { return; }
        App.Ads.slots[13] = googletag.defineOutOfPageSlot(App.Ads.adPath + '/scholarly', 'ad-interstitial')
          .setTargeting('pos', ['interstitial'])
          .addService(googletag.pubads());
        googletag.display('ad-interstitial');
        googletag.pubads().refresh([App.Ads.slots[13]], {changeCorrelator: false});
      });
            </script>
        </div>




    
    <a class="accessible js-skip-to-navigation" href="#skip-to-navigation">[Skip to Navigation]</a>

    <!-- Google Tag Manager --><noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-WNKSNP" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WNKSNP');</script><!-- End Google Tag Manager -->

    
    
    <span class="hide tagmanagervalue" data-attribute="productName" data-value="JAMA" data-type="string"></span>
    <form method="post" action="./184381" id="webform" class="m0">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="jvm6PJ0kxaml5hMyb25PBzUnrtWSOj5m0/XdUSu4VRa8E8wEY9YboT+Kd7IDai0SbZGNSqERf1wnPMDBMbMz7nCcuuk=" />

<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="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" />
        
        <input id="hdnSiteID" type="hidden" value="3" />
        <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

        
        

        
        

    <section class="master-header">
        


<script type='text/javascript'>
    var App = App || {};
    App.LoginUserInfo = {
        isInstLoggedIn: [0],
        currentSessionId: 'wzq4p22oaakj0ogq1zfno3ak'
    };
</script>



<input name="ctl00$ctl00$BodyContent$Header$hfGlobalSearchSiteURL" type="hidden" id="hfGlobalSearchSiteURL" value="https://jamanetwork.com/" />

<input name="ctl00$ctl00$BodyContent$Header$hfAppIsPaidUser" type="hidden" id="hfAppIsPaidUser" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsMember" type="hidden" id="hfAppIsMember" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppSubscribedTo" type="hidden" id="hfAppSubscribedTo" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsIndividual" type="hidden" id="hfAppIsIndividual" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppHasAccess" type="hidden" id="hfAppHasAccess" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsReferredFromGoogle" type="hidden" id="hfAppIsReferredFromGoogle" value="False" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrAutoSuggestMinimumCharactersLength" type="hidden" id="hfSolrAutoSuggestMinimumCharactersLength" value="2" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalName" type="hidden" id="hfSolrJournalName" value="JAMA" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalID" type="hidden" id="hfSolrJournalID" value="J67" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsLucy" type="hidden" id="hfAppIsLucy" value="false" />


<div class="header-wrap">
    <header class="header">
            <div class="widget-GdprCookieBanner widget-instance-GdprCookieBanner">
        <div class="gdpr-cookie-wrapper js-gdpr-banner">
	<div class="gdpr-cookie-body">
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our <a href="https://jamanetwork.com/pages/privacy-policy#cookies">Cookie Policy</a>&nbsp;<span class="pipe">|</span>&nbsp;<a href="javascript:;" class="js-gdpr-cookie-acceptLink at-acceptgdpr">Continue</a>	</div>
            <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

    <input id="hdnDomainGdpr" type="hidden" value=".jamanetwork.com" />
    <input id="hdnClientIdGdpr" type="hidden" value="3" />

</div> 
    </div>

        <div class="network-bar">
            <a class="jama-network" href="/" title="JAMA Network Home">
                <img alt="JAMA Network Home" class="title-image" width="443" height="52" src="//cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg">
            </a>
            
        </div>

        <a class="nav-toggler" href="#nav">
            <div class="nav-toggler-indicator">
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
            </div>
            <div class="nav-toggler-site">
                <span id="BodyContent_Header_siteFullNamenav" class="nav-toggler-microsite"><span class='network'>JAMA</span></span>
            </div>
        </a>
        <nav id="nav" class="nav hide" >
            <div class="nav-journal-level sb-nav-journal-level">
                <a href="https://jamanetwork.com/journals/jama" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_0" class="home">Home</a><a href="https://jamanetwork.com/journals/jama/newonline" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_1" class="new-online">New Online</a><a href="https://jamanetwork.com/journals/jama/currentissue" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_2" class="current-issue">Current Issue</a><a href="https://jamanetwork.com/journals/jama/pages/for-authors" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_3" class="for-authors">For Authors</a>
            </div>
            <div class="nav-journals">
                    <div class="widget-SelfServeContent widget-instance-HamburgerPublicationMenu">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="HamburgerPublicationMenu" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals {margin-bottom: 1em;}
    .nav-heading {color: #B9B9B9;border-bottom: 1px solid #242424;border-top: 1px solid #242424;font-size: 1.15em;font-weight: 400;margin: 0;padding: .7em .75em;text-transform: uppercase;}
    a.no-bullet:before {content:none !important;}
    .nav-heading {font-size: 1.15em;margin-bottom:0;padding-left: 38px;}
    .nav-journals a.theme-jama {background-color: #242424;border-bottom: 1px solid #fff;border-top: 1px solid #fff;color: #fff;font-size: 1.15em;margin-bottom: 8px;padding: 11px 0 9px 37px;}
    .nav-journals a.theme-jama::before {background: unset;content: "\e91b";display: none;font-family: ama_icons !important;font-size: 1.25em;line-height: 1;}
    .nav-journals a.theme-jama-network-open {border-bottom:0;}
    .nav .widget-instance-HamburgerPublicationMenu a {padding-left: 36px;}
    .fake-ribbon {border-left: 8px solid #BE1E32;}
    .fake-ribbon a:before {content:none;}
    .nav .widget-instance-HamburgerPublicationMenu .fake-ribbon a {padding-left:30px;}
</style>
<h2 class="nav-heading">Journals</h2>
<a href="/journals/jama" class="theme-jama">JAMA</a>
<a href="/journals/jamanetworkopen" class="theme-jama-network-open">JAMA Network Open</a>
<a href="/journals/jamacardiology" class="theme-jama-cardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology" class="theme-jama-dermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum" class="theme-jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine" class="theme-jama-internal-medicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology" class="theme-jama-neurology">JAMA Neurology</a>
<a href="/journals/jamaoncology" class="theme-jama-oncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology" class="theme-jama-ophthalmology">JAMA Ophthalmology </a>
<a href="/journals/jamaotolaryngology" class="theme-jama-otolaryngology-head-neck-surgery">JAMA Otolaryngology–Head &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics" class="theme-jama-pediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry" class="theme-jama-psychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery" class="theme-jama-surgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc" class="theme-archives-of-neurology-psychiatry-1919-1959-">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
<h2 class="nav-heading">Podcasts</h2>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/pages/audio" class="no-bullet">More</a>


</div>

 
    </div>
    
            </div>
            <div class="nav-network-other">
                <a href="https://edhub.ama-assn.org/jn-learning" id="BodyContent_Header_rptOtherResources_aItemResourceList_0" class="is-b link-jn-learning-cme" target="_blank">JN Learning / CME</a><a href="https://store.jamanetwork.com/index.aspx?productcode=64" id="BodyContent_Header_rptOtherResources_aItemResourceList_1" class="is-b link-subscribe" target="_blank">Subscribe</a><a href="https://careers.jamanetwork.com/" id="BodyContent_Header_rptOtherResources_aItemResourceList_2" class="is-b link-jobs" target="_blank">Jobs</a><a href="https://jamanetwork.com/pages/resources-for-librarians" id="BodyContent_Header_rptOtherResources_aItemResourceList_3" class="is-b link-institutions-librarians">Institutions / Librarians</a><a href="https://jamanetwork.com/pages/reprints-and-permissions" id="BodyContent_Header_rptOtherResources_aItemResourceList_4" class="is-b link-reprints-permissions" rel="nofollow">Reprints &amp; Permissions</a>
            </div>
            <div class="white text-xxs">
                <div class="p05 ml4 mr3 mb1 mt10 flex hamburger-menu-legal">
                    <a href="/pages/conditions-of-use" class="p0" rel="nofollow">Terms of Use</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/privacy-policy" class="p0" rel="nofollow">Privacy Policy</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/accessibility-statement" class="p0" rel="nofollow">Accessibility Statement</a>
                </div>
                <div class="ta-c">
                    <span class="pb1">2024 American Medical Association. All Rights Reserved</span>
                </div>
            </div>
        </nav>

        

        
        <a class="toolbar-search-trigger is-b" data-mobile-tog-target=".site-search"></a>

        
        <div id="site-search" role="search" class="site-search">
            <div class="site-search-bar">
                
                <div role="search">
                    <select name="ctl00$ctl00$BodyContent$Header$ddlForSearch" id="BodyContent_Header_ddlForSearch" Name="dropDownList" class="cs-select cs-skin-border" title="Search Site Selector" role="options" aria-labelledby="searchLabel">
	<option value="J*">Search All</option>
	<option value="3">JAMA</option>
	<option value="214">JAMA Network Open</option>
	<option value="192">JAMA Cardiology</option>
	<option value="12">JAMA Dermatology</option>
	<option value="261">JAMA Forum Archive</option>
	<option value="193">JAMA Health Forum</option>
	<option value="15">JAMA Internal Medicine</option>
	<option value="16">JAMA Neurology</option>
	<option value="159">JAMA Oncology</option>
	<option value="17">JAMA Ophthalmology</option>
	<option value="18">JAMA Otolaryngology–Head &amp; Neck Surgery</option>
	<option value="19">JAMA Pediatrics</option>
	<option value="14">JAMA Psychiatry</option>
	<option value="20">JAMA Surgery</option>
	<option value="23">Archives of Neurology &amp; Psychiatry</option>

</select>
                </div>
                
                <div class="search-input-container">
                    <input type="search" name="textbox" autocomplete="off" role="textbox" id="search-term" aria-labelledby="searchLabel" class="search-term at-microsite-search-term" placeholder="Enter Search Term" maxlength="255" title="Enter Search Term">
                  
                    <ul id="umbrellaSiteAutoCompleteResults" class="term-list hidden"></ul>
                    
                    <label style="display:none" for="umbrellaSiteSearchInputHint" id="searchLabel">Input Search Term</label>
                      <input class="searchTerm search-input" name="textbox" role="textbox" type="text" id="umbrellaSiteSearchInputHint" aria-labelledby="searchLabel" title="Input Search Term" autocomplete="off">
                </div>
                <!-- /.search-input-container -->
                
                <a name="button" role="button" class="search-button is-b" alt="search button" href="javascript:;"></a>
            </div>
        </div>
        
        <div id="BodyContent_Header_GlobalSignIn_auth" class="auth">
            <a class="auth--trigger is-b is-a" href="javascript:;">
                <span id="BodyContent_Header_GlobalSignIn_spnUserFullName" class="user-full-name">Sign In</span>
            </a>

            <div class="auth--dropdown js-signIn-dropdown">
                
                <div class="auth--option auth--ind">
                    
                    <div id="BodyContent_Header_GlobalSignIn_divUserFullName" class="auth--ind-user"></div>                    
                    
                    <div id="BodyContent_Header_GlobalSignIn_divIndSignIn" class="auth--ind-auth">
                        <div class="auth--title">Individual Sign In</div>
                        <a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381" id="BodyContent_Header_GlobalSignIn_oauthSignInLink" rel="nofollow" class="auth--ind-sign-in">Sign in</a><a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381" id="BodyContent_Header_GlobalSignIn_oauthSignUpLink" rel="nofollow" class="auth--ind-create">Create an Account</a>
                    </div>
                </div>

                
                <div id="BodyContent_Header_GlobalSignIn_divInstSignIn" class="auth--option auth--inst">

                    
                    
                    <div class="auth--inst-auth">
                        <div class="auth--title">Access through your institution</div>
                        <a href="/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381" id="BodyContent_Header_GlobalSignIn_institutionSignIn" rel="nofollow" class="auth--shib">Sign In</a>
                    </div>
                    </div>
 
                                               
                <div id="BodyContent_Header_GlobalSignIn_divPurchaseOptions" class="auth--option auth--purchase">
                    <div class="auth--title">Purchase Options:</div>
                    
                    <a id="BodyContent_Header_GlobalSignIn_lnkSubscribeJournal" class="auth--subscribe" rel="nofollow" href="https://store.jamanetwork.com/index.aspx?productcode=64">Subscribe to the JAMA journal</a>
                </div>

                
                

                
            </div>
        </div>




    </header>
</div>


<div class="editors-choice-header">
</div>

<div id="BodyContent_Header_divAds" class="header-ad-wrap sb-background-primary-dark">
        <div class="leader-ad desktop-only">
            
                <div class="widget-WidgetLoader widget-instance-AMA_AdTag_LeaderboardAd">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_LeaderboardAd" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:1,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;atf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

        </div>
    </div>

<!-- /.header-ad-wrap -->


    </section>


    <section class="master-main">
        
    <div class="social-share hide" data-share-journal="JAMA_current" data-share-title="Aspirin Use and Survival After Diagnosis of Colorectal Cancer"></div>

        <div class="widget-UserContentAccessWrite widget-instance-AMA_LocalStorage_Article">
        <div class="SCM-SharedWidgets-LocalStorage-UserContentAccessWrite" data-values='{"id":"184381","type":"Article","date":"5/5/2024 7:29:15 AM"}'></div>
 
    </div>
    <div class="widget-ArticleToggleView widget-instance-AMA_ArticleToggleView">
        
    <div class="widget-ArticleFullView widget-instance-AMA_ArticleFullView">
        
<script>
    (function () {
        var bodyElem = document.querySelector('body');
        var className = 'split-screen';

        if (bodyElem.classList) {
            bodyElem.classList.add(className);
        } else {
            el.className += ' ' + className;
        }
    })();
</script>


<div id="resources-panel" class="resources-panel">
                <span class="hide tagmanagervalue" data-attribute="template" data-value="splitscreen" data-type="string"></span>


    <div class="tab-nav">
        <a class="tab-nav-trigger tab-nav-full-text tablet-down" href="#full-text-tab">
            <i class="icon-full_text"><span class="sr-t">full text icon</span></i>
            <div class="tab-nav-tab-name">Full Text</div>
        </a>
        <a class="tab-nav-trigger tab-nav-contents target-tab-active" href="#contents-tab">
            <i class="icon-contents"><span class="sr-t">contents icon</span></i>
            <div class="tab-nav-tab-name">Contents</div>
        </a>
        <a class="tab-nav-trigger tab-nav-figure-table" href="#figure-table-tab">
            <i class="icon-figures"><span class="sr-t">figure icon</span></i>
            <div class="tab-nav-tab-name">Figures / <br> Tables</div>
        </a>
        <a class="tab-nav-trigger tab-nav-multimedia" href="#multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="tab-nav-tab-name">Multimedia</div>
        </a>
        <a class="tab-nav-trigger tab-nav-supplemental" href="#supplemental-tab">
            <i class="icon-attach"><span class="sr-t">attach icon</span></i>
            <div class="tab-nav-tab-name">Supplemental <br> Content</div>
        </a>
        <a class="tab-nav-trigger tab-nav-references" href="#references-tab">
            <i class="icon-references"><span class="sr-t">references icon</span></i>
            <div class="tab-nav-tab-name">References</div>
        </a>
        <a class="tab-nav-trigger tab-nav-related" href="#related-tab">
            <i class="icon-related"><span class="sr-t">related icon</span></i>
            <div class="tab-nav-tab-name">Related</div>
        </a>
        <a class="tab-nav-trigger tab-nav-comments" href="#comments-tab">
            <i class="icon-user-comments"><span class="sr-t">comments icon</span></i>
            <div class="tab-nav-tab-name">Comments</div>
        </a>
    </div>



    <div class="resource-tabs">
        <div id="contents-tab" class="resource-tab js-resource-tab contents-tab tab-active">
            <div class="contents-tab-contents">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="184381" data-article-url="/journals/jama/articlepdf/184381/joc90066_649_659.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>
    <div class="widget-ArticleJumpLinks widget-instance-AMA_ArticleJumpLinks_Widget">
            <a href="#top" class="section-jump-link contents-tab-jump-link top-of-article" data-tab-toggle=".tab-nav-full-text">Top of Article</a>
    <ul class="section-jump-links bullet ml2 pl1">
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#24828434" data-tab-toggle=".tab-nav-full-text">Abstract</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#24828438" data-tab-toggle=".tab-nav-full-text">Methods</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#24828472" data-tab-toggle=".tab-nav-full-text">Results</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#24828487" data-tab-toggle=".tab-nav-full-text">Comment</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#24828500" data-tab-toggle=".tab-nav-full-text">Article Information</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#24828501" data-tab-toggle=".tab-nav-full-text">References</a></li>
    </ul>
 
    </div>
    <div class="widget-SelfServeContent widget-instance-AMA_Contents_Tab_SelfServe">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="v2_article_content_tab" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="bc_right_rail_article_promo"><!-- Content Goes Here --></div>


</div>

 
    </div>

            </div>
            <div class="contents-tab-ad">
                <div id="split-screen-contab"></div>
            </div>
        </div>

        
        <div id="figure-table-tab" class="resource-tab js-resource-tab figure-table-tab need-jobs-ad">
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Figures_Tab">
        <div class="figure-table-wrapper thm-bd-top"><div class="figure-label"><strong>Figure 1.</strong> COX-2 Immunohistochemistry in Colorectal Cancer</div><a id="joc90066f1" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc90066f1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f1.png?Expires=1717540240&amp;Signature=frVbcPjwCgQmHKN~VxIfvcSYh9a8Bwvk0dUEDaLWF0-brTF~Ohgbpu70qwm7DNR1u2S44-M3VfA8j3bJzVMVIaf~5RNUV0tD72GfBZc1Uf4Jvx6pBLEHV1EpbzOp4fnFLo26VGgKnpbiEURB6JyttgBz5znXzAgDLN-J6-eSF9pSg4-PdBlAjmdrdZRtZ6Tnx15o9ViBnT~rp9XbNOaQFdOzom8TsNdBwuHSvSNQlRBFW0vpfONRIyHcHXbxDGwRkRkw31-HF6odPiJ3xgVvHdi0O0MtUvFrghRHtO4PgVYfQjkf-dnKRe4oK7gdeNkAssFcrRelNSky5gHSd-S3EQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc90066f1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f1.png?Expires=1717540240&Signature=frVbcPjwCgQmHKN~VxIfvcSYh9a8Bwvk0dUEDaLWF0-brTF~Ohgbpu70qwm7DNR1u2S44-M3VfA8j3bJzVMVIaf~5RNUV0tD72GfBZc1Uf4Jvx6pBLEHV1EpbzOp4fnFLo26VGgKnpbiEURB6JyttgBz5znXzAgDLN-J6-eSF9pSg4-PdBlAjmdrdZRtZ6Tnx15o9ViBnT~rp9XbNOaQFdOzom8TsNdBwuHSvSNQlRBFW0vpfONRIyHcHXbxDGwRkRkw31-HF6odPiJ3xgVvHdi0O0MtUvFrghRHtO4PgVYfQjkf-dnKRe4oK7gdeNkAssFcrRelNSky5gHSd-S3EQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=24828447&ar=184381&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f1.png?Expires=1717540240&amp;Signature=frVbcPjwCgQmHKN~VxIfvcSYh9a8Bwvk0dUEDaLWF0-brTF~Ohgbpu70qwm7DNR1u2S44-M3VfA8j3bJzVMVIaf~5RNUV0tD72GfBZc1Uf4Jvx6pBLEHV1EpbzOp4fnFLo26VGgKnpbiEURB6JyttgBz5znXzAgDLN-J6-eSF9pSg4-PdBlAjmdrdZRtZ6Tnx15o9ViBnT~rp9XbNOaQFdOzom8TsNdBwuHSvSNQlRBFW0vpfONRIyHcHXbxDGwRkRkw31-HF6odPiJ3xgVvHdi0O0MtUvFrghRHtO4PgVYfQjkf-dnKRe4oK7gdeNkAssFcrRelNSky5gHSd-S3EQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc90066f1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/m_joc90066f1.png?Expires=1717540240&amp;Signature=KeMbtWwCp0X5jPYkLgxa33Nstea2sXLymI2c4Yk1gkRWYA0NBPwzdK39eHs881UuZvVIqnylKKTSPuW~Q2UViL9VLi2BE~HFIp6CkKo-FSB4DhtMl58I1m2pD7sxeIYUjdXdi8bYdTXq7aMWwFZPQH3WO0Z6ouuzIwHyG~H8MAGWF5vYDuKrVfAQMq7Hko0e9RN6r8Vznb1JuCSMOt0HNTzl7k3y~N4pmPUkd9iYuYdxW3IcXr77CVFtJaK4HR5OczQMlm7osG8wahjP2llOuWk7yXRp-rKKz83Wv61cXzvb3oBqDDK7FOlTjhT8NDp~hWZDJ1w-oJu~AoBCjRz87Q__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 1. COX-2 Immunohistochemistry in Colorectal Cancer" class="content-img lazy" path-from-xml="joc90066f1" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">Primary anti−cyclooxygenase 2 (COX-2) antibody diluted 1:300 in phosphate-buffered saline was applied overnight at 4°C. We then applied secondary anti-mouse antibody for 20 minutes followed by avidin-biotin complex conjugate. Sections were visualized by diaminobenzidine and methyl-green counterstain. A, Representative section from a COX-2–negative tumor (original magnification ×400). The gray arrowheads indicate colorectal cancer cells without COX-2 overexpression. B, Representative section from a COX-2–positive tumor (original magnification ×400). Black arrowheads indicate colorectal cancer cells with strong COX-2 expression (dark brown color) compared with normal colonic epithelium indicated by white arrowheads.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label"><strong>Figure 2.</strong> Survival According to Aspirin Use After Diagnosis</div><a id="joc90066f2" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc90066f2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f2.png?Expires=1717540240&amp;Signature=1BjA2424FHJ2YyyvbyMSUvfZBzC~plZd-Q6QYvnUwOie8Bro5BCwLn8fR9Iu9hWV5goRMOWPtGN4bdE8YiN6CcmtUtzW25iGVOeOP~CCL42UPQNupWjry~N92FOO3dkF2rl9H7R3t-Vnio~W8GcwEa-lrXErojJfIhUbIvMsrYa4PpYik0lcxU2Y5Zt6kc46M2Vbi2MTYUPuXXFa2g~8gt4U1FPqKVot0UV3yRDoX~J2wwlyJdvOHT~JinnDT6OEO7846qYEywtvtVAY7snIxBKXoyvVoHHXZencQFIt6SGKAWh-MyUGO9--FsrW~FHagxdhYt5sdYe9LkXq3nGQgQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc90066f2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f2.png?Expires=1717540240&Signature=1BjA2424FHJ2YyyvbyMSUvfZBzC~plZd-Q6QYvnUwOie8Bro5BCwLn8fR9Iu9hWV5goRMOWPtGN4bdE8YiN6CcmtUtzW25iGVOeOP~CCL42UPQNupWjry~N92FOO3dkF2rl9H7R3t-Vnio~W8GcwEa-lrXErojJfIhUbIvMsrYa4PpYik0lcxU2Y5Zt6kc46M2Vbi2MTYUPuXXFa2g~8gt4U1FPqKVot0UV3yRDoX~J2wwlyJdvOHT~JinnDT6OEO7846qYEywtvtVAY7snIxBKXoyvVoHHXZencQFIt6SGKAWh-MyUGO9--FsrW~FHagxdhYt5sdYe9LkXq3nGQgQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=24828475&ar=184381&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f2.png?Expires=1717540240&amp;Signature=1BjA2424FHJ2YyyvbyMSUvfZBzC~plZd-Q6QYvnUwOie8Bro5BCwLn8fR9Iu9hWV5goRMOWPtGN4bdE8YiN6CcmtUtzW25iGVOeOP~CCL42UPQNupWjry~N92FOO3dkF2rl9H7R3t-Vnio~W8GcwEa-lrXErojJfIhUbIvMsrYa4PpYik0lcxU2Y5Zt6kc46M2Vbi2MTYUPuXXFa2g~8gt4U1FPqKVot0UV3yRDoX~J2wwlyJdvOHT~JinnDT6OEO7846qYEywtvtVAY7snIxBKXoyvVoHHXZencQFIt6SGKAWh-MyUGO9--FsrW~FHagxdhYt5sdYe9LkXq3nGQgQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc90066f2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/m_joc90066f2.png?Expires=1717540240&amp;Signature=ADNBo3Hcuzk24batjmAHkdCGGM~B6s7Jal6o9iO88k~LmjrC8DwM7ktXthCmXvLKKlB89TPXtgMqQQ5UtHn25d1DdbOs25njdHNxQ9F3gU4qn6w4vPNe2tFV7JbnhBzBNTekcKbxWytoyAAkfX5dy~hll-PLf2oX3mnbv2iGSloogQXjVhbWSke2MsY64o2cSxLbYL4eOU0TDP52eDvmYJW~gpDH5-JwtVIMOOYH1ihbN6l5lcXKSG-sJON7SjDLhPJEDu2yrHySmZB0oawUfrmDYo4gq4a16VTmiEyjHVvFHfWFpIctNgxabjE78SdFRXALRFe33qxEUW0FzQ5c6Q__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 2. Survival According to Aspirin Use After Diagnosis" class="content-img lazy" path-from-xml="joc90066f2" /></a></div></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label"><strong>Figure 3.</strong> Multivariate-Adjusted Stratified Analyses of Colorectal Cancer−Specific Survival According to Aspirin Use After Diagnosis</div><a id="joc90066f3" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc90066f3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f3.png?Expires=1717540240&amp;Signature=Z6GBkVpDGVU7MtXeiKn96hOmlhZNS0juvQFXJ-LhzJemOpiFhfCK6Gzosf0-obzzTVtRtbUF1t2DINRFnoxwOt00QMg5gH3XIC5wojkJWEruXjCv67MJ1l8HdTcPUnU6mvxMQ6dP4q02EmGGSUzEVgr8THZ2PIC1eoxtl90jj-gspQuS369slTw6p7tS~GGIkeSTv5HjeAanzdks1Nmb7oKMx6sJGEkz12x5pACL8FDoTfwA~o7rpI3GfiUIxWMuphOEW7LgWCIYMOJ8fJ8iHrg0bNVa78Bs9buLuqqOspllbHfUE3-tYY8r1K~FIMr5FjQ6uROHPedZLIVG021xwg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc90066f3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f3.png?Expires=1717540240&Signature=Z6GBkVpDGVU7MtXeiKn96hOmlhZNS0juvQFXJ-LhzJemOpiFhfCK6Gzosf0-obzzTVtRtbUF1t2DINRFnoxwOt00QMg5gH3XIC5wojkJWEruXjCv67MJ1l8HdTcPUnU6mvxMQ6dP4q02EmGGSUzEVgr8THZ2PIC1eoxtl90jj-gspQuS369slTw6p7tS~GGIkeSTv5HjeAanzdks1Nmb7oKMx6sJGEkz12x5pACL8FDoTfwA~o7rpI3GfiUIxWMuphOEW7LgWCIYMOJ8fJ8iHrg0bNVa78Bs9buLuqqOspllbHfUE3-tYY8r1K~FIMr5FjQ6uROHPedZLIVG021xwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=24828486&ar=184381&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066f3.png?Expires=1717540240&amp;Signature=Z6GBkVpDGVU7MtXeiKn96hOmlhZNS0juvQFXJ-LhzJemOpiFhfCK6Gzosf0-obzzTVtRtbUF1t2DINRFnoxwOt00QMg5gH3XIC5wojkJWEruXjCv67MJ1l8HdTcPUnU6mvxMQ6dP4q02EmGGSUzEVgr8THZ2PIC1eoxtl90jj-gspQuS369slTw6p7tS~GGIkeSTv5HjeAanzdks1Nmb7oKMx6sJGEkz12x5pACL8FDoTfwA~o7rpI3GfiUIxWMuphOEW7LgWCIYMOJ8fJ8iHrg0bNVa78Bs9buLuqqOspllbHfUE3-tYY8r1K~FIMr5FjQ6uROHPedZLIVG021xwg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc90066f3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/m_joc90066f3.png?Expires=1717540240&amp;Signature=BSHN3IV2r12D2BFXo4b3B4fYzCM0O5c0LmLu0-NMsLXQI1e7Ld8ttiBfqln8urxQRdCS48sXHF2UvfP4PdUs-sXxBZP2UGI29JsQaaSCq0CwhOjDGJpK7JUWt8C3adrkd0kRhoCOvI8~IvyrAoUtOBwiDw3sfhuK8sAS8YlvzVW-EW3jh9wljFxTKEVMYoPkUBNtoflPOe10kEFg2yHrEcfDVmBHxAf5Otzp--iSWNa0zuHzwHdAW9C~LQdU2YtBLJS-4Nk~W1LTg2LlSdo8GheBthR~2D7LoAOgn3L080nWiE9VP2A-TMTqkAc22h7DtED41bZjthRL9C9jgdBF4g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 3. Multivariate-Adjusted Stratified Analyses of Colorectal Cancer−Specific Survival According to Aspirin Use After Diagnosis" class="content-img lazy" path-from-xml="joc90066f3" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">Multivariate hazard ratios are adjusted for age at diagnosis (years), sex, date of cancer diagnosis (years), stage of cancer (I, II, or III), site of primary cancer (colon or rectum), histological grade of cancer (well, moderate, or poor/unknown), time from diagnosis to first measurement of postdiagnosis aspirin use (months), smoking (never vs current/past), metabolic equivalent tasks per week after diagnosis, body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]), and colorectal cancer in a parent or sibling (yes or no). For each stratified analysis, the stratification variable was omitted from the model.</p></div></div> 
    </div>
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Tables_Tab">
        <div class="figure-table-wrapper thm-bd-top"><a id="joc90066t1" class="figure-table-anchor"> </a><div class="table-label"><strong>Table 1.</strong> Baseline Characteristics of the Study Cohort by Aspirin Use<sup>a</sup></div><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc90066t1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t1.png?Expires=1717540240&amp;Signature=DuksUEvi9-j0c-AC5zknSRmaYANtHtT03mu9C6aqgwWOPAI~UK74IyWSN5LGN-h0N1c8pw9BHX8jZFnjrp3zoXzK1zPJWaojxi00veoBn4JuoD7Sz~xfs96lmFhhWjxH-Km1CsqXR2Q9fxdy18LadoBiYh37rqmP~D1yir-WVIz1diPDXSE2224wXuXZEganbqRahdvcWBzpFa2rBOHUpCkwsJUuXAQbwWeTjitwBdSKp7aUQbgprIfw~nX8RNmR51GCaaxux7HGkLxaRn6au4-0mKYB3KkBmDm8T-e~UursVv--x0eGnueMcCsa3apjVSzur6zjpHJFLPfNXoOptA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc90066t1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t1.png?Expires=1717540240&Signature=DuksUEvi9-j0c-AC5zknSRmaYANtHtT03mu9C6aqgwWOPAI~UK74IyWSN5LGN-h0N1c8pw9BHX8jZFnjrp3zoXzK1zPJWaojxi00veoBn4JuoD7Sz~xfs96lmFhhWjxH-Km1CsqXR2Q9fxdy18LadoBiYh37rqmP~D1yir-WVIz1diPDXSE2224wXuXZEganbqRahdvcWBzpFa2rBOHUpCkwsJUuXAQbwWeTjitwBdSKp7aUQbgprIfw~nX8RNmR51GCaaxux7HGkLxaRn6au4-0mKYB3KkBmDm8T-e~UursVv--x0eGnueMcCsa3apjVSzur6zjpHJFLPfNXoOptA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=24828465&ar=184381&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t1.png?Expires=1717540240&amp;Signature=DuksUEvi9-j0c-AC5zknSRmaYANtHtT03mu9C6aqgwWOPAI~UK74IyWSN5LGN-h0N1c8pw9BHX8jZFnjrp3zoXzK1zPJWaojxi00veoBn4JuoD7Sz~xfs96lmFhhWjxH-Km1CsqXR2Q9fxdy18LadoBiYh37rqmP~D1yir-WVIz1diPDXSE2224wXuXZEganbqRahdvcWBzpFa2rBOHUpCkwsJUuXAQbwWeTjitwBdSKp7aUQbgprIfw~nX8RNmR51GCaaxux7HGkLxaRn6au4-0mKYB3KkBmDm8T-e~UursVv--x0eGnueMcCsa3apjVSzur6zjpHJFLPfNXoOptA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc90066t1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/m_joc90066t1.png?Expires=1717540240&amp;Signature=xr1~MVZrfa8CLNGYd9PWW5M-l1q6HfFltrUzZ-vl~DJQSOyXcfnX4C3lOYd4VtFBlmZXwxhDnxKQVpob7D6BMPAaM8wAmK0W3~QNBWBS-0Vv4vrYzetG7721xMAEfuVIIL47IhR3~fW2sstY9CVxs1lncbUTdfccbOEU3d5uWt5JasnqahlckKqaMhn8-eVyV-B3gnLz4KIwfPAjjhLhT9GNFjQ53loYJlfJ8UIKzybnPoAXjx1~H7wqg29McCW9rc~gwCcGvQczMli3PFzCBwLF4eAHx7q7AdSyTmdQfJMslpcmA-YQVYnp7BjJq60Z~ApmxcWzk9KxaDfPNcEpoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Table 1. Baseline Characteristics of the Study Cohort by Aspirin Usea" class="content-img lazy" path-from-xml="joc90066t1" /></a></div></div></div><div class="figure-table-wrapper thm-bd-top"><a id="joc90066t2" class="figure-table-anchor"> </a><div class="table-label"><strong>Table 2.</strong> Risk of Colorectal Cancer−Specific Mortality and Overall Mortality According to Use of Aspirin After Diagnosis<sup>a</sup></div><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc90066t2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t2.png?Expires=1717540240&amp;Signature=QfaNQ41PtNX9b5765eP72js~APHyF7DwhN3kbQ8mf4tpj2PyROuK4vpjakd8QL3eLeao6pEY15jpAytKHjklIagH7f1r4rvADAACdiiKI5g~AwvAczUPJ0JTlTFfIkr4EI56nmOehmMLnyq84blQU0jGh-rPUFX6GERVmMh1HkeJIKdtuiXUh238SJDsYf0dVpuoLvAYr61NT6TQLPnpH7TNBZwFhCyYgtlDti~YYiub8Y0bcAUlpI3Ez~xL1vAq9~3BVOiyx~jaL0nWctDghlTfOurqV4qgD-uwuBD5Q6GoF-WOKIA~1-heS6BQIsNFG22KPmIRXM08w-dQLAGHUg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc90066t2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t2.png?Expires=1717540240&Signature=QfaNQ41PtNX9b5765eP72js~APHyF7DwhN3kbQ8mf4tpj2PyROuK4vpjakd8QL3eLeao6pEY15jpAytKHjklIagH7f1r4rvADAACdiiKI5g~AwvAczUPJ0JTlTFfIkr4EI56nmOehmMLnyq84blQU0jGh-rPUFX6GERVmMh1HkeJIKdtuiXUh238SJDsYf0dVpuoLvAYr61NT6TQLPnpH7TNBZwFhCyYgtlDti~YYiub8Y0bcAUlpI3Ez~xL1vAq9~3BVOiyx~jaL0nWctDghlTfOurqV4qgD-uwuBD5Q6GoF-WOKIA~1-heS6BQIsNFG22KPmIRXM08w-dQLAGHUg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=24828476&ar=184381&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t2.png?Expires=1717540240&amp;Signature=QfaNQ41PtNX9b5765eP72js~APHyF7DwhN3kbQ8mf4tpj2PyROuK4vpjakd8QL3eLeao6pEY15jpAytKHjklIagH7f1r4rvADAACdiiKI5g~AwvAczUPJ0JTlTFfIkr4EI56nmOehmMLnyq84blQU0jGh-rPUFX6GERVmMh1HkeJIKdtuiXUh238SJDsYf0dVpuoLvAYr61NT6TQLPnpH7TNBZwFhCyYgtlDti~YYiub8Y0bcAUlpI3Ez~xL1vAq9~3BVOiyx~jaL0nWctDghlTfOurqV4qgD-uwuBD5Q6GoF-WOKIA~1-heS6BQIsNFG22KPmIRXM08w-dQLAGHUg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc90066t2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/m_joc90066t2.png?Expires=1717540240&amp;Signature=gDzztAVrq1myoF0n4Q-9OvPnYqbTKF21pkXHWT2DttxUq3159fO-22OvzPL0J02PupN6MUkBgnlV8XQx531n1YjUmjlKeDGHN3Gy19PBQFTyS11yIkKPIfbEN7KierQrSMWVyWM21PdNnPBEinKsS7U3rE-RCKfV~-N7lZZ6UgF5jlCjmGh5IT58djvEgvgG0tQcWgBu7JRHudzWl6emCpLl0WuiBR1E4xm9t7ysQgDviGhswnw4hChFwGcYAI1UygZZAI32UGQPanZs00-eiQiSs1Vc~UCMPTQb5Aot8yiK~PhDYXBCX~BLjmoAkaDTCRipsF2d7VYYmosXfBOLRA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Table 2. Risk of Colorectal Cancer−Specific Mortality and Overall Mortality According to Use of Aspirin After Diagnosisa" class="content-img lazy" path-from-xml="joc90066t2" /></a></div></div></div><div class="figure-table-wrapper thm-bd-top"><a id="joc90066t3" class="figure-table-anchor"> </a><div class="table-label"><strong>Table 3.</strong> Risk of Colorectal Cancer−Specific Mortality and Overall Mortality According to Dose of Aspirin Used After Colorectal Cancer Diagnosis<sup>a</sup></div><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc90066t3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t3.png?Expires=1717540240&amp;Signature=YBrlyCcPtvcBl2~QkS5JaluE-kBDiSL-WzE1wCXCO7O3GlVf4MLazMtB2DYlETuC0ttPzmrqdvC-jA3RD--hNxlRKMu49TxQz9hhh5gY3YO0gXtFiJBVdxe6RUqUER6NtBiNWMyw0osqI1EFYrVeDGP2qIfNud0wp1zdoUob1rXtE91xlxV-2882Nxe0SDaSG87JNL7rz1Sj0t0NQe4dWf4BQ4wdnzks18u6Zcpw~vxG-VTncXYBSFdtmDFMjzbpXIecP1WKXKqwlLFQuhIA~~2~wkvhFRkEJ95bVVmAxeBLxPLZnFDveBmV7-zzExiwKEs3oShe7hEajUfW4VfD5g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc90066t3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t3.png?Expires=1717540240&Signature=YBrlyCcPtvcBl2~QkS5JaluE-kBDiSL-WzE1wCXCO7O3GlVf4MLazMtB2DYlETuC0ttPzmrqdvC-jA3RD--hNxlRKMu49TxQz9hhh5gY3YO0gXtFiJBVdxe6RUqUER6NtBiNWMyw0osqI1EFYrVeDGP2qIfNud0wp1zdoUob1rXtE91xlxV-2882Nxe0SDaSG87JNL7rz1Sj0t0NQe4dWf4BQ4wdnzks18u6Zcpw~vxG-VTncXYBSFdtmDFMjzbpXIecP1WKXKqwlLFQuhIA~~2~wkvhFRkEJ95bVVmAxeBLxPLZnFDveBmV7-zzExiwKEs3oShe7hEajUfW4VfD5g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=24828482&ar=184381&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/joc90066t3.png?Expires=1717540240&amp;Signature=YBrlyCcPtvcBl2~QkS5JaluE-kBDiSL-WzE1wCXCO7O3GlVf4MLazMtB2DYlETuC0ttPzmrqdvC-jA3RD--hNxlRKMu49TxQz9hhh5gY3YO0gXtFiJBVdxe6RUqUER6NtBiNWMyw0osqI1EFYrVeDGP2qIfNud0wp1zdoUob1rXtE91xlxV-2882Nxe0SDaSG87JNL7rz1Sj0t0NQe4dWf4BQ4wdnzks18u6Zcpw~vxG-VTncXYBSFdtmDFMjzbpXIecP1WKXKqwlLFQuhIA~~2~wkvhFRkEJ95bVVmAxeBLxPLZnFDveBmV7-zzExiwKEs3oShe7hEajUfW4VfD5g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc90066t3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4475/m_joc90066t3.png?Expires=1717540240&amp;Signature=xbMKjWy0ECS8~jD3hQP9kq09nv8ldjr1EP~Kot7l2idLx5YwlTbkXvwJnpk8bhv3LRE9jtO3d-W4eEJG4r6BbwRolf2zBbjsQMd4e83~qHD3EUJzLUf2w0ZSI~dN8SP-LJsQs4Zg5F80XUMnKYAYLTm5sTFna~v0fYySINaPs8zq~o2TYwJtsNXhNZpjgRUZ0oTYH2Uci6QGUF0itBMnMUMU5RCSTLL3Z~Jo8GRGZsObhrQEfRXninCtqOwUMg~Y9u09ZWcclECWxp3r4MOFhBvCxNEYJvVQEMfwbg9jQws8vJtb3IziKik5yNKmZkE9QbGYDgPdaqLUzcBTE9vm3A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Table 3. Risk of Colorectal Cancer−Specific Mortality and Overall Mortality According to Dose of Aspirin Used After Colorectal Cancer Diagnosisa" class="content-img lazy" path-from-xml="joc90066t3" /></a></div></div></div> 
    </div>

        </div>

        
        <div id="multimedia-tab" class="resource-tab js-resource-tab multimedia-tab need-jobs-ad">

        </div>

        
        <div id="supplemental-tab" class="resource-tab js-resource-tab supplemental-tab need-jobs-ad">

        </div>

        
        <div id="references-tab" class="resource-tab js-resource-tab references-tab need-jobs-ad">
            <div class="references-wrap">
    <div class="widget-SectionDisplay widget-instance-AMA_References_Tab">
        
<div class="references"><div class="reference"><a class="reference-number" id="ref-joc90066-1">1.</a><div class="reference-content">Dubé C, Rostom A, Lewin G, 
     et al; US Preventive Services Task Force.  The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</I>. 2007;146(5):365-37517339622<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17339622" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20use%20of%20aspirin%20for%20primary%20prevention%20of%20colorectal%20cancer%3A%20a%20systematic%20review%20prepared%20for%20the%20US%20Preventive%20Services%20Task%20Force.&amp;author=C%20Dubé&amp;author=A%20Rostom&amp;author=G%20Lewin&amp;publication_year=&amp;journal=Ann%20Intern%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/0003-4819-146-5-200703060-00009" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/0003-4819-146-5-200703060-00009" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-2">2.</a><div class="reference-content">Baron JA, Cole BF, Sandler RS, 
     et al.  A randomized trial of aspirin to prevent colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2003;348(10):891-89912621133<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12621133" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20aspirin%20to%20prevent%20colorectal%20adenomas.&amp;author=JA%20Baron&amp;author=BF%20Cole&amp;author=RS%20Sandler&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa021735" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa021735" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-3">3.</a><div class="reference-content">Sandler RS, Halabi S, Baron JA, 
     et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2003;348(10):883-89012621132<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12621132" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20aspirin%20to%20prevent%20colorectal%20adenomas%20in%20patients%20with%20previous%20colorectal%20cancer.&amp;author=RS%20Sandler&amp;author=S%20Halabi&amp;author=JA%20Baron&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa021633" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa021633" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-4">4.</a><div class="reference-content">Benamouzig R, Deyra J, Martin A, 
     et al.  Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2003;125(2):328-33612891533<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12891533" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Daily%20soluble%20aspirin%20and%20prevention%20of%20colorectal%20adenoma%20recurrence%3A%20one-year%20results%20of%20the%20APACC%20trial.&amp;author=R%20Benamouzig&amp;author=J%20Deyra&amp;author=A%20Martin&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0016-5085(03)00887-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0016-5085(03)00887-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-5">5.</a><div class="reference-content">Logan RF, Grainge MJ, Shepherd VC, Armitage  NC, Muir KR.ukCAP Trial Group.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2008;134(1):29-3818022173<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18022173" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20folic%20acid%20for%20the%20prevention%20of%20recurrent%20colorectal%20adenomas.&amp;author=RF%20Logan&amp;author=MJ%20Grainge&amp;author=VC%20Shepherd&amp;author=NC%20Armitage&amp;author=KR%20Muir&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2007.10.014" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2007.10.014" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-6">6.</a><div class="reference-content">Bertagnolli MM, Eagle CJ, Zauber AG, 
     et al; APC Study Investigators.  Celecoxib for the prevention of sporadic colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2006;355(9):873-88416943400<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16943400" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Celecoxib%20for%20the%20prevention%20of%20sporadic%20colorectal%20adenomas.&amp;author=MM%20Bertagnolli&amp;author=CJ%20Eagle&amp;author=AG%20Zauber&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa061355" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa061355" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-7">7.</a><div class="reference-content">Arber N, Eagle CJ, Spicak J, 
     et al; PreSAP Trial Investigators.  Celecoxib for the prevention of colorectal adenomatous polyps. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2006;355(9):885-89516943401<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16943401" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Celecoxib%20for%20the%20prevention%20of%20colorectal%20adenomatous%20polyps.&amp;author=N%20Arber&amp;author=CJ%20Eagle&amp;author=J%20Spicak&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa061652" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa061652" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-8">8.</a><div class="reference-content">Baron JA, Sandler RS, Bresalier RS, 
     et al;  APPROVe Trial Investigators.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2006;131(6):1674-168217087947<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17087947" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20rofecoxib%20for%20the%20chemoprevention%20of%20colorectal%20adenomas.&amp;author=JA%20Baron&amp;author=RS%20Sandler&amp;author=RS%20Bresalier&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2006.08.079" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2006.08.079" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-9">9.</a><div class="reference-content">Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2007;356(21):2131-214217522398<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17522398" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20the%20risk%20of%20colorectal%20cancer%20in%20relation%20to%20the%20expression%20of%20COX-2.&amp;author=AT%20Chan&amp;author=S%20Ogino&amp;author=CS%20Fuchs&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa067208" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa067208" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-10">10.</a><div class="reference-content">Markowitz SD. Aspirin and colon cancer-targeting prevention? <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2007;356(21):2195-219817522404<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17522404" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20colon%20cancer-targeting%20prevention%3F&amp;author=SD%20Markowitz&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMe078044" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMe078044" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-11">11.</a><div class="reference-content">Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. <I xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</I>. 2005;23(12):2840-285515837998<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15837998" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COX-2%3A%20a%20molecular%20target%20for%20colorectal%20cancer%20prevention.&amp;author=JR%20Brown&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=J%20Clin%20Oncol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2005.09.051" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2005.09.051" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-12">12.</a><div class="reference-content">Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 1994;107(4):1183-11887926468<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7926468" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Up-regulation%20of%20cyclooxygenase%202%20gene%20expression%20in%20human%20colorectal%20adenomas%20and%20adenocarcinomas.&amp;author=CE%20Eberhart&amp;author=RJ%20Coffey&amp;author=A%20Radhika&amp;author=FM%20Giardiello&amp;author=S%20Ferrenbach&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-13">13.</a><div class="reference-content">Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2004;10(24):8465-847115623626<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15623626" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%3A%20a%20significant%20prognostic%20indicator%20for%20patients%20with%20colorectal%20cancer.&amp;author=LT%20Soumaoro&amp;author=H%20Uetake&amp;author=T%20Higuchi&amp;author=Y%20Takagi&amp;author=M%20Enomoto&amp;author=K%20Sugihara&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-0653" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-0653" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-14">14.</a><div class="reference-content">Sheehan KM, Sheahan K, O'Donoghue DP, 
     et al.  The relationship between cyclooxygenase-2 expression and colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 1999;282(13):1254-125710517428<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10517428" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20relationship%20between%20cyclooxygenase-2%20expression%20and%20colorectal%20cancer.&amp;author=KM%20Sheehan&amp;author=K%20Sheahan&amp;author=DP%20O'Donoghue&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.282.13.1254" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.282.13.1254" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-15">15.</a><div class="reference-content">Uchida K, Schneider S, Yochim JM, 
     et al.  Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2005;11(9):3363-336815867236<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15867236" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Intratumoral%20COX-2%20gene%20expression%20is%20a%20predictive%20factor%20for%20colorectal%20cancer%20response%20to%20fluoropyrimidine-based%20chemotherapy.&amp;author=K%20Uchida&amp;author=S%20Schneider&amp;author=JM%20Yochim&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-1650" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-1650" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-16">16.</a><div class="reference-content">Ogino S, Kirkner GJ, Nosho K, 
     et al.  Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2008;14(24):8221-822719088039<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/19088039" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20is%20an%20independent%20predictor%20of%20poor%20prognosis%20in%20colon%20cancer.&amp;author=S%20Ogino&amp;author=GJ%20Kirkner&amp;author=K%20Nosho&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-08-1841" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-08-1841" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-17">17.</a><div class="reference-content">Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Am J Gastroenterol</I>. 2002;97(4):1037-104112003384<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12003384" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Overexpression%20of%20cyclooxygenase-2%20correlates%20with%20advanced%20stages%20of%20colorectal%20cancer.&amp;author=H%20Zhang&amp;author=XF%20Sun&amp;publication_year=&amp;journal=Am%20J%20Gastroenterol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/j.1572-0241.2002.05625.x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/j.1572-0241.2002.05625.x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-18">18.</a><div class="reference-content">Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2005;11(13):4754-476016000571<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16000571" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20in%20human%20colorectal%20cancer%20is%20unrelated%20to%20overall%20patient%20survival.&amp;author=R%20Fux&amp;author=M%20Schwab&amp;author=KP%20Thon&amp;author=CH%20Gleiter&amp;author=P%20Fritz&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-2586" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-2586" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-19">19.</a><div class="reference-content">Tomozawa S, Nagawa H, Tsuno N, 
     et al.  Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. <I xmlns:helper="urn:XsltStringHelper"> Br J Cancer</I>. 1999;81(8):1274-127910604722<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10604722" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20haematogenous%20metastasis%20of%20colon%20cancer%20in%20mice%20by%20a%20selective%20COX-2%20inhibitor%2C%20JTE-522.&amp;author=S%20Tomozawa&amp;author=H%20Nagawa&amp;author=N%20Tsuno&amp;publication_year=&amp;journal=Br%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/sj.bjc.6694262" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/sj.bjc.6694262" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-20">20.</a><div class="reference-content">Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 2000;60(21):6045-605111085526<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11085526" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Celecoxib%20prevents%20tumor%20growth%20in%20vivo%20without%20toxicity%20to%20normal%20gut%3A%20lack%20of%20correlation%20between%20in%20vitro%20and%20in%20vivo%20models.&amp;author=CS%20Williams&amp;author=AJ%20Watson&amp;author=H%20Sheng&amp;author=R%20Helou&amp;author=J%20Shao&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-21">21.</a><div class="reference-content">Williams CS, Sheng H, Brockman JA, 
     et al.  A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. <I xmlns:helper="urn:XsltStringHelper"> Neoplasia</I>. 2001;3(5):428-43611687954<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11687954" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20cyclooxygenase-2%20inhibitor%20%28SC-58125%29%20blocks%20growth%20of%20established%20human%20colon%20cancer%20xenografts.&amp;author=CS%20Williams&amp;author=H%20Sheng&amp;author=JA%20Brockman&amp;publication_year=&amp;journal=Neoplasia&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/sj.neo.7900177" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/sj.neo.7900177" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-22">22.</a><div class="reference-content">Yamauchi T, Watanabe M, Hasegawa H, 
     et al.  The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Anticancer Res</I>. 2003;23(1A):245-24912680220<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12680220" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20potential%20for%20a%20selective%20cyclooxygenase-2%20inhibitor%20in%20the%20prevention%20of%20liver%20metastasis%20in%20human%20colorectal%20cancer.&amp;author=T%20Yamauchi&amp;author=M%20Watanabe&amp;author=H%20Hasegawa&amp;publication_year=&amp;journal=Anticancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-23">23.</a><div class="reference-content">Yao M, Kargman S, Lam EC, 
     et al.  Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 2003;63(3):586-59212566300<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12566300" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20cyclooxygenase-2%20by%20rofecoxib%20attenuates%20the%20growth%20and%20metastatic%20potential%20of%20colorectal%20carcinoma%20in%20mice.&amp;author=M%20Yao&amp;author=S%20Kargman&amp;author=EC%20Lam&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-24">24.</a><div class="reference-content">Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Br J Cancer</I>. 2004;90(3):712-71914760389<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/14760389" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20selective%20inhibition%20with%20NS-398%20suppresses%20proliferation%20and%20invasiveness%20and%20delays%20liver%20metastasis%20in%20colorectal%20cancer.&amp;author=M%20Yao&amp;author=EC%20Lam&amp;author=CR%20Kelly&amp;author=W%20Zhou&amp;author=MM%20Wolfe&amp;publication_year=&amp;journal=Br%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/sj.bjc.6601489" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/sj.bjc.6601489" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-25">25.</a><div class="reference-content">Yao M, Zhou W, Sangha S, 
     et al.  Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2005;11(4):1618-162815746067<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15746067" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20nonselective%20cyclooxygenase%20inhibition%20with%20low-dose%20ibuprofen%20on%20tumor%20growth%2C%20angiogenesis%2C%20metastasis%2C%20and%20survival%20in%20a%20mouse%20model%20of%20colorectal%20cancer.&amp;author=M%20Yao&amp;author=W%20Zhou&amp;author=S%20Sangha&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-1696" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-1696" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-26">26.</a><div class="reference-content">Fuchs C, Meyerhardt JA, Heseltine DL, 
     et al.  Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803 [abstract]. <I xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</I>. 2005;23(suppl 16):3530<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Influence%20of%20regular%20aspirin%20use%20on%20survival%20for%20patients%20with%20stage%20III%20colon%20cancer%3A%20findings%20from%20intergroup%20trial%20CALGB%2089803%20%5Babstract%5D.&amp;author=C%20Fuchs&amp;author=JA%20Meyerhardt&amp;author=DL%20Heseltine&amp;publication_year=&amp;journal=J%20Clin%20Oncol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-27">27.</a><div class="reference-content">Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 2005;294(8):914-92316118381<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16118381" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-term%20use%20of%20aspirin%20and%20nonsteroidal%20anti-inflammatory%20drugs%20and%20risk%20of%20colorectal%20cancer.&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=JA%20Meyerhardt&amp;author=ES%20Schernhammer&amp;author=GC%20Curhan&amp;author=CS%20Fuchs&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.294.8.914" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.294.8.914" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-28">28.</a><div class="reference-content">Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2008;134(1):21-2818005960<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18005960" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20dose%20and%20duration%20of%20use%20and%20risk%20of%20colorectal%20cancer%20in%20men.&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=JA%20Meyerhardt&amp;author=ES%20Schernhammer&amp;author=K%20Wu&amp;author=CS%20Fuchs&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2007.09.035" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2007.09.035" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-29">29.</a><div class="reference-content">Willett WC, Sampson L, Stampfer MJ, 
     et al.  Reproducibility and validity of a semiquantitative food frequency questionnaire. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1985;122(1):51-654014201<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/4014201" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Reproducibility%20and%20validity%20of%20a%20semiquantitative%20food%20frequency%20questionnaire.&amp;author=WC%20Willett&amp;author=L%20Sampson&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-30">30.</a><div class="reference-content">Manson JE, Stampfer MJ, Colditz GA, 
     et al.  A prospective study of aspirin use and primary prevention of cardiovascular disease in women. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 1991;266(4):521-5272061978<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/2061978" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20prospective%20study%20of%20aspirin%20use%20and%20primary%20prevention%20of%20cardiovascular%20disease%20in%20women.&amp;author=JE%20Manson&amp;author=MJ%20Stampfer&amp;author=GA%20Colditz&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.1991.03470040085027" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.1991.03470040085027" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-31">31.</a><div class="reference-content">Rimm EB, Giovannucci E, Stampfer M, Colditz  G, Litin L, Willett W. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1992;135(10):1114-1126, discussion 1127-11361632423<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/1632423" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Reproducibility%20and%20validity%20of%20an%20expanded%20self-administered%20semiquantitative%20food%20frequency%20questionnaire%20among%20male%20health%20professionals.&amp;author=EB%20Rimm&amp;author=E%20Giovannucci&amp;author=M%20Stampfer&amp;author=G%20Colditz&amp;author=L%20Litin&amp;author=W%20Willett&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-32">32.</a><div class="reference-content">Giovannucci E, Rimm EB, Stampfer MJ, Colditz  GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</I>. 1994;121(4):241-2468037405<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/8037405" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20use%20and%20the%20risk%20for%20colorectal%20cancer%20and%20adenoma%20in%20male%20health%20professionals.&amp;author=E%20Giovannucci&amp;author=EB%20Rimm&amp;author=MJ%20Stampfer&amp;author=GA%20Colditz&amp;author=A%20Ascherio&amp;author=WC%20Willett&amp;publication_year=&amp;journal=Ann%20Intern%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/0003-4819-121-4-199408150-00001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/0003-4819-121-4-199408150-00001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-33">33.</a><div class="reference-content">Greene FL, Fleming ID, Fritz A, Balch CM. <em>AJCC Cancer Staging Handbook.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">6th ed. Page DL. New York, NY: Springer-Verlag; 2002</span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-34">34.</a><div class="reference-content">Meyerhardt JA, Giovannucci EL, Holmes MD, 
     et al.  Physical activity and survival after colorectal cancer diagnosis. <I xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</I>. 2006;24(22):3527-353416822844<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16822844" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Physical%20activity%20and%20survival%20after%20colorectal%20cancer%20diagnosis.&amp;author=JA%20Meyerhardt&amp;author=EL%20Giovannucci&amp;author=MD%20Holmes&amp;publication_year=&amp;journal=J%20Clin%20Oncol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2006.06.0855" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2006.06.0855" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-35">35.</a><div class="reference-content">Ogino S, Brahmandam M, Cantor M, 
     et al.  Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. <I xmlns:helper="urn:XsltStringHelper"> Mod Pathol</I>. 2006;19(1):59-6816118624<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16118624" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Distinct%20molecular%20features%20of%20colorectal%20carcinoma%20with%20signet%20ring%20cell%20component%20and%20colorectal%20carcinoma%20with%20mucinous%20component.&amp;author=S%20Ogino&amp;author=M%20Brahmandam&amp;author=M%20Cantor&amp;publication_year=&amp;journal=Mod%20Pathol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/modpathol.3800482" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/modpathol.3800482" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-36">36.</a><div class="reference-content">Stampfer MJ, Willett WC, Speizer FE, 
     et al.  Test of the National Death Index. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1984;119(5):837-8396720679<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/6720679" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Test%20of%20the%20National%20Death%20Index.&amp;author=MJ%20Stampfer&amp;author=WC%20Willett&amp;author=FE%20Speizer&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-37">37.</a><div class="reference-content">Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1994;140(11):1016-10197985649<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7985649" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Test%20of%20the%20National%20Death%20Index%20and%20Equifax%20Nationwide%20Death%20Search.&amp;author=JW%20Rich-Edwards&amp;author=KA%20Corsano&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-38">38.</a><div class="reference-content">Giovannucci E, Egan KM, Hunter DJ, 
     et al.  Aspirin and the risk of colorectal cancer in women. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 1995;333(10):609-6147637720<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7637720" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20the%20risk%20of%20colorectal%20cancer%20in%20women.&amp;author=E%20Giovannucci&amp;author=KM%20Egan&amp;author=DJ%20Hunter&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJM199509073331001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJM199509073331001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-39">39.</a><div class="reference-content">Chan AT, Giovannucci EL, Schernhammer ES, 
     et al.  A prospective study of aspirin use and the risk of colorectal adenoma. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</I>. 2004;140(3):157-16614757613<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/14757613" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20prospective%20study%20of%20aspirin%20use%20and%20the%20risk%20of%20colorectal%20adenoma.&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=ES%20Schernhammer&amp;publication_year=&amp;journal=Ann%20Intern%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/0003-4819-140-3-200402030-00006" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/0003-4819-140-3-200402030-00006" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-40">40.</a><div class="reference-content">Rosner B. <em>Fundamentals of Biostatistics.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">5th ed. Pacific Grove, CA: Duxbury Thomson Learning; 2000</span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-41">41.</a><div class="reference-content">Cochran WG. The combination of estimates from different experiments. <I xmlns:helper="urn:XsltStringHelper"> Biometrics</I>. 1954;10(1):101-129<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20combination%20of%20estimates%20from%20different%20experiments.&amp;author=WG%20Cochran&amp;publication_year=&amp;journal=Biometrics&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.2307/3001666" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.2307/3001666" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-42">42.</a><div class="reference-content">Hosmer DW, Lemeshow S. <em>Applied Logistic Regression.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">2nd ed. Hoboken, NJ: John Wiley &amp; Sons, Inc; 2000</span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-43">43.</a><div class="reference-content">Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 2001;286(10):1187-119411559263<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11559263" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20use%20and%20all-cause%20mortality%20among%20patients%20being%20evaluated%20for%20known%20or%20suspected%20coronary%20artery%20disease%3A%20a%20propensity%20analysis.&amp;author=PA%20Gum&amp;author=M%20Thamilarasan&amp;author=J%20Watanabe&amp;author=EH%20Blackstone&amp;author=MS%20Lauer&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.286.10.1187" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.286.10.1187" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-44">44.</a><div class="reference-content">Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. <I xmlns:helper="urn:XsltStringHelper"> Science</I>. 1994;265(5174):956-9598052854<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/8052854" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20NF-kappa%20B%20by%20sodium%20salicylate%20and%20aspirin.&amp;author=E%20Kopp&amp;author=S%20Ghosh&amp;publication_year=&amp;journal=Science&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.8052854" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.8052854" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-45">45.</a><div class="reference-content">Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. <I xmlns:helper="urn:XsltStringHelper"> Proc Natl Acad Sci U S A</I>. 1997;94(7):2869-28739096313<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9096313" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Sodium%20salicylate%20induces%20apoptosis%20via%20p38%20mitogen-activated%20protein%20kinase%20but%20inhibits%20tumor%20necrosis%20factor-induced%20c-Jun%20N-terminal%20kinase%2Fstress-activated%20protein%20kinase%20activation.&amp;author=P%20Schwenger&amp;author=P%20Bellosta&amp;author=I%20Vietor&amp;author=C%20Basilico&amp;author=EY%20Skolnik&amp;author=J%20Vilcek&amp;publication_year=&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.94.7.2869" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.94.7.2869" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-46">46.</a><div class="reference-content">Martinez ME, O'Brien TG, Fultz KE, 
     et al.  Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. <I xmlns:helper="urn:XsltStringHelper"> Proc Natl Acad Sci U S A </I>. 2003;100(13):7859-786412810952<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12810952" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pronounced%20reduction%20in%20adenoma%20recurrence%20associated%20with%20aspirin%20use%20and%20a%20polymorphism%20in%20the%20ornithine%20decarboxylase%20gene.&amp;author=ME%20Martinez&amp;author=TG%20O'Brien&amp;author=KE%20Fultz&amp;publication_year=&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.1332465100" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.1332465100" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-47">47.</a><div class="reference-content">Lundholm K, Gelin J, Hyltander A, 
     et al.  Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 1994;54(21):5602-56067923204<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7923204" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Anti-inflammatory%20treatment%20may%20prolong%20survival%20in%20undernourished%20patients%20with%20metastatic%20solid%20tumors.&amp;author=K%20Lundholm&amp;author=J%20Gelin&amp;author=A%20Hyltander&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-48">48.</a><div class="reference-content">Masunaga R, Kohno H, Dhar DK, 
     et al.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2000;6(10):4064-406811051257<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11051257" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20correlates%20with%20tumor%20neovascularization%20and%20prognosis%20in%20human%20colorectal%20carcinoma%20patients.&amp;author=R%20Masunaga&amp;author=H%20Kohno&amp;author=DK%20Dhar&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-49">49.</a><div class="reference-content">Cianchi F, Cortesini C, Bechi P, 
     et al.  Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2001;121(6):1339-134711729113<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11729113" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Up-regulation%20of%20cyclooxygenase%202%20gene%20expression%20correlates%20with%20tumor%20angiogenesis%20in%20human%20colorectal%20cancer.&amp;author=F%20Cianchi&amp;author=C%20Cortesini&amp;author=P%20Bechi&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/gast.2001.29691" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/gast.2001.29691" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-50">50.</a><div class="reference-content">Tomozawa S, Tsuno NH, Sunami E, 
     et al.  Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Br J Cancer</I>. 2000;83(3):324-32810917546<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10917546" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20overexpression%20correlates%20with%20tumour%20recurrence%2C%20especially%20haematogenous%20metastasis%2C%20of%20colorectal%20cancer.&amp;author=S%20Tomozawa&amp;author=NH%20Tsuno&amp;author=E%20Sunami&amp;publication_year=&amp;journal=Br%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1054/bjoc.2000.1270" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1054/bjoc.2000.1270" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-51">51.</a><div class="reference-content">Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. <I xmlns:helper="urn:XsltStringHelper"> Anticancer Res</I>. 2002;22(2B):1225-123012168930<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12168930" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COX-2%20expression%20in%20rectal%20carcinoma%3A%20immunohistochemical%20pattern%20and%20clinical%20outcome.&amp;author=S%20Petersen&amp;author=G%20Haroske&amp;author=G%20Hellmich&amp;author=K%20Ludwig&amp;author=C%20Petersen&amp;author=W%20Eicheler&amp;publication_year=&amp;journal=Anticancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-52">52.</a><div class="reference-content">Joo YE, Kim HS, Min SW, 
     et al.  Expression of cyclooxygenase-2 protein in colorectal carcinomas. <I xmlns:helper="urn:XsltStringHelper"> Int J Gastrointest Cancer</I>. 2002;31(1-3):147-15412622426<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12622426" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Expression%20of%20cyclooxygenase-2%20protein%20in%20colorectal%20carcinomas.&amp;author=YE%20Joo&amp;author=HS%20Kim&amp;author=SW%20Min&amp;publication_year=&amp;journal=Int%20J%20Gastrointest%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1385/IJGC:31:1-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1385/IJGC:31:1-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-53">53.</a><div class="reference-content">Yamac D, Celenkoglu G, Coskun U, 
     et al.  Prognostic importance of COX-2 expression in patients with colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Pathol Res Pract</I>. 2005;201(7):497-50216164044<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16164044" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prognostic%20importance%20of%20COX-2%20expression%20in%20patients%20with%20colorectal%20cancer.&amp;author=D%20Yamac&amp;author=G%20Celenkoglu&amp;author=U%20Coskun&amp;publication_year=&amp;journal=Pathol%20Res%20Pract&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.prp.2005.04.006" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.prp.2005.04.006" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-54">54.</a><div class="reference-content">Sheng H, Shao J, Kirkland SC, 
     et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. <I xmlns:helper="urn:XsltStringHelper"> J Clin Invest</I>. 1997;99(9):2254-22599151799<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9151799" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20human%20colon%20cancer%20cell%20growth%20by%20selective%20inhibition%20of%20cyclooxygenase-2.&amp;author=H%20Sheng&amp;author=J%20Shao&amp;author=SC%20Kirkland&amp;publication_year=&amp;journal=J%20Clin%20Invest&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1172/JCI119400" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1172/JCI119400" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-55">55.</a><div class="reference-content">Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. <I xmlns:helper="urn:XsltStringHelper"> Cell</I>. 1998;93(5):705-7169630216<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9630216" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase%20regulates%20angiogenesis%20induced%20by%20colon%20cancer%20cells.&amp;author=M%20Tsujii&amp;author=S%20Kawano&amp;author=S%20Tsuji&amp;author=H%20Sawaoka&amp;author=M%20Hori&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Cell&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0092-8674(00)81433-6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0092-8674(00)81433-6" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-56">56.</a><div class="reference-content">Williams CS, Tsujii M, Reese J, Dey SK, DuBois  RN. Host cyclooxygenase-2 modulates carcinoma growth. <I xmlns:helper="urn:XsltStringHelper"> J Clin Invest</I>. 2000;105(11):1589-159410841517<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10841517" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Host%20cyclooxygenase-2%20modulates%20carcinoma%20growth.&amp;author=CS%20Williams&amp;author=M%20Tsujii&amp;author=J%20Reese&amp;author=SK%20Dey&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=J%20Clin%20Invest&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1172/JCI9621" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1172/JCI9621" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-57">57.</a><div class="reference-content">Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. <I xmlns:helper="urn:XsltStringHelper"> Proc Natl Acad Sci USA</I>. 1997;94(7):3336-33409096394<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9096394" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20in%20human%20colon%20cancer%20cells%20increases%20metastatic%20potential.&amp;author=M%20Tsujii&amp;author=S%20Kawano&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Proc%20Natl%20Acad%20Sci%20USA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.94.7.3336" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.94.7.3336" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-58">58.</a><div class="reference-content">Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2–selective inhibitor, etodolac. <I xmlns:helper="urn:XsltStringHelper"> Int J Cancer</I>. 2001;91(6):894-89911275997<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11275997" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Tumor%20invasiveness%20and%20liver%20metastasis%20of%20colon%20cancer%20cells%20correlated%20with%20cyclooxygenase-2%20%28COX-2%29%20expression%20and%20inhibited%20by%20a%20COX-2%E2%80%93selective%20inhibitor%2C%20etodolac.&amp;author=WS%20Chen&amp;author=SJ%20Wei&amp;author=JM%20Liu&amp;author=M%20Hsiao&amp;author=J%20Kou-Lin&amp;author=WK%20Yang&amp;publication_year=&amp;journal=Int%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/(ISSN)1097-0215" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/(ISSN)1097-0215" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-59">59.</a><div class="reference-content">Trifan OC, Durham WF, Salazar VS, 
     et al.  Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 2002;62(20):5778-578412384538<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12384538" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20inhibition%20with%20celecoxib%20enhances%20antitumor%20efficacy%20and%20reduces%20diarrhea%20side%20effect%20of%20CPT-11.&amp;author=OC%20Trifan&amp;author=WF%20Durham&amp;author=VS%20Salazar&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-60">60.</a><div class="reference-content">Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. <I xmlns:helper="urn:XsltStringHelper"> Biochem Pharmacol</I>. 2005;70(5):658-66716004971<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16004971" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Combination%20of%20cyclooxygenase-2%20inhibitors%20and%20oxaliplatin%20increases%20the%20growth%20inhibition%20and%20death%20in%20human%20colon%20cancer%20cells.&amp;author=J%20Lin&amp;author=PW%20Hsiao&amp;author=TH%20Chiu&amp;author=JI%20Chao&amp;publication_year=&amp;journal=Biochem%20Pharmacol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.bcp.2005.05.028" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.bcp.2005.05.028" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-61">61.</a><div class="reference-content">Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2003;9(1):383-39012538492<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12538492" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20novel%20mechanism%20for%20aspirin-mediated%20growth%20inhibition%20of%20human%20colon%20cancer%20cells.&amp;author=A%20Goel&amp;author=DK%20Chang&amp;author=L%20Ricciardiello&amp;author=C%20Gasche&amp;author=CR%20Boland&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-62">62.</a><div class="reference-content">Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. <I xmlns:helper="urn:XsltStringHelper"> J Biol Chem</I>. 2001;276(21):18075-1808111278548<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11278548" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prostaglandin%20E2%20increases%20growth%20and%20motility%20of%20colorectal%20carcinoma%20cells.&amp;author=H%20Sheng&amp;author=J%20Shao&amp;author=MK%20Washington&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=J%20Biol%20Chem&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1074/jbc.M009689200" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1074/jbc.M009689200" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-63">63.</a><div class="reference-content">Buchanan FG, Chang W, Sheng H, Shao J, Morrow JD, DuBois RN. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2004;127(5):1391-140015521009<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15521009" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Up-regulation%20of%20the%20enzymes%20involved%20in%20prostacyclin%20synthesis%20via%20Ras%20induces%20vascular%20endothelial%20growth%20factor.&amp;author=FG%20Buchanan&amp;author=W%20Chang&amp;author=H%20Sheng&amp;author=J%20Shao&amp;author=JD%20Morrow&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2004.07.025" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2004.07.025" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-64">64.</a><div class="reference-content">Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2005;352(5):476-48715689586<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15689586" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Systemic%20therapy%20for%20colorectal%20cancer.&amp;author=JA%20Meyerhardt&amp;author=RJ%20Mayer&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMra040958" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMra040958" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-65">65.</a><div class="reference-content">Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. <I xmlns:helper="urn:XsltStringHelper"> Cancer Epidemiol Biomarkers Prev</I>. 2008;17(8):1852-185718708371<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18708371" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20inhibitors%20in%20colorectal%20cancer%20prevention%3A%20point.&amp;author=N%20Arber&amp;publication_year=&amp;journal=Cancer%20Epidemiol%20Biomarkers%20Prev&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1055-9965.EPI-08-0167" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1055-9965.EPI-08-0167" xmlns:helper="urn:XsltStringHelper"> </span></div></div></div> 
    </div>

            </div>
        </div>

        
        <div id="related-tab" class="resource-tab js-resource-tab related-tab need-jobs-ad">
    <div class="widget-ArticleLinks widget-instance-AMA_See_Also_Related_Content">
        
    <ul class="article-links related-content">

            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/184364" class="td-n">
                        <div class="related-article-title">Aspirin as Adjuvant Therapy for Colorectal Cancer</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Editorial</div>
                    <div class="related-article-date">August 12, 2009</div>
                    <div class="related-article-excerpt"></div>
                    <div class="related-article-authors">Alfred I. Neugut, MD, PhD</div>
                </a>
            </li>
    </ul>
 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
 
    </div>
    <div class="widget-RelatedTopics widget-instance-AMA_Related_Topics">
        
        <div class="related-topics-block">
            <h4 class="related-topics-heading topic-suggestions-heading sb-sc">
See More About            </h4>
            <div class="related-topics topic-suggestions">
    <a href="https://jamanetwork.com/collections/5571/colorectal-cancer" id="item_Link" class="related-topic topic-suggestion no-wrap sb-anchor-light">Colorectal Cancer</a>    <a href="https://jamanetwork.com/collections/5655/gastroenterology" id="item_Link_1" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gastroenterology</a>    <a href="https://jamanetwork.com/collections/5657/gastrointestinal-cancer" id="item_Link_2" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gastrointestinal Cancer</a>    <a href="https://jamanetwork.com/collections/5801/oncology" id="item_Link_3" class="related-topic topic-suggestion no-wrap sb-anchor-light">Oncology</a>    <a href="https://jamanetwork.com/collections/42143/anticoagulation" id="item_Link_4" class="related-topic topic-suggestion no-wrap sb-anchor-light">Anticoagulation</a>    <a href="https://jamanetwork.com/collections/44012/gastroenterology-and-hepatology" id="item_Link_5" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gastroenterology and Hepatology</a>            </div>
        </div>
 
    </div>
                <div class="ymal--footer">
    <div class="widget-WidgetLoader widget-instance-AMA_PersonalizedContent_SplitScreenView_Footer">
        <div class="SCM-SharedWidgets-AsyncWidgetLoader" data-url="/Personalization/PersonalizedContent/AMA_PersonalizedContent_SplitScreenView_Footer" data-params="{&quot;parameters&quot;:{&quot;resourceIdToExclude&quot;:184381,&quot;resourceTypeToExclude&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

                </div>
                <hr />
                <div class="manage-interest">
                    <h4><a href="#" class="manage-interests-link-no-access thm-col-sec">Select Your Interests</a></h4>
    <div class="widget-ManageCollectionInterests widget-instance-ManageCollectionInterests_SplitScreen">
        <div class="manage-interests-modal reveal-modal small modal" data-reveal>
<div class="manage-interests--header">
    <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests_Header">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="AllSitesManageInterestsHeader" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style>
    h4 {
    font-size: 20px !important;
    }
</style>
<h4>Select Your Interests</h4>
<p>Customize your JAMA Network experience by selecting one or more topics from the list below.</p>


</div>

 
    </div>

</div><div class="manage-interests--categories">
    <ul class="category-list">
            <li><span class="category-list-item " data-categoryid="46425">Academic Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5489">Acid Base, Electrolytes, Fluids</span></li>
            <li><span class="category-list-item " data-categoryid="5504">Allergy and Clinical Immunology</span></li>
            <li><span class="category-list-item " data-categoryid="46447">American Indian or Alaska Natives</span></li>
            <li><span class="category-list-item " data-categoryid="5510">Anesthesiology</span></li>
            <li><span class="category-list-item " data-categoryid="42143">Anticoagulation</span></li>
            <li><span class="category-list-item " data-categoryid="6261">Art and Images in Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44024">Artificial Intelligence</span></li>
            <li><span class="category-list-item " data-categoryid="42097">Assisted Reproduction</span></li>
            <li><span class="category-list-item " data-categoryid="42099">Bleeding and Transfusion</span></li>
            <li><span class="category-list-item " data-categoryid="5548">Cardiology</span></li>
            <li><span class="category-list-item " data-categoryid="44036">Caring for the Critically Ill Patient</span></li>
            <li><span class="category-list-item " data-categoryid="6255">Challenges in Clinical Electrocardiography</span></li>
            <li><span class="category-list-item " data-categoryid="46435">Climate and Health</span></li>
            <li><span class="category-list-item " data-categoryid="46448">Climate Change</span></li>
            <li><span class="category-list-item " data-categoryid="44038">Clinical Challenge</span></li>
            <li><span class="category-list-item " data-categoryid="5589">Clinical Decision Support</span></li>
            <li><span class="category-list-item " data-categoryid="44039">Clinical Implications of Basic Neuroscience</span></li>
            <li><span class="category-list-item " data-categoryid="5614">Clinical Pharmacy and Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5575">Complementary and Alternative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="44040">Consensus Statements</span></li>
            <li><span class="category-list-item " data-categoryid="46099">Coronavirus (COVID-19)</span></li>
            <li><span class="category-list-item " data-categoryid="5584">Critical Care Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46325">Cultural Competency</span></li>
            <li><span class="category-list-item " data-categoryid="44019">Dental Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5598">Dermatology</span></li>
            <li><span class="category-list-item " data-categoryid="44011">Diabetes and Endocrinology</span></li>
            <li><span class="category-list-item " data-categoryid="46320">Diagnostic Test Interpretation</span></li>
            <li><span class="category-list-item " data-categoryid="42054">Drug Development</span></li>
            <li><span class="category-list-item " data-categoryid="5620">Electronic Health Records</span></li>
            <li><span class="category-list-item " data-categoryid="5621">Emergency Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5819">End of Life, Hospice, Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="42107">Environmental Health</span></li>
            <li><span class="category-list-item " data-categoryid="46387">Equity, Diversity, and Inclusion</span></li>
            <li><span class="category-list-item " data-categoryid="42108">Ethics</span></li>
            <li><span class="category-list-item " data-categoryid="5644">Facial Plastic Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44012">Gastroenterology and Hepatology</span></li>
            <li><span class="category-list-item " data-categoryid="5664">Genetics and Genomics</span></li>
            <li><span class="category-list-item " data-categoryid="44041">Genomics and Precision Health</span></li>
            <li><span class="category-list-item " data-categoryid="5668">Geriatrics</span></li>
            <li><span class="category-list-item " data-categoryid="5670">Global Health</span></li>
            <li><span class="category-list-item " data-categoryid="46427">Guide to Statistics and Methods</span></li>
            <li><span class="category-list-item " data-categoryid="5672">Guidelines</span></li>
            <li><span class="category-list-item " data-categoryid="5674">Hair Disorders</span></li>
            <li><span class="category-list-item " data-categoryid="42113">Health Care Delivery Models</span></li>
            <li><span class="category-list-item " data-categoryid="42114">Health Care Economics, Insurance, Payment</span></li>
            <li><span class="category-list-item " data-categoryid="42116">Health Care Quality</span></li>
            <li><span class="category-list-item " data-categoryid="5680">Health Care Reform</span></li>
            <li><span class="category-list-item " data-categoryid="5830">Health Care Safety</span></li>
            <li><span class="category-list-item " data-categoryid="5682">Health Care Workforce</span></li>
            <li><span class="category-list-item " data-categoryid="5679">Health Disparities</span></li>
            <li><span class="category-list-item " data-categoryid="46328">Health Inequities</span></li>
            <li><span class="category-list-item " data-categoryid="44020">Health Policy</span></li>
            <li><span class="category-list-item " data-categoryid="46451">Health Systems Science</span></li>
            <li><span class="category-list-item " data-categoryid="5688">Hematology</span></li>
            <li><span class="category-list-item " data-categoryid="5692">History of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5514">Humanities</span></li>
            <li><span class="category-list-item " data-categoryid="5697">Hypertension</span></li>
            <li><span class="category-list-item " data-categoryid="44043">Images in Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="45887">Implementation Science</span></li>
            <li><span class="category-list-item " data-categoryid="5702">Infectious Diseases</span></li>
            <li><span class="category-list-item " data-categoryid="44044">Innovations in Health Care Delivery</span></li>
            <li><span class="category-list-item " data-categoryid="44070">JAMA Infographic</span></li>
            <li><span class="category-list-item " data-categoryid="5716">Law and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45308">Leading Change</span></li>
            <li><span class="category-list-item " data-categoryid="44045">Less is More</span></li>
            <li><span class="category-list-item " data-categoryid="46327">LGBTQIA Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5720">Lifestyle Behaviors</span></li>
            <li><span class="category-list-item " data-categoryid="45311">Medical Coding</span></li>
            <li><span class="category-list-item " data-categoryid="5738">Medical Devices and Equipment</span></li>
            <li><span class="category-list-item " data-categoryid="44023">Medical Education</span></li>
            <li><span class="category-list-item " data-categoryid="5739">Medical Education and Training</span></li>
            <li><span class="category-list-item " data-categoryid="5713">Medical Journals and Publishing</span></li>
            <li><span class="category-list-item " data-categoryid="5746">Melanoma</span></li>
            <li><span class="category-list-item " data-categoryid="44025">Mobile Health and Telemedicine</span></li>
            <li><span class="category-list-item " data-categoryid="5766">Narrative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5769">Nephrology</span></li>
            <li><span class="category-list-item " data-categoryid="5777">Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="44052">Neuroscience and Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44053">Notable Notes</span></li>
            <li><span class="category-list-item " data-categoryid="5787">Nursing</span></li>
            <li><span class="category-list-item " data-categoryid="5788">Nutrition</span></li>
            <li><span class="category-list-item " data-categoryid="44027">Nutrition, Obesity, Exercise</span></li>
            <li><span class="category-list-item " data-categoryid="5791">Obesity</span></li>
            <li><span class="category-list-item " data-categoryid="44013">Obstetrics and Gynecology</span></li>
            <li><span class="category-list-item " data-categoryid="5796">Occupational Health</span></li>
            <li><span class="category-list-item " data-categoryid="5801">Oncology</span></li>
            <li><span class="category-list-item " data-categoryid="5804">Ophthalmology</span></li>
            <li><span class="category-list-item " data-categoryid="5808">Orthopedics</span></li>
            <li><span class="category-list-item " data-categoryid="5811">Otolaryngology</span></li>
            <li><span class="category-list-item " data-categoryid="44028">Pain Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46446">Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="44029">Pathology and Laboratory Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45306">Patient Care</span></li>
            <li><span class="category-list-item " data-categoryid="6258">Patient Information</span></li>
            <li><span class="category-list-item " data-categoryid="5843">Pediatrics</span></li>
            <li><span class="category-list-item " data-categoryid="44060">Performance Improvement</span></li>
            <li><span class="category-list-item " data-categoryid="45315">Performance Measures</span></li>
            <li><span class="category-list-item " data-categoryid="42050">Perioperative Care and Consultation</span></li>
            <li><span class="category-list-item " data-categoryid="42125">Pharmacoeconomics</span></li>
            <li><span class="category-list-item " data-categoryid="42126">Pharmacoepidemiology</span></li>
            <li><span class="category-list-item " data-categoryid="5851">Pharmacogenetics</span></li>
            <li><span class="category-list-item " data-categoryid="44030">Pharmacy and Clinical Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5856">Physical Medicine and Rehabilitation</span></li>
            <li><span class="category-list-item " data-categoryid="42059">Physical Therapy</span></li>
            <li><span class="category-list-item " data-categoryid="45313">Physician Leadership</span></li>
            <li><span class="category-list-item " data-categoryid="44061">Poetry</span></li>
            <li><span class="category-list-item " data-categoryid="45316">Population Health</span></li>
            <li><span class="category-list-item " data-categoryid="46445">Primary Care</span></li>
            <li><span class="category-list-item " data-categoryid="45309">Professional Well-being</span></li>
            <li><span class="category-list-item " data-categoryid="44064">Professionalism</span></li>
            <li><span class="category-list-item " data-categoryid="5871">Psychiatry and Behavioral Health</span></li>
            <li><span class="category-list-item " data-categoryid="42128">Public Health</span></li>
            <li><span class="category-list-item " data-categoryid="5877">Pulmonary Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42129">Radiology</span></li>
            <li><span class="category-list-item " data-categoryid="42058">Regulatory Agencies</span></li>
            <li><span class="category-list-item " data-categoryid="46443">Reproductive Health</span></li>
            <li><span class="category-list-item " data-categoryid="5916">Research, Methods, Statistics</span></li>
            <li><span class="category-list-item " data-categoryid="42142">Resuscitation</span></li>
            <li><span class="category-list-item " data-categoryid="5896">Rheumatology</span></li>
            <li><span class="category-list-item " data-categoryid="46326">Risk Management</span></li>
            <li><span class="category-list-item " data-categoryid="38802">Scientific Discovery and the Future of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5833">Shared Decision Making and Communication</span></li>
            <li><span class="category-list-item " data-categoryid="5912">Sleep Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5915">Sports Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5533">Stem Cell Transplantation</span></li>
            <li><span class="category-list-item " data-categoryid="5921">Substance Use and Addiction Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5923">Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44065">Surgical Innovation</span></li>
            <li><span class="category-list-item " data-categoryid="44066">Surgical Pearls</span></li>
            <li><span class="category-list-item " data-categoryid="44067">Teachable Moment</span></li>
            <li><span class="category-list-item " data-categoryid="45310">Technology and Finance</span></li>
            <li><span class="category-list-item " data-categoryid="44034">The Art of JAMA</span></li>
            <li><span class="category-list-item " data-categoryid="44037">The Arts and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="6257">The Rational Clinical Examination</span></li>
            <li><span class="category-list-item " data-categoryid="5936">Tobacco and e-Cigarettes</span></li>
            <li><span class="category-list-item " data-categoryid="5938">Toxicology</span></li>
            <li><span class="category-list-item " data-categoryid="46433">Translational Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42136">Trauma and Injury</span></li>
            <li><span class="category-list-item " data-categoryid="5942">Treatment Adherence</span></li>
            <li><span class="category-list-item " data-categoryid="46323">Ultrasonography</span></li>
            <li><span class="category-list-item " data-categoryid="5947">Urology</span></li>
            <li><span class="category-list-item " data-categoryid="44069">Users&#39; Guide to the Medical Literature</span></li>
            <li><span class="category-list-item " data-categoryid="5950">Vaccination</span></li>
            <li><span class="category-list-item " data-categoryid="5955">Venous Thromboembolism</span></li>
            <li><span class="category-list-item " data-categoryid="45312">Veterans Health</span></li>
            <li><span class="category-list-item " data-categoryid="5957">Violence</span></li>
            <li><span class="category-list-item " data-categoryid="42139">Women&#39;s Health</span></li>
            <li><span class="category-list-item " data-categoryid="45307">Workflow and Process</span></li>
            <li><span class="category-list-item " data-categoryid="42140">Wound Care, Infection, Healing</span></li>
    </ul>
</div>

    
<div class="manage-interests--save-preferences">
    <div class="save-preferences-btn thm-bg ">
        <span class="save-preferences-btn-text fw-b">Save Preferences</span>
    </div>
</div>
<div class="manage-interests--privacy-terms"> <a class="manage-interests--privacy-terms-color" href="/pages/privacy-policy">Privacy Policy</a> | <a class="manage-interests--privacy-terms-color" href="/pages/terms-of-use">Terms of Use</a></div>

    
    <a class="close-reveal-modal icon-close"></a>
</div> 
    </div>

                </div>
                <h4 class="thm-col-sec" align="center">
                    Others Also Liked
                </h4>
                <div id="trendmd-suggestions"></div>

        </div>


        
        <div id="comments-tab" class="resource-tab js-resource-tab comments-tab js-comments-tab single-comment-view">



        </div>
    </div>
</div>

<a id="skip-to-navigation" href="#" tabindex="-1"></a>
<div id="content-panel" class="content-panel">
    <a id="top"></a>

    <div id="full-text-tab" class="resource-tab js-resource-tab full-text-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_ErrataArticleLinks_FullText">
         
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_ArticleLinks_ToErrata_FullText">
        
 
    </div>
    <div class="widget-ArticleNavLinks widget-instance-AMA_ArticleNavLinks">
                <a class="toc-link btn" href="https://jamanetwork.com/journals/jama/issue/302/6">This Issue</a>
 
    </div>



            <div class="article-metrics-wrapper" id="divArticleLevelMetrics">
    <div class="widget-ArticleLevelMetrics widget-instance-AMA_ArticleMetrics">
        

    <div class="artmet-condensed-wrap clearfix">
        <div class="artmet-condensed-stats clearfix">
                                <div class="artmet-item artmet-citations">
                            <a class="artmet-citations-link" href="https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=silverchair&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000268852300023&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL" target="_blank">
                                <span class="artmet-text">Citations</span>
                                <span class="artmet-number">442</span>
                            </a>
                    </div>
            
        </div>

        <div class="artmet-modal-trigger-wrap">
            <a rel="nofollow" class="artmet-modal-trigger" data-article-id="184381"><i class="icon-metrics"></i><span>View Metrics</span></a>
        </div>
    </div>

 
    </div>

            </div>
        <ul class="toolbar">
            <li class="toolbar-pdf-wrap toolbar-tool-wrap">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="184381" data-article-url="/journals/jama/articlepdf/184381/joc90066_649_659.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>

            </li>
            <li class="toolbar-share-wrap toolbar-tool-wrap">
                <div class="toolbar-tool">
                    <a class="st-custom-button addthis_button_twitter is-b toolbar-twitter toolbar-share"
                       data-network="twitter"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">X</span>
                    </a>
                    <a class="st-custom-button addthis_button_facebook is-b toolbar-facebook toolbar-share"
                       data-network="facebook"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">Facebook</span>
                    </a>
                    <a class="toolbar-share-more-link is-a" rel="nofollow"><span class="icon icon-carrot_down social-arrow"></span><span class="more-text-wrap">More</span></a>
                    <div class="toolbar-share-more">
                        <a class="st-custom-button addthis_button_linkedin is-b toolbar-linkedin toolbar-share"
                           data-network="linkedin"
                           data-title=""
                           data-url=""
                           data-email-subject=""
                           rel="nofollow"
                           href="javascript:;">
                            <span class="share-text">LinkedIn</span>
                        </a>
                    </div>
                </div>
            </li>

            <li class="toolbar-citation-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxGetCitation widget-instance-AMA_Get_Citation">
        
        <a class="toolbar-tool toolbar-citation is-b stats-citation" rel="nofollow" data-reveal-id="get-citation" data-reveal>
            <span class="toolbar-link-text">Cite</span>
            <span class="toolbar-link-text-extra">This</span>
        </a>
    <div id="get-citation" class="reveal-modal get-citation" data-reveal>
        <h3 class="get-citation-title">Citation</h3>
        <p class="get-citation-citation">Chan AT<span class='al-author-delim'>, </span>Ogino S<span class='al-author-delim'>, </span>Fuchs CS. Aspirin Use and Survival After Diagnosis of Colorectal Cancer. <em>JAMA.</em> 2009;302(6):649–658. doi:10.1001/jama.2009.1112</p>
        <h4 class="get-citation-download-heading">Manage citations:</h4>
        <div class="get-citation-types">
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=0">Ris (Zotero)</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=1">EndNote</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=2">BibTex</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=3">Medlars</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=0">ProCite</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=3">RefWorks</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=0">Reference Manager</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=184381&amp;resourceType=3&amp;citationFormat=0">Mendeley</a>
        </div>

        <p class="get-citation-copyright">&#169; 2024 </p>
        <a class="close-reveal-modal icon-close" rel="nofollow"></a>
    </div>


 
    </div>

            </li>
            <li class="toolbar-permissions-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxPermissions widget-instance-AMA_Get_Permissions">
            <a href="http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&amp;publication=0098-7484&amp;title=Aspirin+Use+and+Survival+After+Diagnosis+of+Colorectal+Cancer&amp;publicationDate=2009-08-12&amp;volumeNum=302&amp;issueNum=6&amp;author=Chan%2c+Andrew+T.%3b+Ogino%2c+Shuji&amp;startPage=649&amp;endPage=658&amp;contentId=10.1001%2fjama.2009.1112&amp;oa=&amp;orderBeanReset=True" rel="nofollow" id="PermissionsLink" class="toolbar-tool toolbar-permissions is-b" target="_blank"><span class="toolbar-link-text">Permissions</span></a>
 
    </div>

            </li>
        </ul>

    <div class="widget-ArticleTopInfo widget-instance-AMA_ArticleTop_Info_Widget">
        

    <div class="meta-access-type free-access is-b"></div>


            <span class="hide tagmanagervalue" data-attribute="articleId" data-value="184381" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="arrArticleAuthor" data-value="Andrew%20T.%20Chan%2C%20MD%2C%20MPH,Shuji%20Ogino%2C%20MD%2C%20PhD,Charles%20S.%20Fuchs%2C%20MD%2C%20MPH" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="articleDOI" data-value="10.1001/jama.2009.1112" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articleTitle" data-value="Aspirin Use and Survival After Diagnosis of Colorectal Cancer" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="type" data-value="Original Contribution" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueVolume" data-value="302" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueNo" data-value="6" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="publishDate" data-value="August 12, 2009" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="topics" data-value="Colorectal Cancer, Gastroenterology, Gastrointestinal Cancer, Oncology, Anticoagulation, Gastroenterology and Hepatology" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="topicCode" data-value="5571, 5655, 5657, 5801, 42143, 44012" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="category" data-value="Research" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="journalClub" data-value="No" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentStatus" data-value="Free" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articlePubState" data-value="Final" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentMedium" data-value="Article" data-type="string"></span>


        <div class="meta-article-type-wrap">
            <div class="meta-article-type thm-col">Original Contribution </div>
        </div>
        <div class="meta-date">August 12, 2009</div>
        <div class="meta-article-title-wrap">
            
            <h1 class="meta-article-title ">Aspirin Use and Survival After Diagnosis of Colorectal Cancer</h1>

            
        </div>
            <div class="meta-authors">
                <span class="wi-fullname brand-fg"><a href="/searchresults?author=Andrew+T.+Chan&q=Andrew+T.+Chan" rel=nofollow target="_blank">Andrew T. Chan, MD, MPH<sup></sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Shuji+Ogino&q=Shuji+Ogino" rel=nofollow target="_blank">Shuji Ogino, MD, PhD<sup></sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Charles+S.+Fuchs&q=Charles+S.+Fuchs" rel=nofollow target="_blank">Charles S. Fuchs, MD, MPH<sup></sup></a></span>
            </div>
            <div class="meta-author">
                <a class="meta-author-title is-b stats-meta-author-toggle" data-tog-target=".meta-author-content">Author Affiliations</a>
                    <a class="meta-articleinfo-jumplink section-jump-link scroll-to stats-scroll-to-articleinfo" data-tab-toggle=".tab-nav-full-text" href="#24828500">Article Information</a>


                <div class="meta-author-content">



                            <div class="meta-author-notes"><p class="para"><div class="authorInfo" xmlns:ml="http://www.w3.org/1998/Math/MathML"><p class="para"><strong>Author Affiliations:</strong> Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School (Dr Chan); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, and Department of Epidemiology, Harvard School of Public Health (Dr Ogino); Department of Medical Oncology, Dana-Farber Cancer Institute (Drs Ogino and Fuchs); Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School (Drs Chan and Fuchs) Boston, Massachusetts.</p></div></p></div>
                </div>
            </div>
        <div class="meta-citation-wrap">
            <span class="meta-citation-journal-name">JAMA. </span><span class="meta-citation"> 2009;302(6):649-658. doi:10.1001/jama.2009.1112</span>
        </div>

 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
 
    </div>
    <div class="widget-LinkedContentToolbar widget-instance-AMA_LinkedContentToolbar">
        
<div class="linked-content-toolbar">
    
    <div class="hidden js-search-open-multimedia-by-default" showContentByDefault="False"></div>
    <div class="linked-content-controls">
        <a class="linked-content-trigger td-n stats-graphical-abstract" href="#graphical-abstract-tab">
            <i class="icon-visual-abstract"><span class="sr-t">visual abstract icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Visual <div>Abstract</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-editorial-comment" href="#editorial-comment-tab">
            <i class="icon-document"><span class="sr-t">editorial comment icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Editorial <div>Comment</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-related-articles" href="#related-articles-tab">
            <i class="icon-related"><span class="sr-t">related articles icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Related <div>Articles</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-author-interviews" href="#author-interviews-tab">
            <i class="icon-author_interview"><span class="sr-t">author interview icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Interviews</div>
        </a>
        <a class="linked-content-trigger td-n stats-more-multimedia" href="#more-multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Multimedia</div>
        </a>
        <a class="linked-content-trigger td-n stats-listen-to-this-article" href="#listen-to-this-article-tab">
            <i class="icon-audio"><span class="sr-t">audio icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Listen to <div>this article</div></div>
        </a>
    </div>

    
<div class="linked-content-tabs">
    <div id="graphical-abstract-tab" class="linked-content-tab graphical-abstract-tab">
    <div class="widget-SectionDisplay widget-instance-AMA_GraphicalAbstract_Tab">
        
 
    </div>

    </div>

    
    <div id="editorial-comment-tab" class="linked-content-tab editorial-comment-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_EditorialComments">
        
    <ul class="article-abstract-links related-abstract-content">
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/184364">
                            <div class="related-article-type">Editorial</div>
                        <div class="related-article-title sb-tc">Aspirin as Adjuvant Therapy for Colorectal Cancer</div>
                    </a>
                    <div class="related-article-authors">Alfred I. Neugut, MD, PhD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
    </ul>
 
    </div>

    </div>

    
    <div id="related-articles-tab" class="linked-content-tab related-article-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedArticle">
        
 
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedEditorsChoices">
        
 
    </div>

    </div>

    
    <div id="author-interviews-tab" class="linked-content-tab linked-author-interviews-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_AuthorInterviews">
         
    </div>

    </div>

    
    <div id="listen-to-this-article-tab" class="linked-content-tab linked-listen-to-this-article-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_ListenToThisArticle">
         
    </div>

    </div>

    
    <div id="more-multimedia-tab" class="linked-content-tab more-multimedia-tab">

    </div>
</div>
</div> 
    </div>

            <div class="widget-ArticleFulltext widget-instance-AMA_Article_FullText_Widget">
        <div class="article-full-text" data-userHasAccess="True">
    

            <a class="article-section-id-anchor" id="24828434"></a>
                        <div class="h3 cb section-type-abstract decorated-hed ">

                            <div class="heading-text thm-col sb-sc">
                                Abstract
                            </div>
                        </div>
<p><strong>Context</strong> Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown.</p><p><strong>Objective</strong> To examine the association between aspirin use after colorectal cancer diagnosis on colorectal cancer−specific and overall survival.</p><p><strong>Design, Setting, and Participants</strong> Prospective cohort study of 1279 men and women diagnosed with stage I, II, or III colorectal cancer. Participants were enrolled in 2 nationwide health professional cohorts in 1980 and 1986 prior to diagnosis and followed up through June 1, 2008.</p><p><strong>Main Outcome Measure</strong> Colorectal cancer−specific and overall mortality.</p><p><strong>Results</strong> After a median follow-up of 11.8 years, there were 193 total deaths (35%) and 81 colorectal cancer−specific deaths (15%) among 549 participants who regularly used aspirin after colorectal cancer diagnosis, compared with 287 total deaths (39%) and 141 colorectal cancer−specific deaths (19%) among 730 participants who did not use aspirin. Compared with nonusers, participants who regularly used aspirin after diagnosis experienced a multivariate hazard ratio (HR) for colorectal cancer−specific mortality of 0.71 (95% confidence interval [CI], 0.53-0.95) and for overall mortality of 0.79 (95% CI, 0.65-0.97). Among 719 participants who did not use aspirin before diagnosis, aspirin use initiated after diagnosis was associated with a multivariate HR for colorectal cancer−specific mortality of 0.53 (95% CI, 0.33-0.86). Among 459 participants with colorectal cancers that were accessible for immunohistochemical assessment, the effect of aspirin differed significantly according to cyclooxygenase 2 (COX-2) expression (<em>P</em> for interaction = .04). Regular aspirin use after diagnosis was associated with a lower risk of colorectal cancer−specific mortality among participants in whom primary tumors overexpressed COX-2 (multivariate HR, 0.39; 95% CI, 0.20-0.76), whereas aspirin use was not associated with lower risk among those with primary tumors with weak or absent expression (multivariate HR, 1.22; 95% CI, 0.36-4.18).</p><p><strong>Conclusion</strong> Regular aspirin use after the diagnosis of colorectal cancer is associated with lower risk of colorectal cancer−specific and overall mortality, especially among individuals with tumors that overexpress COX-2.</p>            <div class="movable-ad-target bta"> </div>
            <a class="article-section-id-anchor" id="24828435"></a>
<p class="para">Numerous prospective, observational studies demonstrate that regular aspirin use is associated with a lower risk of colorectal adenoma or cancer.<sup><a href="#ref-joc90066-1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> In addition, randomized, placebo-controlled trials have shown that use of aspirin,<sup><a href="#ref-joc90066-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup><sup>-<a href="#ref-joc90066-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">5</a></sup> as well as celecoxib and rofecoxib,<sup><a href="#ref-joc90066-6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup><sup>-<a href="#ref-joc90066-6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> significantly reduces the risk of adenoma among high-risk patients with a prior history of colorectal neoplasia. Aspirin is likely, at least in part, to prevent colorectal neoplasia through inhibition of cyclooxygenase 2 (COX-2), the rate-limiting step for the conversion of arachidonic acid to prostaglandins and related eicosanoids.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup> COX-2 promotes inflammation and cell proliferation,<sup><a href="#ref-joc90066-11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup> and is overexpressed in the majority of human colorectal cancers.<sup><a href="#ref-joc90066-12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup><sup>,<a href="#ref-joc90066-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup> Overexpression of COX-2 in tumor tissue has been associated with a poorer prognosis among colorectal cancer patients in some<sup><a href="#ref-joc90066-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup><sup>-<a href="#ref-joc90066-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">16</a></sup> but not all studies.<sup><a href="#ref-joc90066-17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup><sup>,<a href="#ref-joc90066-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup></p>            <a class="article-section-id-anchor" id="24828436"></a>
<p class="para">Nevertheless, it remains uncertain if aspirin use can influence the prognosis for patients with established colorectal cancer. In animal models, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) with activity against COX-2 isoenzyme have been shown to inhibit tumor growth and metastases, as well as prolong survival.<sup><a href="#ref-joc90066-19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup><sup>-<a href="#ref-joc90066-19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup> In a study of patients with stage III colon cancer enrolled in an adjuvant chemotherapy trial, aspirin use was associated with a lower risk of disease recurrence and death.<sup><a href="#ref-joc90066-26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup> However, this study only assessed aspirin use after diagnosis.</p>            <a class="article-section-id-anchor" id="24828437"></a>
<p class="para">We therefore studied the effect of aspirin use among patients with nonmetastatic (stage I, II, and III) colorectal cancer who were participating in 2 large prospective cohort studies (the Nurses' Health Study [NHS] and the Health Professionals Follow-up Study [HPFS]) that were initiated prior to cancer diagnosis. Within these cohorts, we previously have demonstrated that regular aspirin use was associated with a reduction in the subsequent risk of developing an initial primary colorectal cancer,<sup><a href="#ref-joc90066-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup><sup>,<a href="#ref-joc90066-28" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">28</a></sup> particularly tumors with COX-2 overexpression.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> Because these participants have provided biennially updated data on aspirin use, we had a unique opportunity to extend these findings by examining the influence of prediagnosis and postdiagnosis aspirin use on the survival of patients with established colorectal cancer. In addition, we assessed whether the effect of aspirin differed according to levels of tumoral expression of COX-2. Specificity in the association between aspirin and colorectal cancer survival to particular tumor markers would further enhance the case for causality, provide important insight into the anticancer mechanism of aspirin, and suggest the potential for use of these markers to tailor cancer therapy.</p>            <a class="article-section-id-anchor" id="24828438"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Methods
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828439"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Study Population
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828440"></a>
<p class="para">The NHS was established in 1976 when 121 701 US women who were registered nurses aged 30 to 55 years completed a mailed questionnaire. The HPFS was established in 1986 as a parallel cohort of 51 529 US men who were dentists, optometrists, osteopathic physicians, podiatrists, pharmacists, and veterinarians aged 40 to 75 years at entry. In each cohort, with a follow-up rate of 92%, we mailed biennial questionnaires to update information and identify new cases of cancer. In 1980, the NHS questionnaire was expanded to include a validated assessment of diet and aspirin use<sup><a href="#ref-joc90066-29" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">29</a></sup><sup>,<a href="#ref-joc90066-30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup>; a similar instrument was administered in the 1986 HPFS questionnaire.<sup><a href="#ref-joc90066-31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">31</a></sup><sup>,<a href="#ref-joc90066-32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup> In both cohorts, participants self-reported their race and ethnicity.</p>            <a class="article-section-id-anchor" id="24828441"></a>
<p class="para">On each biennial follow-up questionnaire, participants were asked whether they had received a diagnosis of colorectal cancer during the prior 2 years. When a participant reported a diagnosis of colorectal cancer, we asked for permission to obtain hospital medical records and pathology reports. Study physicians, blinded to exposure data, reviewed all medical records related to colorectal cancer and classified disease stage according to the sixth version of the American Joint Committee on Cancer.<sup><a href="#ref-joc90066-33" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup> In the NHS, beginning in 1993, we also sent participants who reported a diagnosis of colorectal cancer a supplementary questionnaire that inquired if patients had received chemotherapy. For this analysis, we included the 1279 participants (840 women from NHS and 439 men from HPFS) with pathologically confirmed stage I, II, or III colorectal adenocarcinoma who were diagnosed through 2002 and provided data on aspirin use before and after their diagnosis of the disease. The 154 patients who did not provide data on aspirin use after diagnosis, compared with those included in the analysis, were more likely to have stage III disease (56% vs 32%; <em>P</em> &lt; .0001), but were otherwise similar according to other baseline characteristics (mean age at diagnosis, 65.8 vs 65.0 years; nonwhite, 4% vs 3%; former or current smoker, 62% vs 58%; mean body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]), 26.6 vs 26.2; and aspirin users before diagnosis, 47% vs 44%; <em>P</em> &gt; .21 for all comparisons). We excluded participants if they reported any cancer (other than nonmelanoma skin) previous to colorectal cancer diagnosis. Similar to prior analyses in this cohort, we did not include patients with stage IV colorectal cancer since the vast majority would die of their disease within 1 year of diagnosis.<sup><a href="#ref-joc90066-34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup> We were not funded to collect information on chemotherapy received after diagnosis until 1993, when we began to administer a supplementary treatment questionnaire among participants in the NHS.</p>            <a class="article-section-id-anchor" id="24828442"></a>
<p class="para">The institutional review boards at the Brigham and Women's Hospital and the Harvard School of Public Health approved this study; completion and return of the questionnaire was considered to imply informed consent.</p>            <a class="article-section-id-anchor" id="24828443"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Assessment of COX-2 Expression
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828444"></a>
<p class="para">We have previously described our procurement of tumor specimens and methodology for COX-2 immunostaining in detail.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-35" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">35</a></sup> Beginning in 1997 in the HPFS and 2001 in the NHS, we began retrieving, from treating hospital pathology departments, representative pathological specimens from the primary tumor for participants in whom we confirmed development of colorectal cancer. We successfully obtained specimens for 76% of cases over 16 years of follow-up in HPFS and 58% of cases over 22 years of follow-up in NHS. We did not obtain tissue specimens for recurrent cancers. To determine COX-2 tumor expression, we limited our analysis to those participants for whom we were able to obtain sufficient amounts of tumor tissue from unstained paraffin blocks as well as adjacent mucosa for comparison (n = 459; 207 from NHS and 252 from HPFS). Baseline characteristics among participants with colorectal cancer whom we did and did not analyze for COX-2 expression were largely similar (mean age at diagnosis, 66.3 vs 64.4 years; nonwhite, 3% vs 4%; stage I, 32% vs 34%; stage II, 36% vs 34%; stage III, 32% vs 32%; rectal site, 24% vs 23%; former or current smoker, 61% vs 57%; mean BMI, 26.5 vs 26.1; aspirin users before diagnosis, 42% vs 45%; and aspirin use after diagnosis, 42% vs 43%; <em>P</em> &gt; .21 for all comparisons).<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup></p>            <a class="article-section-id-anchor" id="24828446"></a>
<p class="para">We incubated deparaffinized tissue sections in a citrate buffer by microwave for 15 minutes and cooled for 40 minutes (BioGenex, San Ramon, California). Tissue sections were then incubated with 3% H<sub>2</sub>O<sub>2</sub> for 20 minutes, then avidin block for 15 minutes (Vector Laboratories, Burlingame, California), and then biotin block for 15 minutes (Vector Laboratories). Primary anti-COX-2 antibody (Cayman Chemical, Ann Arbor, Michigan) diluted 1:300 in phosphate-buffered saline was applied overnight at 4°C. We then applied secondary anti−mouse antibody for 20 minutes followed by avidin-biotin complex conjugate (Vector Laboratories). Sections were visualized by diaminobenzidine and methyl-green counterstain. For each assay run, we included a positive control (cancer with COX-2 overexpression) and a negative control (normal colonic tissue). We also treated a positive control specimen with phosphate-buffered saline without anti−COX-2 antibody. As previously described,<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-35" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">35</a></sup> a pathologist (blinded to any other participant data) interpreted tumor COX-2 expression using a standardized grading system (absent, weak, moderate, or strong) comparing the immunohistochemical reactions of tumor cells with adjacent normal colonic epithelium and inflammatory cells, which served as internal built-in controls (<a href="#joc90066f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>). A random sample of 108 cancers was reread by a second pathologist and the concordance between readers was 0.92 (κ = 0.62; <em>P</em> &lt; .001). If immunostaining intensity was moderate or strong, tumors were classified as cancers with COX-2 overexpression (COX-2–positive). If immunostaining intensity was weak or absent, tumors were classified as cancers with negative COX-2 overexpression (COX-2–negative). These specific categories were defined a priori based on our prior analysis and additional categories were not examined.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup></p>            <a class="article-section-id-anchor" id="24828448"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Ascertainment of Death
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828449"></a>
<p class="para">We included deaths that occurred after the completion of the baseline aspirin use questionnaire (1980 in the NHS and 1986 in the HPFS) and before June 1, 2008. We identified deaths through the National Death Index and next of kin. Mortality follow-up was more than 98% complete.<sup><a href="#ref-joc90066-36" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">36</a></sup><sup>,<a href="#ref-joc90066-37" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">37</a></sup> For all deaths, we sought information to determine the cause (including death certificates) and when appropriate, requested permission from next of kin to review medical records.</p>            <a class="article-section-id-anchor" id="24828450"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Assessment of Medication Use
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828451"></a>
<p class="para">We have previously detailed our assessment of aspirin use in both the NHS and HPFS cohorts.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup><sup>,<a href="#ref-joc90066-30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup><sup>,<a href="#ref-joc90066-38" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">38</a></sup><sup>,<a href="#ref-joc90066-39" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">39</a></sup> In 1980 we asked NHS participants if they regularly used aspirin in most weeks, the number of pills or capsules taken each week, and the number of years of use. We updated this information biennially (except in 1986) with specific questions on the number of aspirin tablets used per week (in categories). In the 1986 HPFS questionnaire and every 2 years thereafter, we inquired if participants regularly used aspirin 2 or more times per week. Beginning in 1992, we also asked the average number of tablets used per week (in categories). In both cohorts, we specifically inquired about standard-dose (325 mg) aspirin tablets. However, to reflect secular trends in consumption of low-dose ([baby], 81 mg) aspirin, questionnaires after 1992 asked participants to convert intake of 4 baby aspirin to 1 adult standard-dose tablet when responding. We did not collect consistent data over follow-up on nonaspirin NSAIDs in both cohorts. In addition, there was insufficient follow-up after the introduction of COX-2–selective inhibitors in the United States in 1999 and only 17 participants used these agents. Thus, we did not examine these drugs in the present study.</p>            <a class="article-section-id-anchor" id="24828452"></a>
<p class="para">Reasons for aspirin use were not assessed for the entire cohort, but supplementary validation questionnaires were sent in 1990 to a sample of 200 women (91% response) and in 1993 to a sample of 211 men (88% response) who reported aspirin use on the main questionnaire. The major reasons for use among women taking 1 to 6 aspirin and 7 or more aspirin per week were headache (32% and 18%, respectively); arthritis and other musculoskeletal pain (30% and 50%); a combination of headache and musculoskeletal pain (16% and 15%); cardiovascular disease prevention (9% and 8%); and other reasons (13% and 9%).<sup><a href="#ref-joc90066-30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup> Among men, the major reasons for use were cardiovascular disease (25.4%); to decrease risk of cardiovascular disease (58.4%); headaches (25.4%); joint or musculoskeletal pain (33.0%); and other reasons (7.0%).<sup><a href="#ref-joc90066-32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup></p>            <a class="article-section-id-anchor" id="24828453"></a>
<p class="para">As previously described, we asked NHS participants in 2004 and HPFS participants in 2006 to report any major episodes of gastrointestinal bleeding that required either hospitalization or a blood transfusion. Among the women, the incidence of events per 1000 person-years was 0.77 among those who reported no aspirin use; 1.07 for 0.5 to 1.5 standard aspirin tablets per week; 1.07 for 2 to 5 aspirin per week; 1.40 for 6 to 14 aspirin per week; and 1.57 for more than 14 aspirin per week. Among the men, the incidence of events per 1000 person-years was 0.92 among those who reported no aspirin use; 1.02 for 0.5 to 1.5 standard aspirin tablets per week; 1.65 for 2 to 5 aspirin per week; and 1.84 for 6 or more aspirin per week.<sup><a href="#ref-joc90066-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup></p>            <a class="article-section-id-anchor" id="24828454"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Power Analysis
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828455"></a>
<p class="para">Our a priori hypothesis was that aspirin use after diagnosis is associated with a lower risk of colorectal cancer−related death among participants with nonmetastatic colorectal cancer. Based on the sample size of 1279 participants diagnosed with stage I, II, and III colorectal cancer between 1980 and 2002 in the NHS cohort and 1986 and 2002 in the HPFS cohort, the number of colorectal cancer−related deaths, and the prevalence of aspirin use after diagnosis, we had 80% power to detect a hazard ratio (HR) of 0.70 comparing aspirin users with nonusers.<sup><a href="#ref-joc90066-40" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">40</a></sup></p>            <a class="article-section-id-anchor" id="24828456"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Statistical Analysis
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828457"></a>
<p class="para">In both the NHS and HPFS cohorts, we have administered similar biennial questionnaires, ascertained cancers and deaths with comparable methodologies, collected pathological specimens through a common biospecimen repository, and concurrently assayed for COX-2 with a uniform protocol. Thus, as in our prior analysis,<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> we pooled data from both cohorts and tested for heterogeneity using the Cochran <em>Q</em> statistic. We observed no heterogeneity between the cohorts regarding the association of aspirin use after diagnosis and colorectal cancer−specific survival (P  = .93, Cochran <em>Q</em> test).<sup><a href="#ref-joc90066-41" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">41</a></sup></p>            <a class="article-section-id-anchor" id="24828458"></a>
<p class="para">Participants eligible for analysis accrued follow-up time beginning on the month of their diagnosis of colorectal cancer and ending on the month of death from colorectal cancer, death from any cause, or June 1, 2008, whichever came first. We categorized participants according to aspirin data provided prior to the date of diagnosis of colorectal cancer and after the date of diagnosis. We used Kaplan-Meier curves and the log-rank test to compare colorectal cancer−specific and overall mortality according to aspirin use.</p>            <a class="article-section-id-anchor" id="24828459"></a>
<p class="para">We used Cox proportional hazards modeling to control for multiple risk factors that have been shown to influence colorectal cancer survival to compute 95% confidence intervals (CIs). We have used this model-building approach in previous analyses of these cohorts.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup><sup>,<a href="#ref-joc90066-28" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">28</a></sup> The validity of the proportional hazards assumption was assessed by using time-dependent covariates; the Wald test showed no evidence of departure from this assumption. We assessed overfitting and collinearity of the model by using collinearity diagnostics; variance inflation factors showed no significant collinearity between each of our included covariates.</p>            <a class="article-section-id-anchor" id="24828460"></a>
<p class="para">We conducted preplanned stratified analyses according to COX-2 status of the primary tumors as well as subgroups defined by our prior study of physical activity and survival in this cohort. Consistent with this prior analysis, we also observed, comparing extreme tertile categories, a significant association between colorectal cancer−specific mortality and postdiagnosis physical activity (multivariate HR, 0.50; 95% CI, 0.36-0.71), but not BMI at diagnosis (multivariate HR, 0.99; 95% CI, 0.71-1.39).<sup><a href="#ref-joc90066-34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup> We assessed statistical interaction of subgroups by including cross-product terms in our models and assessing their significance using the Wald test. As in our prior study, we also performed an analysis excluding deaths that occurred within 12 months of completing the postdiagnosis aspirin assessment.</p>            <a class="article-section-id-anchor" id="24828461"></a>
<p class="para">In a secondary analysis, to further evaluate for potential bias related to differences among participants who chose to use aspirin after diagnosis compared with those who did not, we computed a propensity score by using logistic regression assigning postdiagnosis aspirin use as the dependent variable and the risk factors listed in <a href="#joc90066t1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1</a> as independent variables. We categorized the propensity scores into quintiles and adjusted for these quintile categories in Cox proportional hazards models.<sup><a href="#ref-joc90066-42" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">42</a></sup><sup>,<a href="#ref-joc90066-43" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">43</a></sup></p>            <a class="article-section-id-anchor" id="24828471"></a>
<p class="para">The linear trend test across categories was calculated by using the median value of each category as a continuous variable, consistent with prior studies.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup><sup>,<a href="#ref-joc90066-34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup> We used SAS software version 9.1.3 (SAS Institute Inc, Cary, North Carolina). All <em>P</em> values were 2-sided and a level of significance of less than .05 was considered statistically significant.</p>            <a class="article-section-id-anchor" id="24828472"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Results
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828473"></a>
<p class="para">Among the 1279 eligible participants with stage I, II, or III colorectal cancer, we documented 480 total deaths among which 222 deaths were due to colorectal cancer. For participants who were alive through the end of follow-up, the median time of follow-up from date of diagnosis was 11.8 years (interquartile range, 7.6-16.2). There were 536 participants who did not regularly use aspirin before and after diagnosis (42%), 366 regularly used aspirin before and after diagnosis (29%), 194 regularly used aspirin before diagnosis but then discontinued use after diagnosis (15%), and 183 did not regularly use aspirin before diagnosis but initiated use after diagnosis (14%). Baseline characteristics of the participants are shown in <a href="#joc90066t1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1</a>. Compared with nonusers, regular users of aspirin before diagnosis appeared to be less physically active. After diagnosis, regular users of aspirin after also appeared to be less physically active, were more likely to have previously smoked cigarettes, and were less likely to be diagnosed with stage III disease compared with nonusers.</p>            <a class="article-section-id-anchor" id="24828474"></a>
<p class="para">There were 193 total deaths (35%) and 81 colorectal cancer−specific deaths (15%) among 549 participants who regularly used aspirin after colorectal cancer diagnosis, compared with 287 (39%) total and 141 (19%) colorectal cancer−specific deaths among 730 participants who did not use aspirin. For the entire cohort, the overall 5-year survival was 88% for those participants who used aspirin compared with 83% for those who did not. The corresponding 10-year survival rates were 74% and 69%. Regular use of aspirin after diagnosis was associated with a significant reduction in risk of colorectal cancer−specific mortality (log-rank <em>P</em> = .02; <a href="#joc90066f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>A) and a reduction in overall mortality (log-rank <em>P</em> = .03; <a href="#joc90066f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>B). The relationship remained largely unchanged even after adjusting for use of aspirin before diagnosis as well as other predictors of cancer recurrence (<a href="#joc90066t2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). Compared with nonusers, the multivariate HR associated with regular aspirin use after diagnosis was 0.71 (95% CI, 0.53-0.95) for colorectal cancer−specific mortality and 0.79 (95% CI, 0.65-0.97) for overall mortality. Because the prognosis among stage I participants is generally favorable, we also examined the influence of aspirin use among those diagnosed with stage II or III disease and observed similar results (multivariate HR, 0.72; 95% CI, 0.53-0.99 for colorectal cancer−specific mortality and multivariate HR, 0.82; 95% CI, 0.66-1.04 for overall mortality).</p>            <a class="article-section-id-anchor" id="24828477"></a>
<p class="para">In contrast to aspirin use after diagnosis, aspirin use prior to cancer diagnosis did not appear to be associated with either colorectal cancer−specific mortality (multivariate HR, 1.05; 95% CI, 0.80-1.37) or overall mortality (multivariate HR, 0.93; 95% CI, 0.77-1.11). This relationship was consistent after including those participants with colorectal cancer who did not return a postdiagnosis aspirin questionnaire (multivariate HR, 1.00; 95% CI, 0.81-1.25). A formal test for interaction between aspirin use before diagnosis vs aspirin use after diagnosis on colorectal cancer−specific mortality was not statistically significant (<em>P</em> = .09). However, simultaneous inclusion of both prediagnosis and postdiagnosis aspirin use in models confirmed that postdiagnosis aspirin use remained independently associated with colorectal cancer−specific mortality (<em>P</em> = .008) and overall mortality (<em>P</em> = .03), while prediagnosis aspirin use was not significantly associated with either colorectal cancer−specific mortality (<em>P</em> = .14) or overall mortality (<em>P</em> = .98).</p>            <a class="article-section-id-anchor" id="24828478"></a>
<p class="para">To better characterize this relationship, we examined postdiagnosis aspirin use according to use of aspirin prior to cancer diagnosis (<a href="#joc90066t2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). Among the 719 participants who did not use aspirin before diagnosis, initiation of use postdiagnosis was associated with a multivariate HR for colorectal cancer−specific mortality of 0.53 (95% CI, 0.33-0.86) and overall mortality of 0.68 (95% CI, 0.51-0.92). In contrast, among participants who were using aspirin before diagnosis, continuation of aspirin use postdiagnosis was not associated with a significant reduction in colorectal cancer−specific survival (multivariate HR, 0.89; 95% CI, 0.59-1.35) or overall survival (multivariate HR, 0.95; 95% CI, 0.71-1.28).</p>            <a class="article-section-id-anchor" id="24828479"></a>
<p class="para">We have previously shown that aspirin use is associated with a lower risk of subsequently developing colorectal COX-2–positive cancers but not colorectal COX-2–negative cancers.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> Thus, we examined whether the effect of postdiagnosis aspirin use on survival differed according to COX-2 expression status within the primary tumors. Among 459 participants for whom we had sufficient tumor tissue with adjacent normal mucosa to assay for COX-2, the benefit of aspirin use after diagnosis appeared to be confined to those with COX-2–positive primary tumors (<a href="#joc90066t2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). Among participants with COX-2–positive tumors, regular aspirin use after diagnosis was associated with a lower risk of colorectal cancer−specific (multivariate HR, 0.39; 95% CI, 0.20-0.76) and overall (HR, 0.62; 95% CI, 0.42-0.93) mortality, whereas postdiagnosis aspirin use was not associated with lower risk of either colorectal cancer−specific or overall mortality for those with COX-2–negative tumors. A test for heterogeneity of the effect of regular aspirin use after diagnosis on survival for COX-2–positive tumors vs COX-2–negative tumors was statistically significant (<em>P</em> for interaction = .04).</p>            <a class="article-section-id-anchor" id="24828480"></a>
<p class="para">We considered the possibility that the superior benefit of postdiagnosis aspirin use among COX-2–positive cancers reflected the observation that COX-2–positive cancers are more likely to develop among individuals who abstain from aspirin use prior to cancer diagnosis. In a post hoc analysis, we therefore examined the joint effect of prediagnosis and postdiagnosis aspirin use according to tumoral COX-2 expression. Although participants who reported aspirin use following diagnosis but not before diagnosis (postdiagnosis use only) experienced a significant reduction in colorectal cancer−specific mortality from COX-2–positive cancers (HR, 0.22; 95% CI, 0.07-0.74), COX-2–positive participants who reported aspirin use both before and after diagnosis also experienced a nonsignificant reduction in colorectal cancer−specific mortality (HR, 0.56; 95% CI, 0.23-1.33).</p>            <a class="article-section-id-anchor" id="24828481"></a>
<p class="para">Among participants who did not use aspirin before diagnosis, the association between postdiagnosis aspirin use and survival was modestly dose-responsive (<a href="#joc90066t3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a>). Compared with individuals who used any aspirin, the multivariate-adjusted HR for colorectal cancer−specific mortality was 0.57 (95% CI, 0.32-0.99) for those who used 0.5 to 5 standard aspirin tablets and 0.49 (95% CI, 0.18-1.35) for individuals who used 6 or more tablets per week (<em>P</em> for trend = .04).</p>            <a class="article-section-id-anchor" id="24828483"></a>
<p class="para">Since the decision to use or avoid aspirin could be influenced by occult cancer recurrence or impending death, we performed a secondary analysis in which we excluded participants who died within 12 months of completing the assessment of postdiagnosis aspirin use. Our results were essentially unchanged. Compared with nonusers, participants who regularly used any aspirin after diagnosis had a multivariate-adjusted HR for colorectal cancer−specific mortality of 0.71 (95% CI, 0.53-0.95) and a multivariate HR for overall mortality of 0.80 (95% CI, 0.65-0.97). Moreover, when we examined survival from the date of return of the questionnaire regarding postdiagnosis aspirin use rather than the date of diagnosis of colorectal cancer, we also observed similar results (multivariate HR, 0.71; 95% 0.53-0.95 for colorectal cancer−specific mortality and multivariate HR, 0.79; 95% CI, 0.65-0.97 for overall mortality).</p>            <a class="article-section-id-anchor" id="24828484"></a>
<p class="para">Because aspirin use was not randomly assigned in this population, we also conducted a secondary analysis using a propensity score in which we computed each participant's probability to use aspirin after diagnosis of colorectal cancer without regard to outcome. Adjusting for quintile categories of this propensity score did not alter our findings (propensity-adjusted HR, 0.70; 95% CI, 0.52-0.94 for colorectal cancer−specific mortality and propensity-adjusted HR, 0.82; 95% CI, 0.67-0.99 for overall mortality).</p>            <a class="article-section-id-anchor" id="24828485"></a>
<p class="para">We also evaluated potential differences in the influence of aspirin according to strata of clinical characteristics. There were no significant differences in the influence of aspirin in strata defined by sex (cohort), age, cancer stage, site of primary tumor, year of diagnosis, or BMI (<a href="#joc90066f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>). We also confirmed that the inverse association between postdiagnosis aspirin use and colorectal cancer−specific mortality was also observed among the 241 participants for whom we collected data on treatment. Although statistical power was limited, the association between postdiagnosis aspirin use and mortality did not appear to be materially changed, even after accounting for receipt of chemotherapy (multivariate HR, 0.40; 95% CI, 0.15-1.10 for colorectal cancer−specific mortality and multivariate HR, 0.53; 95% CI, 0.26-1.07 for overall mortality). Moreover, postdiagnosis aspirin use was not associated with likelihood of receiving adjuvant chemotherapy across stages of colorectal cancer. Among participants with stage I colorectal cancer, 11% of aspirin users received chemotherapy compared with 12% of nonusers (<em>P</em> for difference = .82). Similarly, among participants with stage II or III colorectal cancer, 73% of aspirin users received chemotherapy compared with 77% of nonusers (<em>P</em> for difference = .53).</p>            <a class="article-section-id-anchor" id="24828487"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Comment
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="24828488"></a>
<p class="para">In summary, we observed that use of aspirin after a diagnosis of nonmetastatic colorectal cancer was associated with a decreased risk of colorectal cancer−specific mortality. This inverse association appeared to be strongest among participants whose primary tumors overexpressed COX-2. This relationship appeared to be independent of the intake of aspirin prior to diagnosis and was modestly related to increasing aspirin dose.</p>            <a class="article-section-id-anchor" id="24828489"></a>
<p class="para">Our results are consistent with findings based on a detailed survey of medication use and lifestyle administered to 846 patients with stage III colon cancer enrolled in a postoperative adjuvant chemotherapy trial comparing bolus fluorouracil and leucovorin to bolus irinotecan and bolus fluorouracil and leucovorin.<sup><a href="#ref-joc90066-26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup> In that study, consistent aspirin use was associated with an HR for cancer recurrence, death, or both combined of 0.48 (95% CI, 0.24-0.99), comparable with our findings. Moreover, regular use of the COX-2–selective inhibitors celecoxib or rofecoxib was similarly associated with a lower risk of cancer recurrence and mortality. However, aspirin use was only assessed after initial diagnosis of cancer. Thus, it was unclear if the observed benefit might actually reflect a more favorable behavior of tumors initiated within an environment of aspirin use before diagnosis rather than an effect of aspirin on established cancer. Our data demonstrate that aspirin intake after, but not before the development of stage I, II, or III cancer is associated with improved survival. This suggests that aspirin may have a specific effect on the prevention or progression of micrometastases among individuals with established disease. Notably, among participants who used aspirin before diagnosis, continuation of aspirin use after diagnosis did not appear to influence survival. This suggests the possibility that tumors that initially developed despite exposure to aspirin may be less susceptible to any potential effect of aspirin on tumor progression.</p>            <a class="article-section-id-anchor" id="24828490"></a>
<p class="para">Several mechanisms have been hypothesized to underlie the influence of aspirin on colorectal neoplasia, including inhibition of nuclear factor-κB,<sup><a href="#ref-joc90066-44" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">44</a></sup> induction of apoptosis by activation of p38 kinase,<sup><a href="#ref-joc90066-45" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">45</a></sup> and catabolism of polyamines.<sup><a href="#ref-joc90066-46" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">46</a></sup> However, we had previously shown that regular aspirin use was associated with a significant reduction in the subsequent risk of developing a primary COX-2–positive colorectal cancer but not a COX-2–negative tumor, suggesting that aspirin works principally by inhibiting COX-2 or its downstream effectors.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#ref-joc90066-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup> In the current study, we found that aspirin use after diagnosis was associated with lower colorectal cancer−specific mortality among individuals with COX-2–positive tumors but not COX-2–negative tumors. This supports the hypothesis that COX-2–positive tumors may be relatively sensitive to the anticancer effect of aspirin, whereas COX-2–negative tumors may be relatively aspirin-resistant. Moreover, it potentially explains the observation that the benefit of postdiagnosis aspirin use on patient survival was not apparent among patients who used aspirin prior to cancer diagnosis.</p>            <a class="article-section-id-anchor" id="24828491"></a>
<p class="para">Our findings are also supported by other studies in humans. A placebo-controlled study of 135 malnourished patients with various solid tumors reported that patients randomized to indomethacin had a prolonged survival that was statistically significant.<sup><a href="#ref-joc90066-47" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">47</a></sup> A randomized trial of standard-dose aspirin in patients with prior Dukes stage A or B1 colon or rectal cancer who had undergone curative resection of their primary tumor demonstrated a 35% reduction in risk of colorectal adenoma after a median 30 months of treatment.<sup><a href="#ref-joc90066-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup> In addition, intratumoral expression of COX-2 has been independently associated with tumor differentiation,<sup><a href="#ref-joc90066-17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup> angiogenesis,<sup><a href="#ref-joc90066-48" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">48</a></sup><sup>,<a href="#ref-joc90066-49" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">49</a></sup> recurrence,<sup><a href="#ref-joc90066-50" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">50</a></sup> and metastasis.<sup><a href="#ref-joc90066-51" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">51</a></sup> Moreover, COX-2 expression has been correlated with worsened patient survival in some<sup><a href="#ref-joc90066-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup><sup>-<a href="#ref-joc90066-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">16</a>,<a href="#ref-joc90066-48" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">48</a></sup> but not all studies.<sup><a href="#ref-joc90066-17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup><sup>,<a href="#ref-joc90066-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a>,<a href="#ref-joc90066-52" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">52</a></sup><sup>,<a href="#ref-joc90066-53" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">53</a></sup></p>            <a class="article-section-id-anchor" id="24828492"></a>
<p class="para">Our results are also supported by substantial experimental data. In colon cancer cell lines and mice, aspirin and other NSAIDs interrupt tumor growth,<sup><a href="#ref-joc90066-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup><sup>,<a href="#ref-joc90066-21" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a>,<a href="#ref-joc90066-23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup><sup>-<a href="#ref-joc90066-23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a>,<a href="#ref-joc90066-54" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">54</a></sup> inhibit angiogenesis,<sup><a href="#ref-joc90066-22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup><sup>,<a href="#ref-joc90066-25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup><sup>,<a href="#ref-joc90066-55" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">55</a></sup><sup>,<a href="#ref-joc90066-56" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">56</a></sup> abrogate invasiveness,<sup><a href="#ref-joc90066-24" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">24</a></sup><sup>,<a href="#ref-joc90066-57" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">57</a></sup><sup>,<a href="#ref-joc90066-58" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">58</a></sup> and retard metastasis.<sup><a href="#ref-joc90066-19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup><sup>,<a href="#ref-joc90066-22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup><sup>-<a href="#ref-joc90066-22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup> Aspirin and NSAIDs also enhance responsiveness to chemotherapy,<sup><a href="#ref-joc90066-23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup><sup>,<a href="#ref-joc90066-25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup><sup>,<a href="#ref-joc90066-59" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">59</a></sup><sup>,<a href="#ref-joc90066-60" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">60</a></sup> increase expression of mismatch repair proteins,<sup><a href="#ref-joc90066-61" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">61</a></sup> and improve overall survival.<sup><a href="#ref-joc90066-23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup><sup>,<a href="#ref-joc90066-25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup> Moreover, aspirin and NSAIDs inhibit the production of prostaglandins that promote cancer cell growth and the production of angiogenic factors.<sup><a href="#ref-joc90066-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup><sup>,<a href="#ref-joc90066-62" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">62</a></sup><sup>,<a href="#ref-joc90066-63" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">63</a></sup></p>            <a class="article-section-id-anchor" id="24828493"></a>
<p class="para">Our study has several important strengths. First, we used prospectively collected data on aspirin use. Thus, we were able to minimize potential bias related to differential recall of aspirin use according to disease activity, and any errors in recall would have tended to attenuate rather than exaggerate true associations. Second, we obtained data on aspirin use both before and after cancer diagnosis. This permitted us to disentangle the effect of aspirin use after diagnosis from aspirin use before diagnosis. We considered the possibility that regular aspirin users who develop colorectal cancer simply acquire tumors that are biologically less aggressive. However, the benefit of regular aspirin use was largely restricted to patients who initiated aspirin use following cancer diagnosis; after adjusting for postdiagnosis aspirin use, regular aspirin use before cancer diagnosis was not associated with any reduction in colorectal cancer or overall mortality. Finally, since all participants were health professionals, the accuracy of self-reported aspirin use is likely to be high and more likely to reflect actual consumption of these largely over-the-counter medications.</p>            <a class="article-section-id-anchor" id="24828494"></a>
<p class="para">Several limitations of this study warrant comment. First, our study was observational and aspirin use was self-selected. Thus, despite the strong biological plausibility of our results, it is possible that our findings could be related to the reason for which participants used aspirin. However, most participants reported using aspirin primarily for analgesia.<sup><a href="#ref-joc90066-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup> During much of the study period, data regarding an association between aspirin and colorectal neoplasia were also not widely available, suggesting that it is unlikely participants took aspirin for the purpose of cancer prevention. Moreover, an analysis adjusting for an individual's propensity to use aspirin also did not materially change our results. We also cannot completely exclude the possibility that aspirin use may be reflective of other occult predictors for improved prognosis. However, we did not observe any significant association between aspirin use and other predictors of cancer outcome and our findings remained unchanged after adjusting for other potential risk factors for colorectal cancer mortality. Finally, the differential effect of aspirin according to COX-2 expression is consistent with a causal mechanism. To minimize any bias by occult cancer recurrence, we also performed a secondary analysis in which we excluded deaths within 12 months of the aspirin assessment and continued to observe a significant influence of regular aspirin use on patient outcome.</p>            <a class="article-section-id-anchor" id="24828495"></a>
<p class="para">Beyond causes of mortality, data on cancer recurrences were not available in this cohort. Nonetheless, since median survival for recurrent (metastatic) colorectal cancer was approximately 10 to 12 months during much of the time period of this study,<sup><a href="#ref-joc90066-64" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">64</a></sup> colorectal cancer−specific mortality should be a reasonable surrogate for cancer-specific outcome. In this cohort, we also had limited data on chemotherapy. However, it is unlikely that differential receipt of chemotherapy could explain the observed findings. First, the association of aspirin use and survival was similar among participants with stage I or II disease (for which surgery alone would represent a standard of care) and among those with stage III cancer (for which adjuvant chemotherapy would represent a routine approach). Second, since our cohort consisted of health professionals, considerable heterogeneity in use of adjuvant chemotherapy would be unlikely. Third, in this cohort, aspirin use was not associated with the likelihood of receiving adjuvant chemotherapy. Among participants with stage I colorectal cancer, 11% of aspirin users received chemotherapy compared with 12% of nonusers (<em>P</em> for difference = .82). Similarly, among participants with stage II or III colorectal cancer, 73% of aspirin users received chemotherapy compared with 77% of nonusers (<em>P</em> for difference = .53). Fourth, when we repeated our analyses adjusting for receipt of chemotherapy among participants for whom data on chemotherapy use was available, the association between aspirin use and survival was not materially altered.</p>            <a class="article-section-id-anchor" id="24828496"></a>
<p class="para">Importantly, our results are consistent with findings in a separate cohort nested in a National Cancer Institute−sponsored adjuvant chemotherapy trial that similarly found that regular aspirin use was associated with a significant reduction in cancer recurrence and mortality. In that latter cohort, data on disease recurrence as well as mortality were consistently collected and chemotherapy treatment was uniformly administered by protocol.<sup><a href="#ref-joc90066-26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup></p>            <a class="article-section-id-anchor" id="24828497"></a>
<p class="para">We were unable to obtain tumor tissue on all cases of confirmed colorectal cancer over follow-up. However, it is unlikely that COX-2 expression or mortality would be differential according to retrieval success. Moreover, an assessment of risk factors and the effect of aspirin on colorectal cancer risk did not appreciably differ among those participants for whom we were unable to obtain tumor tissue.<sup><a href="#ref-joc90066-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup></p>            <a class="article-section-id-anchor" id="24828498"></a>
<p class="para">Finally, although we had sufficient statistical power for our primary analysis of postdiagnosis aspirin use and risk of colorectal cancer−specific and overall mortality, we had comparatively limited sample sizes in some of our subgroups, such as the cohort of participants with treatment data or available archived tumor tissue. Thus, although the results of our secondary analyses within these subgroups support our primary findings, the precise risk estimates should be cautiously interpreted in light of the relatively wide associated CIs.</p>            <a class="article-section-id-anchor" id="24828499"></a>
<p class="para">Our findings show that use of aspirin after diagnosis of nonmetastatic colorectal cancer is associated with improved survival from the disease, particularly among individuals with primary tumors that overexpress COX-2. These results suggest that aspirin may influence the biology of established colorectal tumors in addition to preventing their occurrence. Our data also highlight the potential for using COX-2 or related markers to tailor aspirin use among patients with newly diagnosed colorectal cancer. Nonetheless, because our data are observational, routine use of aspirin or related agents as cancer therapy cannot be recommended, especially in light of concerns over their related toxicities, such as gastrointestinal bleeding.<sup><a href="#ref-joc90066-1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup><sup>,<a href="#ref-joc90066-65" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">65</a></sup> Further studies among patients with colorectal cancer, including placebo-controlled trials of aspirin or related agents as adjuncts to other routine therapies, are required.</p>            <a class="article-section-id-anchor" id="24828500"></a>
                        <div class="h3 cb section-type-acknowledgements  has-back-to-top">
                                <a href="#top" class="section-jump-link back-to-top" data-tab-toggle=".tab-nav-full-text">Back to top</a>

                            <div class="heading-text thm-col sb-sc">
                                Article Information
                            </div>
                        </div>
<p class="authorInfoSection"><strong>Corresponding Author:</strong> Andrew T. Chan, MD, MPH, Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit St, GRJ 722 Boston, MA 02114 (<a href="mailto:achan@partners.org" target="_blank">achan@partners.org</a>).</p><p class="para"><strong>Author Contributions:</strong> Dr Chan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p class="para"><em>Study concept and design</em>: Chan, Fuchs.</p><p class="para"><em>Acquisition of data</em>: Chan, Ogino, Fuchs.</p><p class="para"><em>Analysis and interpretation of data</em>: Chan, Ogino, Fuchs.</p><p class="para"><em>Drafting of the manuscript</em>: Chan, Fuchs.</p><p class="para"><em>Critical revision of the manuscript for important intellectual content</em>: Chan, Ogino, Fuchs.</p><p class="para"><em>Statistical analysis</em>: Chan.</p><p class="para"><em>Obtained funding</em>: Chan, Fuchs.</p><p class="para"><em>Administrative, technical, or material support</em>: Chan, Ogino, Fuchs.</p><p class="para"><em>Study supervision</em>: Chan, Fuchs.</p><div class="findDisclosureSection"><p class="para"><strong>Financial Disclosures:</strong> None reported.</p></div><p class="para"><strong>Funding/Support:</strong> This work was supported by grants CA87969, CA55075, CA118553, CA127003, and CA137178 from the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr Chan is a recipient of the Damon Runyon Cancer Research Foundation Clinical Investigator Award and a career development award from the NCI (CA107412). Dr Ogino is a recipient of a career development award from the NCI (CA122826).</p><p class="para"><strong>Role of the Sponsor:</strong> The NCI, the NIH, and the Damon Runyon Cancer Research Foundation had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.</p><p class="para"><strong>Previous Presentations:</strong> An abstract of this data was presented on June 1, 2009, at the clinical plenary session of the American Gastroenterological Association/Digestive Disease Week, Chicago, Illinois.</p>            <a class="article-section-id-anchor" id="24828501"></a>
                        <div class="h3 cb section-type-references  ">

                            <div class="heading-text thm-col sb-sc">
                                References
                            </div>
                        </div>
<div class="references"><div class="reference"><a class="reference-number" id="ref-joc90066-1">1.</a><div class="reference-content">Dubé C, Rostom A, Lewin G, 
     et al; US Preventive Services Task Force.  The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</I>. 2007;146(5):365-37517339622<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17339622" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20use%20of%20aspirin%20for%20primary%20prevention%20of%20colorectal%20cancer%3A%20a%20systematic%20review%20prepared%20for%20the%20US%20Preventive%20Services%20Task%20Force.&amp;author=C%20Dubé&amp;author=A%20Rostom&amp;author=G%20Lewin&amp;publication_year=&amp;journal=Ann%20Intern%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/0003-4819-146-5-200703060-00009" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/0003-4819-146-5-200703060-00009" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-2">2.</a><div class="reference-content">Baron JA, Cole BF, Sandler RS, 
     et al.  A randomized trial of aspirin to prevent colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2003;348(10):891-89912621133<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12621133" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20aspirin%20to%20prevent%20colorectal%20adenomas.&amp;author=JA%20Baron&amp;author=BF%20Cole&amp;author=RS%20Sandler&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa021735" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa021735" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-3">3.</a><div class="reference-content">Sandler RS, Halabi S, Baron JA, 
     et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2003;348(10):883-89012621132<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12621132" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20aspirin%20to%20prevent%20colorectal%20adenomas%20in%20patients%20with%20previous%20colorectal%20cancer.&amp;author=RS%20Sandler&amp;author=S%20Halabi&amp;author=JA%20Baron&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa021633" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa021633" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-4">4.</a><div class="reference-content">Benamouzig R, Deyra J, Martin A, 
     et al.  Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2003;125(2):328-33612891533<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12891533" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Daily%20soluble%20aspirin%20and%20prevention%20of%20colorectal%20adenoma%20recurrence%3A%20one-year%20results%20of%20the%20APACC%20trial.&amp;author=R%20Benamouzig&amp;author=J%20Deyra&amp;author=A%20Martin&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0016-5085(03)00887-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0016-5085(03)00887-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-5">5.</a><div class="reference-content">Logan RF, Grainge MJ, Shepherd VC, Armitage  NC, Muir KR.ukCAP Trial Group.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2008;134(1):29-3818022173<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18022173" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20folic%20acid%20for%20the%20prevention%20of%20recurrent%20colorectal%20adenomas.&amp;author=RF%20Logan&amp;author=MJ%20Grainge&amp;author=VC%20Shepherd&amp;author=NC%20Armitage&amp;author=KR%20Muir&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2007.10.014" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2007.10.014" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-6">6.</a><div class="reference-content">Bertagnolli MM, Eagle CJ, Zauber AG, 
     et al; APC Study Investigators.  Celecoxib for the prevention of sporadic colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2006;355(9):873-88416943400<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16943400" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Celecoxib%20for%20the%20prevention%20of%20sporadic%20colorectal%20adenomas.&amp;author=MM%20Bertagnolli&amp;author=CJ%20Eagle&amp;author=AG%20Zauber&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa061355" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa061355" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-7">7.</a><div class="reference-content">Arber N, Eagle CJ, Spicak J, 
     et al; PreSAP Trial Investigators.  Celecoxib for the prevention of colorectal adenomatous polyps. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2006;355(9):885-89516943401<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16943401" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Celecoxib%20for%20the%20prevention%20of%20colorectal%20adenomatous%20polyps.&amp;author=N%20Arber&amp;author=CJ%20Eagle&amp;author=J%20Spicak&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa061652" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa061652" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-8">8.</a><div class="reference-content">Baron JA, Sandler RS, Bresalier RS, 
     et al;  APPROVe Trial Investigators.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2006;131(6):1674-168217087947<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17087947" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20rofecoxib%20for%20the%20chemoprevention%20of%20colorectal%20adenomas.&amp;author=JA%20Baron&amp;author=RS%20Sandler&amp;author=RS%20Bresalier&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2006.08.079" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2006.08.079" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-9">9.</a><div class="reference-content">Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2007;356(21):2131-214217522398<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17522398" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20the%20risk%20of%20colorectal%20cancer%20in%20relation%20to%20the%20expression%20of%20COX-2.&amp;author=AT%20Chan&amp;author=S%20Ogino&amp;author=CS%20Fuchs&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa067208" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa067208" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-10">10.</a><div class="reference-content">Markowitz SD. Aspirin and colon cancer-targeting prevention? <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2007;356(21):2195-219817522404<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17522404" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20colon%20cancer-targeting%20prevention%3F&amp;author=SD%20Markowitz&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMe078044" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMe078044" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-11">11.</a><div class="reference-content">Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. <I xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</I>. 2005;23(12):2840-285515837998<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15837998" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COX-2%3A%20a%20molecular%20target%20for%20colorectal%20cancer%20prevention.&amp;author=JR%20Brown&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=J%20Clin%20Oncol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2005.09.051" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2005.09.051" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-12">12.</a><div class="reference-content">Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 1994;107(4):1183-11887926468<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7926468" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Up-regulation%20of%20cyclooxygenase%202%20gene%20expression%20in%20human%20colorectal%20adenomas%20and%20adenocarcinomas.&amp;author=CE%20Eberhart&amp;author=RJ%20Coffey&amp;author=A%20Radhika&amp;author=FM%20Giardiello&amp;author=S%20Ferrenbach&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-13">13.</a><div class="reference-content">Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2004;10(24):8465-847115623626<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15623626" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%3A%20a%20significant%20prognostic%20indicator%20for%20patients%20with%20colorectal%20cancer.&amp;author=LT%20Soumaoro&amp;author=H%20Uetake&amp;author=T%20Higuchi&amp;author=Y%20Takagi&amp;author=M%20Enomoto&amp;author=K%20Sugihara&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-0653" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-0653" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-14">14.</a><div class="reference-content">Sheehan KM, Sheahan K, O'Donoghue DP, 
     et al.  The relationship between cyclooxygenase-2 expression and colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 1999;282(13):1254-125710517428<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10517428" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20relationship%20between%20cyclooxygenase-2%20expression%20and%20colorectal%20cancer.&amp;author=KM%20Sheehan&amp;author=K%20Sheahan&amp;author=DP%20O'Donoghue&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.282.13.1254" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.282.13.1254" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-15">15.</a><div class="reference-content">Uchida K, Schneider S, Yochim JM, 
     et al.  Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2005;11(9):3363-336815867236<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15867236" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Intratumoral%20COX-2%20gene%20expression%20is%20a%20predictive%20factor%20for%20colorectal%20cancer%20response%20to%20fluoropyrimidine-based%20chemotherapy.&amp;author=K%20Uchida&amp;author=S%20Schneider&amp;author=JM%20Yochim&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-1650" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-1650" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-16">16.</a><div class="reference-content">Ogino S, Kirkner GJ, Nosho K, 
     et al.  Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2008;14(24):8221-822719088039<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/19088039" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20is%20an%20independent%20predictor%20of%20poor%20prognosis%20in%20colon%20cancer.&amp;author=S%20Ogino&amp;author=GJ%20Kirkner&amp;author=K%20Nosho&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-08-1841" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-08-1841" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-17">17.</a><div class="reference-content">Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Am J Gastroenterol</I>. 2002;97(4):1037-104112003384<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12003384" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Overexpression%20of%20cyclooxygenase-2%20correlates%20with%20advanced%20stages%20of%20colorectal%20cancer.&amp;author=H%20Zhang&amp;author=XF%20Sun&amp;publication_year=&amp;journal=Am%20J%20Gastroenterol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/j.1572-0241.2002.05625.x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/j.1572-0241.2002.05625.x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-18">18.</a><div class="reference-content">Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2005;11(13):4754-476016000571<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16000571" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20in%20human%20colorectal%20cancer%20is%20unrelated%20to%20overall%20patient%20survival.&amp;author=R%20Fux&amp;author=M%20Schwab&amp;author=KP%20Thon&amp;author=CH%20Gleiter&amp;author=P%20Fritz&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-2586" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-2586" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-19">19.</a><div class="reference-content">Tomozawa S, Nagawa H, Tsuno N, 
     et al.  Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. <I xmlns:helper="urn:XsltStringHelper"> Br J Cancer</I>. 1999;81(8):1274-127910604722<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10604722" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20haematogenous%20metastasis%20of%20colon%20cancer%20in%20mice%20by%20a%20selective%20COX-2%20inhibitor%2C%20JTE-522.&amp;author=S%20Tomozawa&amp;author=H%20Nagawa&amp;author=N%20Tsuno&amp;publication_year=&amp;journal=Br%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/sj.bjc.6694262" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/sj.bjc.6694262" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-20">20.</a><div class="reference-content">Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 2000;60(21):6045-605111085526<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11085526" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Celecoxib%20prevents%20tumor%20growth%20in%20vivo%20without%20toxicity%20to%20normal%20gut%3A%20lack%20of%20correlation%20between%20in%20vitro%20and%20in%20vivo%20models.&amp;author=CS%20Williams&amp;author=AJ%20Watson&amp;author=H%20Sheng&amp;author=R%20Helou&amp;author=J%20Shao&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-21">21.</a><div class="reference-content">Williams CS, Sheng H, Brockman JA, 
     et al.  A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. <I xmlns:helper="urn:XsltStringHelper"> Neoplasia</I>. 2001;3(5):428-43611687954<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11687954" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20cyclooxygenase-2%20inhibitor%20%28SC-58125%29%20blocks%20growth%20of%20established%20human%20colon%20cancer%20xenografts.&amp;author=CS%20Williams&amp;author=H%20Sheng&amp;author=JA%20Brockman&amp;publication_year=&amp;journal=Neoplasia&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/sj.neo.7900177" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/sj.neo.7900177" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-22">22.</a><div class="reference-content">Yamauchi T, Watanabe M, Hasegawa H, 
     et al.  The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Anticancer Res</I>. 2003;23(1A):245-24912680220<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12680220" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20potential%20for%20a%20selective%20cyclooxygenase-2%20inhibitor%20in%20the%20prevention%20of%20liver%20metastasis%20in%20human%20colorectal%20cancer.&amp;author=T%20Yamauchi&amp;author=M%20Watanabe&amp;author=H%20Hasegawa&amp;publication_year=&amp;journal=Anticancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-23">23.</a><div class="reference-content">Yao M, Kargman S, Lam EC, 
     et al.  Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 2003;63(3):586-59212566300<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12566300" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20cyclooxygenase-2%20by%20rofecoxib%20attenuates%20the%20growth%20and%20metastatic%20potential%20of%20colorectal%20carcinoma%20in%20mice.&amp;author=M%20Yao&amp;author=S%20Kargman&amp;author=EC%20Lam&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-24">24.</a><div class="reference-content">Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Br J Cancer</I>. 2004;90(3):712-71914760389<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/14760389" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20selective%20inhibition%20with%20NS-398%20suppresses%20proliferation%20and%20invasiveness%20and%20delays%20liver%20metastasis%20in%20colorectal%20cancer.&amp;author=M%20Yao&amp;author=EC%20Lam&amp;author=CR%20Kelly&amp;author=W%20Zhou&amp;author=MM%20Wolfe&amp;publication_year=&amp;journal=Br%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/sj.bjc.6601489" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/sj.bjc.6601489" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-25">25.</a><div class="reference-content">Yao M, Zhou W, Sangha S, 
     et al.  Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2005;11(4):1618-162815746067<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15746067" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20nonselective%20cyclooxygenase%20inhibition%20with%20low-dose%20ibuprofen%20on%20tumor%20growth%2C%20angiogenesis%2C%20metastasis%2C%20and%20survival%20in%20a%20mouse%20model%20of%20colorectal%20cancer.&amp;author=M%20Yao&amp;author=W%20Zhou&amp;author=S%20Sangha&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-04-1696" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-04-1696" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-26">26.</a><div class="reference-content">Fuchs C, Meyerhardt JA, Heseltine DL, 
     et al.  Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803 [abstract]. <I xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</I>. 2005;23(suppl 16):3530<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Influence%20of%20regular%20aspirin%20use%20on%20survival%20for%20patients%20with%20stage%20III%20colon%20cancer%3A%20findings%20from%20intergroup%20trial%20CALGB%2089803%20%5Babstract%5D.&amp;author=C%20Fuchs&amp;author=JA%20Meyerhardt&amp;author=DL%20Heseltine&amp;publication_year=&amp;journal=J%20Clin%20Oncol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-27">27.</a><div class="reference-content">Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 2005;294(8):914-92316118381<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16118381" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-term%20use%20of%20aspirin%20and%20nonsteroidal%20anti-inflammatory%20drugs%20and%20risk%20of%20colorectal%20cancer.&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=JA%20Meyerhardt&amp;author=ES%20Schernhammer&amp;author=GC%20Curhan&amp;author=CS%20Fuchs&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.294.8.914" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.294.8.914" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-28">28.</a><div class="reference-content">Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2008;134(1):21-2818005960<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18005960" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20dose%20and%20duration%20of%20use%20and%20risk%20of%20colorectal%20cancer%20in%20men.&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=JA%20Meyerhardt&amp;author=ES%20Schernhammer&amp;author=K%20Wu&amp;author=CS%20Fuchs&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2007.09.035" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2007.09.035" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-29">29.</a><div class="reference-content">Willett WC, Sampson L, Stampfer MJ, 
     et al.  Reproducibility and validity of a semiquantitative food frequency questionnaire. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1985;122(1):51-654014201<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/4014201" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Reproducibility%20and%20validity%20of%20a%20semiquantitative%20food%20frequency%20questionnaire.&amp;author=WC%20Willett&amp;author=L%20Sampson&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-30">30.</a><div class="reference-content">Manson JE, Stampfer MJ, Colditz GA, 
     et al.  A prospective study of aspirin use and primary prevention of cardiovascular disease in women. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 1991;266(4):521-5272061978<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/2061978" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20prospective%20study%20of%20aspirin%20use%20and%20primary%20prevention%20of%20cardiovascular%20disease%20in%20women.&amp;author=JE%20Manson&amp;author=MJ%20Stampfer&amp;author=GA%20Colditz&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.1991.03470040085027" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.1991.03470040085027" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-31">31.</a><div class="reference-content">Rimm EB, Giovannucci E, Stampfer M, Colditz  G, Litin L, Willett W. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1992;135(10):1114-1126, discussion 1127-11361632423<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/1632423" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Reproducibility%20and%20validity%20of%20an%20expanded%20self-administered%20semiquantitative%20food%20frequency%20questionnaire%20among%20male%20health%20professionals.&amp;author=EB%20Rimm&amp;author=E%20Giovannucci&amp;author=M%20Stampfer&amp;author=G%20Colditz&amp;author=L%20Litin&amp;author=W%20Willett&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-32">32.</a><div class="reference-content">Giovannucci E, Rimm EB, Stampfer MJ, Colditz  GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</I>. 1994;121(4):241-2468037405<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/8037405" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20use%20and%20the%20risk%20for%20colorectal%20cancer%20and%20adenoma%20in%20male%20health%20professionals.&amp;author=E%20Giovannucci&amp;author=EB%20Rimm&amp;author=MJ%20Stampfer&amp;author=GA%20Colditz&amp;author=A%20Ascherio&amp;author=WC%20Willett&amp;publication_year=&amp;journal=Ann%20Intern%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/0003-4819-121-4-199408150-00001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/0003-4819-121-4-199408150-00001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-33">33.</a><div class="reference-content">Greene FL, Fleming ID, Fritz A, Balch CM. <em>AJCC Cancer Staging Handbook.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">6th ed. Page DL. New York, NY: Springer-Verlag; 2002</span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-34">34.</a><div class="reference-content">Meyerhardt JA, Giovannucci EL, Holmes MD, 
     et al.  Physical activity and survival after colorectal cancer diagnosis. <I xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</I>. 2006;24(22):3527-353416822844<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16822844" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Physical%20activity%20and%20survival%20after%20colorectal%20cancer%20diagnosis.&amp;author=JA%20Meyerhardt&amp;author=EL%20Giovannucci&amp;author=MD%20Holmes&amp;publication_year=&amp;journal=J%20Clin%20Oncol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2006.06.0855" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2006.06.0855" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-35">35.</a><div class="reference-content">Ogino S, Brahmandam M, Cantor M, 
     et al.  Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. <I xmlns:helper="urn:XsltStringHelper"> Mod Pathol</I>. 2006;19(1):59-6816118624<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16118624" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Distinct%20molecular%20features%20of%20colorectal%20carcinoma%20with%20signet%20ring%20cell%20component%20and%20colorectal%20carcinoma%20with%20mucinous%20component.&amp;author=S%20Ogino&amp;author=M%20Brahmandam&amp;author=M%20Cantor&amp;publication_year=&amp;journal=Mod%20Pathol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/modpathol.3800482" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/modpathol.3800482" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-36">36.</a><div class="reference-content">Stampfer MJ, Willett WC, Speizer FE, 
     et al.  Test of the National Death Index. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1984;119(5):837-8396720679<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/6720679" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Test%20of%20the%20National%20Death%20Index.&amp;author=MJ%20Stampfer&amp;author=WC%20Willett&amp;author=FE%20Speizer&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-37">37.</a><div class="reference-content">Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. <I xmlns:helper="urn:XsltStringHelper"> Am J Epidemiol</I>. 1994;140(11):1016-10197985649<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7985649" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Test%20of%20the%20National%20Death%20Index%20and%20Equifax%20Nationwide%20Death%20Search.&amp;author=JW%20Rich-Edwards&amp;author=KA%20Corsano&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Am%20J%20Epidemiol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-38">38.</a><div class="reference-content">Giovannucci E, Egan KM, Hunter DJ, 
     et al.  Aspirin and the risk of colorectal cancer in women. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 1995;333(10):609-6147637720<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7637720" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20and%20the%20risk%20of%20colorectal%20cancer%20in%20women.&amp;author=E%20Giovannucci&amp;author=KM%20Egan&amp;author=DJ%20Hunter&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJM199509073331001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJM199509073331001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-39">39.</a><div class="reference-content">Chan AT, Giovannucci EL, Schernhammer ES, 
     et al.  A prospective study of aspirin use and the risk of colorectal adenoma. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</I>. 2004;140(3):157-16614757613<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/14757613" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20prospective%20study%20of%20aspirin%20use%20and%20the%20risk%20of%20colorectal%20adenoma.&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=ES%20Schernhammer&amp;publication_year=&amp;journal=Ann%20Intern%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/0003-4819-140-3-200402030-00006" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/0003-4819-140-3-200402030-00006" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-40">40.</a><div class="reference-content">Rosner B. <em>Fundamentals of Biostatistics.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">5th ed. Pacific Grove, CA: Duxbury Thomson Learning; 2000</span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-41">41.</a><div class="reference-content">Cochran WG. The combination of estimates from different experiments. <I xmlns:helper="urn:XsltStringHelper"> Biometrics</I>. 1954;10(1):101-129<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20combination%20of%20estimates%20from%20different%20experiments.&amp;author=WG%20Cochran&amp;publication_year=&amp;journal=Biometrics&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.2307/3001666" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.2307/3001666" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-42">42.</a><div class="reference-content">Hosmer DW, Lemeshow S. <em>Applied Logistic Regression.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">2nd ed. Hoboken, NJ: John Wiley &amp; Sons, Inc; 2000</span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-43">43.</a><div class="reference-content">Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. <I xmlns:helper="urn:XsltStringHelper"> JAMA</I>. 2001;286(10):1187-119411559263<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11559263" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Aspirin%20use%20and%20all-cause%20mortality%20among%20patients%20being%20evaluated%20for%20known%20or%20suspected%20coronary%20artery%20disease%3A%20a%20propensity%20analysis.&amp;author=PA%20Gum&amp;author=M%20Thamilarasan&amp;author=J%20Watanabe&amp;author=EH%20Blackstone&amp;author=MS%20Lauer&amp;publication_year=&amp;journal=JAMA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.286.10.1187" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.286.10.1187" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-44">44.</a><div class="reference-content">Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. <I xmlns:helper="urn:XsltStringHelper"> Science</I>. 1994;265(5174):956-9598052854<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/8052854" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20NF-kappa%20B%20by%20sodium%20salicylate%20and%20aspirin.&amp;author=E%20Kopp&amp;author=S%20Ghosh&amp;publication_year=&amp;journal=Science&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.8052854" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.8052854" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-45">45.</a><div class="reference-content">Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. <I xmlns:helper="urn:XsltStringHelper"> Proc Natl Acad Sci U S A</I>. 1997;94(7):2869-28739096313<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9096313" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Sodium%20salicylate%20induces%20apoptosis%20via%20p38%20mitogen-activated%20protein%20kinase%20but%20inhibits%20tumor%20necrosis%20factor-induced%20c-Jun%20N-terminal%20kinase%2Fstress-activated%20protein%20kinase%20activation.&amp;author=P%20Schwenger&amp;author=P%20Bellosta&amp;author=I%20Vietor&amp;author=C%20Basilico&amp;author=EY%20Skolnik&amp;author=J%20Vilcek&amp;publication_year=&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.94.7.2869" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.94.7.2869" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-46">46.</a><div class="reference-content">Martinez ME, O'Brien TG, Fultz KE, 
     et al.  Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. <I xmlns:helper="urn:XsltStringHelper"> Proc Natl Acad Sci U S A </I>. 2003;100(13):7859-786412810952<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12810952" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pronounced%20reduction%20in%20adenoma%20recurrence%20associated%20with%20aspirin%20use%20and%20a%20polymorphism%20in%20the%20ornithine%20decarboxylase%20gene.&amp;author=ME%20Martinez&amp;author=TG%20O'Brien&amp;author=KE%20Fultz&amp;publication_year=&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.1332465100" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.1332465100" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-47">47.</a><div class="reference-content">Lundholm K, Gelin J, Hyltander A, 
     et al.  Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 1994;54(21):5602-56067923204<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7923204" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Anti-inflammatory%20treatment%20may%20prolong%20survival%20in%20undernourished%20patients%20with%20metastatic%20solid%20tumors.&amp;author=K%20Lundholm&amp;author=J%20Gelin&amp;author=A%20Hyltander&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-48">48.</a><div class="reference-content">Masunaga R, Kohno H, Dhar DK, 
     et al.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2000;6(10):4064-406811051257<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11051257" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20correlates%20with%20tumor%20neovascularization%20and%20prognosis%20in%20human%20colorectal%20carcinoma%20patients.&amp;author=R%20Masunaga&amp;author=H%20Kohno&amp;author=DK%20Dhar&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-49">49.</a><div class="reference-content">Cianchi F, Cortesini C, Bechi P, 
     et al.  Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2001;121(6):1339-134711729113<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11729113" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Up-regulation%20of%20cyclooxygenase%202%20gene%20expression%20correlates%20with%20tumor%20angiogenesis%20in%20human%20colorectal%20cancer.&amp;author=F%20Cianchi&amp;author=C%20Cortesini&amp;author=P%20Bechi&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/gast.2001.29691" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/gast.2001.29691" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-50">50.</a><div class="reference-content">Tomozawa S, Tsuno NH, Sunami E, 
     et al.  Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Br J Cancer</I>. 2000;83(3):324-32810917546<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10917546" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20overexpression%20correlates%20with%20tumour%20recurrence%2C%20especially%20haematogenous%20metastasis%2C%20of%20colorectal%20cancer.&amp;author=S%20Tomozawa&amp;author=NH%20Tsuno&amp;author=E%20Sunami&amp;publication_year=&amp;journal=Br%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1054/bjoc.2000.1270" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1054/bjoc.2000.1270" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-51">51.</a><div class="reference-content">Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. <I xmlns:helper="urn:XsltStringHelper"> Anticancer Res</I>. 2002;22(2B):1225-123012168930<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12168930" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COX-2%20expression%20in%20rectal%20carcinoma%3A%20immunohistochemical%20pattern%20and%20clinical%20outcome.&amp;author=S%20Petersen&amp;author=G%20Haroske&amp;author=G%20Hellmich&amp;author=K%20Ludwig&amp;author=C%20Petersen&amp;author=W%20Eicheler&amp;publication_year=&amp;journal=Anticancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-52">52.</a><div class="reference-content">Joo YE, Kim HS, Min SW, 
     et al.  Expression of cyclooxygenase-2 protein in colorectal carcinomas. <I xmlns:helper="urn:XsltStringHelper"> Int J Gastrointest Cancer</I>. 2002;31(1-3):147-15412622426<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12622426" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Expression%20of%20cyclooxygenase-2%20protein%20in%20colorectal%20carcinomas.&amp;author=YE%20Joo&amp;author=HS%20Kim&amp;author=SW%20Min&amp;publication_year=&amp;journal=Int%20J%20Gastrointest%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1385/IJGC:31:1-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1385/IJGC:31:1-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-53">53.</a><div class="reference-content">Yamac D, Celenkoglu G, Coskun U, 
     et al.  Prognostic importance of COX-2 expression in patients with colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> Pathol Res Pract</I>. 2005;201(7):497-50216164044<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16164044" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prognostic%20importance%20of%20COX-2%20expression%20in%20patients%20with%20colorectal%20cancer.&amp;author=D%20Yamac&amp;author=G%20Celenkoglu&amp;author=U%20Coskun&amp;publication_year=&amp;journal=Pathol%20Res%20Pract&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.prp.2005.04.006" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.prp.2005.04.006" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-54">54.</a><div class="reference-content">Sheng H, Shao J, Kirkland SC, 
     et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. <I xmlns:helper="urn:XsltStringHelper"> J Clin Invest</I>. 1997;99(9):2254-22599151799<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9151799" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20human%20colon%20cancer%20cell%20growth%20by%20selective%20inhibition%20of%20cyclooxygenase-2.&amp;author=H%20Sheng&amp;author=J%20Shao&amp;author=SC%20Kirkland&amp;publication_year=&amp;journal=J%20Clin%20Invest&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1172/JCI119400" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1172/JCI119400" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-55">55.</a><div class="reference-content">Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. <I xmlns:helper="urn:XsltStringHelper"> Cell</I>. 1998;93(5):705-7169630216<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9630216" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase%20regulates%20angiogenesis%20induced%20by%20colon%20cancer%20cells.&amp;author=M%20Tsujii&amp;author=S%20Kawano&amp;author=S%20Tsuji&amp;author=H%20Sawaoka&amp;author=M%20Hori&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Cell&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0092-8674(00)81433-6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0092-8674(00)81433-6" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-56">56.</a><div class="reference-content">Williams CS, Tsujii M, Reese J, Dey SK, DuBois  RN. Host cyclooxygenase-2 modulates carcinoma growth. <I xmlns:helper="urn:XsltStringHelper"> J Clin Invest</I>. 2000;105(11):1589-159410841517<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10841517" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Host%20cyclooxygenase-2%20modulates%20carcinoma%20growth.&amp;author=CS%20Williams&amp;author=M%20Tsujii&amp;author=J%20Reese&amp;author=SK%20Dey&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=J%20Clin%20Invest&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1172/JCI9621" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1172/JCI9621" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-57">57.</a><div class="reference-content">Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. <I xmlns:helper="urn:XsltStringHelper"> Proc Natl Acad Sci USA</I>. 1997;94(7):3336-33409096394<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/9096394" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20expression%20in%20human%20colon%20cancer%20cells%20increases%20metastatic%20potential.&amp;author=M%20Tsujii&amp;author=S%20Kawano&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Proc%20Natl%20Acad%20Sci%20USA&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.94.7.3336" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.94.7.3336" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-58">58.</a><div class="reference-content">Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2–selective inhibitor, etodolac. <I xmlns:helper="urn:XsltStringHelper"> Int J Cancer</I>. 2001;91(6):894-89911275997<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11275997" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Tumor%20invasiveness%20and%20liver%20metastasis%20of%20colon%20cancer%20cells%20correlated%20with%20cyclooxygenase-2%20%28COX-2%29%20expression%20and%20inhibited%20by%20a%20COX-2%E2%80%93selective%20inhibitor%2C%20etodolac.&amp;author=WS%20Chen&amp;author=SJ%20Wei&amp;author=JM%20Liu&amp;author=M%20Hsiao&amp;author=J%20Kou-Lin&amp;author=WK%20Yang&amp;publication_year=&amp;journal=Int%20J%20Cancer&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/(ISSN)1097-0215" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/(ISSN)1097-0215" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-59">59.</a><div class="reference-content">Trifan OC, Durham WF, Salazar VS, 
     et al.  Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. <I xmlns:helper="urn:XsltStringHelper"> Cancer Res</I>. 2002;62(20):5778-578412384538<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12384538" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20inhibition%20with%20celecoxib%20enhances%20antitumor%20efficacy%20and%20reduces%20diarrhea%20side%20effect%20of%20CPT-11.&amp;author=OC%20Trifan&amp;author=WF%20Durham&amp;author=VS%20Salazar&amp;publication_year=&amp;journal=Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-60">60.</a><div class="reference-content">Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. <I xmlns:helper="urn:XsltStringHelper"> Biochem Pharmacol</I>. 2005;70(5):658-66716004971<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16004971" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Combination%20of%20cyclooxygenase-2%20inhibitors%20and%20oxaliplatin%20increases%20the%20growth%20inhibition%20and%20death%20in%20human%20colon%20cancer%20cells.&amp;author=J%20Lin&amp;author=PW%20Hsiao&amp;author=TH%20Chiu&amp;author=JI%20Chao&amp;publication_year=&amp;journal=Biochem%20Pharmacol&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.bcp.2005.05.028" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.bcp.2005.05.028" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-61">61.</a><div class="reference-content">Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. <I xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</I>. 2003;9(1):383-39012538492<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12538492" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20novel%20mechanism%20for%20aspirin-mediated%20growth%20inhibition%20of%20human%20colon%20cancer%20cells.&amp;author=A%20Goel&amp;author=DK%20Chang&amp;author=L%20Ricciardiello&amp;author=C%20Gasche&amp;author=CR%20Boland&amp;publication_year=&amp;journal=Clin%20Cancer%20Res&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-62">62.</a><div class="reference-content">Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. <I xmlns:helper="urn:XsltStringHelper"> J Biol Chem</I>. 2001;276(21):18075-1808111278548<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/11278548" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prostaglandin%20E2%20increases%20growth%20and%20motility%20of%20colorectal%20carcinoma%20cells.&amp;author=H%20Sheng&amp;author=J%20Shao&amp;author=MK%20Washington&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=J%20Biol%20Chem&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1074/jbc.M009689200" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1074/jbc.M009689200" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-63">63.</a><div class="reference-content">Buchanan FG, Chang W, Sheng H, Shao J, Morrow JD, DuBois RN. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. <I xmlns:helper="urn:XsltStringHelper"> Gastroenterology</I>. 2004;127(5):1391-140015521009<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15521009" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Up-regulation%20of%20the%20enzymes%20involved%20in%20prostacyclin%20synthesis%20via%20Ras%20induces%20vascular%20endothelial%20growth%20factor.&amp;author=FG%20Buchanan&amp;author=W%20Chang&amp;author=H%20Sheng&amp;author=J%20Shao&amp;author=JD%20Morrow&amp;author=RN%20DuBois&amp;publication_year=&amp;journal=Gastroenterology&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.gastro.2004.07.025" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.gastro.2004.07.025" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-64">64.</a><div class="reference-content">Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med</I>. 2005;352(5):476-48715689586<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/15689586" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Systemic%20therapy%20for%20colorectal%20cancer.&amp;author=JA%20Meyerhardt&amp;author=RJ%20Mayer&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMra040958" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMra040958" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="ref-joc90066-65">65.</a><div class="reference-content">Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. <I xmlns:helper="urn:XsltStringHelper"> Cancer Epidemiol Biomarkers Prev</I>. 2008;17(8):1852-185718708371<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18708371" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20inhibitors%20in%20colorectal%20cancer%20prevention%3A%20point.&amp;author=N%20Arber&amp;publication_year=&amp;journal=Cancer%20Epidemiol%20Biomarkers%20Prev&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1055-9965.EPI-08-0167" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1055-9965.EPI-08-0167" xmlns:helper="urn:XsltStringHelper"> </span></div></div></div>

</div>
 
    </div>

        <div class="movable-ad bta">
    <div class="widget-WidgetLoader widget-instance-AMA_AdTag_textbreak_bta_dual">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_textbreak_bta_dual" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:8,&quot;adSection&quot;:&quot;textbreak&quot;,&quot;adPosition&quot;:&quot;bta&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{}}"></div>
 
    </div>

        </div>
    </div> 

</div> 

<div class="hidden-jobs-ad hide">
    <div class="widget-WidgetLoader widget-instance-AMA_JobsAd">
        
<div class="SCM-SharedWidgets-AsyncJobsAdLoader" data-url="/AMA/JobsAd/AMA_JobsAd" data-params="{&quot;parameters&quot;:{&quot;SiteId&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

</div>



<script>
                var App = App || {};
                App.ArticleSplitScreen = App.ArticleSplitScreen || {};
                App.ArticleSplitScreen.siteName = 'jama';
                App.ArticleSplitScreen.siteId = 3;
                App.ArticleSplitScreen.journalId = 67;
                App.ArticleSplitScreen.adDisplay = 'ArticleContentsSkyBox';
                App.ArticleSplitScreen.adSection = "scholarly";
                App.ArticleSplitScreen.adPosition = "contab";
                App.ArticleSplitScreen.controlId = "AMA_AdTag_Contents_Skybox";
                App.ArticleSplitScreen.fromGoogle = "False";
                App.ArticleSplitScreen.slotLocationOverride = "50";

</script> 
    </div>


 
    </div>

    </section>


    <section id="secFooterControl" class="master-footer">
        

        <script>
            var App = App || {};

            function scmByClass(className) {
                return document.getElementsByClassName(className);
            }

            function scmById(id) {
                return document.getElementById(id);
            }

            function scmquery(selector) {
                return document.querySelector(selector);
            }

            function queryAll(selector) {
                return document.querySelectorAll(selector);
            }

            function isTrueString(string) {
                if (typeof string === 'string') {
                    return string.toLowerCase() === 'true';
                }

                return undefined;
            }

            function updateViewportDimensions() {
                var w = window, d = document, e = d.documentElement, g = d.getElementsByTagName('body')[0], x = w.innerWidth || e.clientWidth || g.clientWidth, y = w.innerHeight || e.clientHeight || g.clientHeight;
                return { width: x, height: y };
            }

            var viewport = updateViewportDimensions();

            var debounce = function (func, wait, immediate) {
                var timeout;
                return function () {
                    var context = this, args = arguments;
                    var later = function () {
                        timeout = null;
                        if (!immediate) func.apply(context, args);
                    };
                    var callNow = immediate && !timeout;
                    clearTimeout(timeout);
                    timeout = setTimeout(later, wait);
                    if (callNow) func.apply(context, args);
                };
            };

            (function (App) {
                App.mobileUpperBreakpoint = 767;
                App.mobileAltBreakpoint = 640;
                App.mobileMinBreakpoint = 547;
                App.tabletUpperBreakpoint = 1023;

                function setVariables() {
                    viewport = updateViewportDimensions();
                    App.isMobile = (viewport.width <= App.mobileUpperBreakpoint);
                    App.isMobileAlt = (viewport.width <= App.mobileAltBreakpoint);
                    App.isTablet = (viewport.width > App.mobileUpperBreakpoint && viewport.width <= App.tabletUpperBreakpoint);
                    App.isTabletDown = (viewport.width <= App.tabletUpperBreakpoint);
                    App.isDesktop = (viewport.width > App.tabletUpperBreakpoint);
                    App.activeViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                }

                setVariables();

                App.cachedViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                App.isAnyArticle = !!(scmByClass('widget-ArticleFullView').length || scmByClass('pg_abstract').length
                    || scmByClass('widget-MagazineView').length || scmByClass('widget-ChannelsMagazineView').length);
                App.isSplitScreen = !!scmByClass('widget-ArticleFullView').length;
                App.isAbstract = !!scmByClass('pg_abstract').length;
                App.isMag = !!(scmByClass('widget-MagazineView').length);
                App.isChannel = !!(scmByClass('channel-site').length);
                App.isChannelMag = !!(scmByClass('widget-ChannelsMagazineView').length);
                App.isFreeArticle = !!(scmquery('.widget-ArticleTopInfo .free-access') ||
                                        scmquery('.widget-ArticleTopInfo .open-access') ||
                                        scmquery('.widget-ArticleTopInfo .icon-free') || 
                                        scmquery('.widget-ChannelsMagazineView .free-access'));
                App.isTollFreeAccess = false;
                App.isIssue = !!scmByClass('pg_issue').length || !!scmByClass('pg_newonline').length || !!scmByClass('pg_currentissue').length || !!scmByClass('pg_pastissues').length;
                App.isNewOnline = !!scmByClass('pg_newonline').length;
                App.isCurrentIssue = !!scmByClass('pg_currentissue').length;
                App.isPastIssues = !!scmByClass('pg_pastissues').length;
                App.isJournal = !!scmByClass('pg_journal').length;
                App.isNetworkHome = !!scmByClass('pg_index').length;
                App.isSearch = !!scmByClass('pg_searchresults').length;
                App.isAdvancedSearch = !!scmByClass('pg_advancedsearch').length;
                App.isPlayer= !!scmByClass('pg_multimediaplayer').length;
                App.isSelfServe = !!scmByClass('pg_sspage').length;
                App.isCmsPage = !!scmByClass('pg_cmspage').length; 
                App.isMyAccount = !!scmByClass('pg_myaccount').length;
                App.supportsFlexbox = !!scmByClass('flexbox').length;
                App.isCollection = !!scmByClass('pg_collection').length;
                App.isPaidUser = isTrueString(scmById('hfAppIsPaidUser').getAttribute('value'));
                App.isMember = isTrueString(scmById('hfAppIsMember').getAttribute('value'));
                App.isIndividual = isTrueString(scmById('hfAppIsIndividual').getAttribute('value'));
                App.hasAccess = isTrueString(scmById('hfAppHasAccess').getAttribute('value'));
                App.isReferredFromGoogle = isTrueString(scmById('hfAppIsReferredFromGoogle').getAttribute('value'));
                var subscribedTo = scmById('hfAppSubscribedTo').getAttribute('value');
                App.userSubscribedTo = subscribedTo ? subscribedTo.split(',') : undefined;
                App.isLucy = isTrueString(scmById('hfAppIsLucy').getAttribute('value'));
                App.currentJournalCount = 26;
                App.isChannelPage = !!(scmByClass('channels-page'));
                App.updateAppVariables = debounce(function () {
                    setVariables();
                }, 50, false);
            })(App);
        </script>
        

        
<div class="footer-ad-wrapper">
    <div id="BodyContent_Footer_divAds" class="footer-ad desktop-only">
        
            <div class="widget-WidgetLoader widget-instance-AMA_AdTag_AnchorboardAd_btf">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_AnchorboardAd_btf" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:11,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;btf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>
</div>
</div>

 
 <div class="ad-riser-wrap desktop-only">
     <div class="ad-riser--dismiss t-c">X</div>
         <div class="widget-WidgetLoader widget-instance-AMA_AdTag_Riser">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_Riser" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:12,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;Riser&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

 </div>


<div class="footer-wrap">
    
    <footer class="footer" id="footer">
        
        <div id="footer-microsite" class="footer-microsite">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Left" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    @media (min-width: 1024px) {.split-screen .footer-microsite-contents {border-bottom:0 !important;}}
    .footer-microsite-contents {margin-bottom:1em;width:100%;}
    .footer-network-other .link-apps:before {width: 23px;}
    .footer-network-other .link-institutions-librarians:before {width: 23px;}
    .jn-ss-footer-border-top {border-top:1px solid #555;padding-top:15px;}
    .jn-ss-footer-border-bottom {border-bottom:1px solid #555;padding-bottom:10px;padding-right:3px;}
</style>
<div class="footer-heading-wrap">
<h3 id="BodyContent_Footer_h3SiteName" class="footer-heading is-b footer-microsite-heading" data-mobile-tog-target=".footer-microsite-links-wrap">JAMA</h3>
</div>
<div class="footer-microsite-links-wrap">
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 id="BodyContent_Footer_ContentHeader" class="footer-subheading">Content</h4>
<a href="/journals/jama">Home</a>
<a href="/journals/jama/newonline">New Online</a>
<a href="/journals/jama/currentissue">Current Issue</a>
</div>
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 class="footer-subheading">Podcasts</h4>
<a href="/journals/jama/pages/covid-19-interviews#audio">Coronavirus (COVID-19)&nbsp;Q&amp;A</a>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/journals/jama/pages/jamaevidence-jama-guide-to-statistics-and-methods">JAMAevidence: <em>JAMA Guide to Statistics and Methods</em></a>
<a href="/journals/jama/pages/jamaevidence-the-rational-clinical-examination">JAMAevidence: The Rational Clinical Examination</a>
<a href="/journals/jama/pages/jamaevidence-users-guides-to-the-medical-literature">JAMAevidence: Users' Guides to the Medical Literature</a>
</div>
<div class="footer-microsite-services cf">
<h4 id="BodyContent_Footer_ServiceHeader" class="footer-subheading">Journal Information</h4>
<a href="/journals/jama/pages/for-authors">For Authors</a>
<a href="/journals/jama/pages/jama-editors">JAMA Editors</a>
<a href="/journals/jama/editors-and-publishers">Editors &amp; Publishers</a>
<a href="/pages/rss">RSS</a>
<a href="/journals/jama/pages/contact-us">Contact Us</a>
</div>
<div class="footer-network-other  jn-ss-footer-border-bottom">
<a href="https://edhub.ama-assn.org/jn-learning" class="link-network-other is-b link-learning">JN Learning / CME</a>
<a href="https://store.jamanetwork.com" class="link-network-other is-b link-store" target="_blank">Store</a>
<a href="/pages/apps" class="link-network-other is-b link-mobile" target="_blank">Apps</a>
<a href="https://careers.jamanetwork.com/" class="link-network-other is-b link-jobs" target="_blank">Jobs</a>
<a href="/pages/resources-for-librarians" class="link-network-other is-b link-institutions-librarians" target="_blank">Institutions</a>
<a href="/pages/reprints-and-permissions" class="link-network-other is-b link-reprints-permissions">Reprints &amp; Permissions</a>
</div>
<div id="BodyContent_Footer_divSubscribe" class="footer-microsite-subscribe">
<img src="//cdn.jamanetwork.com/UI/app/img/covers/jama.jpg" class="subscribe-image" alt="Journal Cover">
<div class="subscribe-meta">
<h4 class="subscribe-heading footer-subheading">Subscribe</h4>
<a href="https://store.jamanetwork.com/productDetails.aspx?productcodeID=64" class="subscribe-submit btn">Go</a>
</div>
</div>
</div>





        </div>

        
        <div id="footer-network" class="footer-network">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Middle" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-network-sites {width: 62.85542%;}
    .footer-network-info {width: 35.93976%}
    .jn-ss-subheading-mt {margin-top: 1.5em;}
    .jn-registered:after {content: "\00AE";font-size: 50%;vertical-align: top;}
    .jn-trademark:after {content: "\2122";font-size: 50%;vertical-align: top;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b jn-registered" data-mobile-tog-target=".footer-network-links-wrap"><strong>JAMA</strong> Network</h3>
</div>
<div class="footer-network-links-wrap">
<div class="footer-network-sites">
<div class="internal">
<h4 id="BodyContent_Footer_JournalHeader" class="footer-subheading">Publications</h4>
<a href="/journals/jama">JAMA</a>
<a href="/journals/jamanetworkopen" target="_blank">JAMA Network Open</a>
<a href="/journals/jamacardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology">JAMA Neurology</a>
<a href="/journals/jamaoncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology">JAMA Ophthalmology</a>
<a href="/journals/jamaotolaryngology">JAMA Otolaryngology–Head &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
</div>
<div class="external">
<h4 class="footer-subheading">Sites</h4>
<div id="BodyContent_Footer_ssFooterSiteMenu">
<div class="selfServe">
<a target="_blank" href="https://sites.jamanetwork.com/art-and-images-in-psychiatry/">Art and Images in Psychiatry</a>
<a target="_blank" href="/channels/ai">Artificial Intelligence (AI) Resource Center</a>
<a target="_blank" href="/journals/jama/pages/2023-most-viewed-jama">Best of the JAMA Network</a>
<a target="_blank" href="/channels/caring-for-the-critically-ill-patient">Caring for the Critically Ill Patient</a>
<a target="_blank" href="/journals/jama/pages/crosswords">Clinical Crosswords from JAMA</a>
<a target="_blank" href="/journals/jama/pages/coronavirus-alert">Coronavirus Resource Center</a>
<a target="_blank" href="https://ebm.jamanetwork.com/index.html">Evidence-Based Medicine: An Oral History</a>
<a target="_blank" href="/pages/fishbein-fellowship">Fishbein Fellowship</a>
<a target="_blank" href="/channels/genomics/">Genomics and Precision Health</a>
<a target="_blank" href="/channels/hypertension">Hypertension</a>
<a target="_blank" href="/channels/health-forum/archive">JAMA Forum Archive</a>
<a target="_blank" href="https://sites.jamanetwork.com/audio">JAMA Network Audio</a>
<a target="_blank" href="/pages/video">JAMA Network Video</a>
<a target="_blank" href="/pages/conferences">JAMA Network Conferences </a>
<a target="_blank" href="/pages/jama-summit">JAMA Summit </a>
<a target="_blank" href="/journals/jamasurgery/pages/statistics-and-methods">JAMA Surgery Guide to Statistics and Methods</a>
<a target="_blank" href="/channels/medical-news">Medical News</a>
<a target="_blank" href="/channels/monkeypox">Mpox (Monkeypox)</a>
<a target="_blank" href="https://sites.jamanetwork.com/research-ethics/">Research Ethics</a>
<a target="_blank" href="/pages/collections">Topics and Collections</a>
<a target="_blank" href="/pages/visual-abstracts">Visual Abstracts</a>
<a target="_blank" href="/channels/war">War and Health</a>
<a target="_blank" href="/channels/womens-health">Women's Health</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Featured Articles</h4>
<a href="/journals/jama/fullarticle/2799240">Antiretroviral Drugs for HIV Treatment and Prevention in Adults - 2022 IAS-USA Recommendations</a>
<a href="/journals/jama/fullarticle/2781397">CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic</a>
<a href="/journals/jama/fullarticle/2808296">Creation and Adoption of Large Language Models in&nbsp;Medicine</a>
<a href="/journals/jamaoncology/fullarticle/2787350">Global Burden of Cancer, 2010-2019</a>
<a href="/journals/jama/fullarticle/2797443">Global Burden of Long COVID</a>
<a href="/journals/jamadermatology/fullarticle/2790344">Global Burden of Melanoma</a>
<a href="/journals/jamadermatology/fullarticle/2787350">Global Burden of Skin Diseases, 1990-2017</a>
<a href="/journals/jamaneurology/fullarticle/2793874">Global Disparities in Parkinson Disease</a>
<a href="/journals/jama/fullarticle/2799547">Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension</a>
<a href="/journals/jamapsychiatry/fullarticle/2799486">Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning</a>
<a href="/journals/jamapsychiatry/fullarticle/2793903">Neuropsychiatry Sequelae of COVID-19</a>
<a href="/journals/jamaneurology/fullarticle/2810313">A New Framework for Dementia Nomenclature</a>
<a href="/journals/jama/fullarticle/2800656">Organization and Performance of US Health Systems</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Promoting EDI in Genetics Research</a>
<a href="/journals/jamacardiology/fullarticle/2781972">PTSD and Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2810754">Red Blood Cell Transfusion: 2023 AABB International Guidelines</a>
<a href="/journals/jamapediatrics/fullarticle/2797600">Reimagining Children’s Rights in the US</a>
<a href="/journals/jama/fullarticle/2794049">Spirituality in Serious Illness and Health</a>
<a href="/journals/jama/fullarticle/2796374">The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity</a>
<h4 class="footer-subheading jn-ss-subheading-mt">USPSTF Recommendation Statements</h4>
<a href="/journals/jama/fullarticle/2779985">Screening for Colorectal Cancer</a>
<a href="/journals/jama/fullarticle/2779190">Screening for Hypertension</a>
<a href="/journals/jama/fullarticle/2777244">Screening for Lung Cancer</a>
<a href="/journals/jama/fullarticle/2796244">Screening for Prediabetes and Type 2 Diabetes In Children</a>
<a href="/journals/jama/fullarticle/2783414">Screening for Prediabetes and Type 2 Diabetes In Adults</a>
<a href="/journals/jama/fullarticle/2795521">Statins for Primary Prevention of Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2793446">Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Blogs</h4>
<a target="_blank" href="https://amastyleinsider.com/">AMA Style Insider</a>
</div>
</div>
</div>
</div>
<div id="footer-network-info" class="footer-network-info">
<div class="information-for-links">
<h4 id="BodyContent_Footer_InfoHeader" class="footer-subheading">Information</h4>
<a href="/pages/for-authors">For Authors</a>
<a href="/pages/resources-for-librarians">For Institutions &amp; Librarians</a>
<a href="/pages/advertisers">For Advertisers</a>
<a href="/pages/subscription-agents">For Subscription Agents</a>
<a href="https://careers.jamanetwork.com/" target="_blank">For Employers &amp; Job Seekers</a>
<a href="https://media.jamanetwork.com" rel="nofollow" target="_blank">For the Media</a>
<a href="/pages/equity-diversity-inclusion">Equity, Diversity, Inclusion</a>
<a href="/pages/commenting-policy">Online Commenting Policy</a>
<a href="/pages/access-at-jama-network">Public Access and Open Access Policy</a>
<a href="/pages/offensive-content-statement">Statement on Potentially Offensive Content</a>
</div>
<div class="services-links">
<h4 id="BodyContent_Footer_JAMANetworkProductsHeader" class="footer-subheading">JAMA Network Products</h4>
<a href="http://www.amamanualofstyle.com/" class="footer-service-link" target="_blank">AMA Manual of Style</a>
<a href="https://jamaevidence.mhmedical.com/" class="footer-service-link" target="_blank"><span class="jn-registered">JAMAevidence</span></a>
<a href="http://www.peerreviewcongress.org/" class="footer-service-link" target="_blank">Peer Review Congress</a>
</div>
<div class="learning-links">
<h4 id="BodyContent_Footer_LearningHeader" class="footer-subheading">JN Learning</h4>
<a href="https://edhub.ama-assn.org/jn-learning">Home</a>
<a href="https://edhub.ama-assn.org/jn-learning/state-cme">State CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses">Clinical Challenge CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/288 ">Atrial Fibrillation Course</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/294 ">Women's Health Course</a>
<a target="_blank" href="https://edhub.ama-assn.org/pages/auto-credit-reporting">CME / MOC Reporting Preferences</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/about-cme">About CME &amp; MOC</a>
</div>
</div>
</div>





        </div>
        
        <div id="footer-resources-wrap" class="footer-resources-wrap">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Right" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-resources-wrap .footer-subheading {color: grey;display:block !important;font-size: 1.17647em;font-weight: 400;text-transform: uppercase;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b footer-resources-heading" data-mobile-tog-target=".footer-resources">Help</h3>
</div>
<div class="footer-resources">
<a href="https://store.jamanetwork.com" class="footer-service-link" target="_blank">Subscriptions &amp; Renewals</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts" class="footer-service-link" rel="nofollow">Manage Emails</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile" class="footer-service-link" rel="nofollow">Update My Address</a>
<a href="https://support.jamanetwork.com/hc/en-us" class="footer-service-link">Support Center</a>
<a href="/myaccount " class="footer-service-link">My Account</a>
<h4 class="footer-subheading jn-ss-subheading-mt">JAMA Career Center</h4>
<a href="https://careers.jamanetwork.com/" class="footer-service-link" target="_blank">Physician Job Listings</a>
</div>








    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Socials" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .widget-instance-AMA_Journal_Home_Socials .iconsocial {display: inline-block !important;width: 34px;height: 34px;min-width: unset !important;margin: 0 2px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 7px 7px;background-repeat: no-repeat;background-size: 18px;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:hover, .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:focus {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png);border-color: #C13584;}
    .footer-resources-wrap .iconsocial {display: inline-block !important;width: 32px;height: 32px;min-width: unset !important;margin: 0 2px 0 3px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .footer-resources-wrap .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 6px 6px;background-repeat: no-repeat;background-size: 18px;}
    .footer-resources-wrap .iconsocial.instagram:hover, .footer-resources-wrap .iconsocial.instagram:focus {background-color: #C13584;border-color: #191919;}
    #load-instagram-image { background: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png) no-repeat -9999px -9999px; }
</style>
<div id="BodyContent_Footer_divSocial" class="social-links footer-social-links">
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.facebook.com/JAMAJournal/" class="social-link is-b facebook"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://twitter.com/JAMA_current" class="social-link is-b twitter"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.instagram.com/jamanetwork/?hl=en" class="iconsocial instagram"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.linkedin.com/company/jamanetwork/" class="social-link is-b linked-in"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.youtube.com/jamanetwork" class="social-link is-b you-tube"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.pinterest.com/jamanetwork/" class="social-link is-b pinterest"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="/rss/site_3/67.xml" class="social-link is-b rss"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://jamanetwork.com/journals/jama/pages/jama-editors-summary" class="social-link is-b podcast"></a>
<div id="load-instagram-image">&nbsp;</div>
</div>




<div id="BodyContent_Footer_divEmailUpdate" class="footer-email-updates">
                
                    <div class="widget-EmailListSignUp widget-instance-AMAv2_EmailListSignUp_Footer">
        <div class="email-signup">
    
    <div class="email-signup--text sb-pc">Get the latest from JAMA</div>
    <div class="email-signup--input-wrap is-b">
        <input type="text" name="email" class="email-signup--input" placeholder="Email address" title="Email address" />
        <a rel="nofollow" href="javascript:;" class="email-signup--submit sb-sc btn">Sign Up</a>
    </div>
    <div class="email-signup--link"> <a class="email-signup--privacy" href="/pages/privacy-policy">Privacy Policy</a> | <a class="email-signup--terms" href="/pages/terms-of-use">Terms of Use</a></div>
    <div class="email-signup--user-message"></div>
</div> 
    </div>
</div>
        </div>

        
        <div class="footer-bar" itemscope itemtype="https://schema.org/Organization">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Bottom_Bar" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals a.theme-jama-health-forum:before {background: #133763;}
    .jn-bottom-bar {color: #fff; float: left;font-size: 10px;padding: 13px 20px;width: 33.33%;}
    .jn-bottom-bar p {line-height: 2;}
    @media (max-width: 900px) {.jn-bottom-bar {float: none;width: 100%;}}
    .jn-footer-copyright {font-size:12px;line-height:1.5;margin-bottom:10px;}
    .jn-footer-pipe {margin:0 10px;}
    .footer-bar-jn-logo img {width: 230px;}
    @media (max-width: 900px) {.footer-bar-jn-logo img {width: 200px;}}
    [data-thm=umb] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jama] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jaman] .jobs-ad--text h6 {color: #ed0973 !important;}
    [data-thm=cardi] .jobs-ad--text h6 {color: #be1e32 !important;}
    [data-thm=derm] .jobs-ad--text h6 {color: #006f3b !important;}
    [data-thm=faci] .jobs-ad--text h6 {color: #ed1c24 !important;}
    [data-thm=jama-] .jobs-ad--text h6 {color: #fb5252 !important;}
    [data-thm=intem] .jobs-ad--text h6 {color: #006e96 !important;}
    [data-thm=neur] .jobs-ad--text h6 {color: #981b1e !important;}
    [data-thm=oncol] .jobs-ad--text h6 {color: #3b923f !important;}
    [data-thm=ophth] .jobs-ad--text h6 {color: #66bc29 !important;}
    [data-thm=otol] .jobs-ad--text h6 {color: #34b6e4 !important;}
    [data-thm=peds] .jobs-ad--text h6 {color: #0084c0 !important;}
    [data-thm=psych] .jobs-ad--text h6 {color: #005276 !important;}
    [data-thm=surg] .jobs-ad--text h6 {color: #f47920 !important;}
    .blockquote .para {margin: 0 0 1em 1em;}
    .jn-footer-copyright {display: block;}
    .inline-block {display: inline-block;}
    #selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
</style>
<a class="footer-bar-jn-logo d-b no-mw mb1" href="/" title="JAMA Network Home"><img class="mw-100" src="https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=81373" alt="Jama Network Logo"></a>
<div class="jn-bottom-bar">
<p>
<span class="jn-footer-copyright">© 2024 American Medical Association. <span class="inline-block">All rights reserved,</span> including those for text and data mining, AI training, <span class="inline-block">and similar technologies.</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/terms-use" rel="nofollow" class="p0">Terms of Use</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/privacy-policy" rel="nofollow" class="p0">Privacy Policy</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/accessibility-statement" rel="nofollow" class="p0">Accessibility Statement</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a onclick="OneTrust.ToggleInfoDisplay()" rel="nofollow" class="p0" id="CookieFooter">Cookie Settings</a></span>
</p>
</div>
<!-- 
	#selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
	-->





            <a class="footer-bar-sis no-mw relative nudge-down" href="https://www.silverchair.com" target="_blank"><img class="footer-bar-sis-img mt05 mw-100" width="600" height="70" src="//cdn.jamanetwork.com/UI/app/img/powered.png" alt="Silverchair Logo" /></a>
        </div>
    </footer>

</div>
<div class="ss-ui-only">
        <div class="widget-SelfServeContent widget-instance-AMA_SS_UI_Only">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SsUiOnly" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

.


</div>

 
    </div>

</div>

    </section>


        

        
        
        <div id="revealModal" class="reveal-modal" data-reveal>
            <div id="revealContent"></div>
            <a class="close-reveal-modal icon-close"></a>
        </div>

        
        <div class="artmet-modal" id="MetricsModal">
            <div class="artmet-modal-contents">
                <a class="artmet-close-modal">&#215;</a>
            </div>
        </div>

        
        
    


            <div class="widget-SigninModals widget-instance-AMA_SigninModals">
        <div class="js-modal-no-access-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_NoAccess_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_NoAccess_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.2009.1112&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.2009.1112" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-paid-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_PaidPdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_PaidPDF_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.2009.1112&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.2009.1112" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-free-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Sign in to access free PDF</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_FreePdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_FreePdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-save-search-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Save your search</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_SaveSearch_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_SaveSearch">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_SaveSearch" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
		<hr />
		<button class="modal--btn js-btn-subscribe-now">Subscribe now</button>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_SaveSearch</div>-->


</div>

 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-follow-collection-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Customize your interests</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_FollowCollection_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_FollowCollection">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_FollowCollection" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_FollowCollection</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-user-comment-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Make a comment</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f184381">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_UserComment_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_UserComment">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_UserComment" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_UserComment</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="hidden-true js-modal-page-data"
     data-store-url="https://store.jamanetwork.com"
     data-store-purchase-url="https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com"
     data-store-subscribe-url="https://store.jamanetwork.com/index.aspx?productcode=64">
</div>






 
    </div>

        

        
        <script src="//cdn.jamanetwork.com/UI/app/vendor/jquery-2.2.4.min.js?v=638473295270790799"></script>
        <script>window.jQuery || document.write('<script src="/UI/app/vendor/jquery-2.2.4.min.js">\x3C/script>')</script>

        <script src="//cdn.jamanetwork.com/UI/app/dist/app.min.js?v=638488852374030681"></script>
        
    
    
    <script src="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.js" type="text/javascript"></script>

    
    
        <script src="//d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script>
    
    <script defer src='//js.trendmd.com/trendmd.min.js' data-trendmdconfig='{"element":"#trendmd-suggestions"}'></script>
        <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=643701de45aa460012e1032e&amp;product=sop' async='async'></script>


    <script>
        var App = App || {};
        App.showCmePromo = false;
    </script>


    </form>
    

    
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/scss/modules/_trendMD.css">
</body>
</html>

 contentType 9 text/html url 60 https://jamanetwork.com:443/journals/jama/fullarticle/184381 responseCode 3 200 